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UPDATE STATEMENT
 
A Toxicological Profile for Phenol, Draft for Public Comment was released in October 2006.  This
edition supersedes any previously released draft or final profile.  
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
 
1600 Clifton Road NE
 
Mailstop F-32
 
Atlanta, Georgia 30333
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vPHENOL
FOREWORD
 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein. Each peer-reviewed profile identifies and 
reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other pertinent
literature is also presented, but is described in less detail than the key studies.  The profile is not intended 
to be an exhaustive document; however, more comprehensive sources of specialty information are 
referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile
begins with a public health statement that describes, in nontechnical language, a substance’s relevant
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance’s health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel
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and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR.
Howard Frumkin M.D., Dr.P.H. Julie Louise Gerberding, M.D., M.P.H.
Director Administrator
National Center for Environmental Health/ Agency for Toxic Substances and
Agency for Toxic Substances and Disease Registry
Disease Registry
*Legislative Background
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This public law directed ATSDR to 
prepare toxicological profiles for hazardous substances most commonly found at facilities on the
CERCLA National Priorities List and that pose the most significant potential threat to human health, as
determined by ATSDR and the EPA.  The availability of the revised priority list of 275 hazardous 
substances was announced in the Federal Register on December 7, 2005 (70 FR 72840).  For prior
versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866);
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,1990 (55 FR 42067);
October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486);
April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999(64 FR 56792);
October 25, 2001 (66 FR 54014) and November 7, 2003 (68 FR 63098).  Section 104(i)(3) of CERCLA, 
as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on 
the list.
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide
Toxicity; and numerous chemical-specific case studies.
  
 
 
 
 
 
 
 
 
 
   
 
   
    
  
 
 
   
 
 
 
 
 
   
 
  
 
   
   
 
 
 
    
 
 
 
 
 
 
 
    
  
  
 
   
   
 
   
PHENOL viii
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266.
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substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
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PEER REVIEW
A peer review panel was assembled for phenol.  The panel consisted of the following members:
1.	 Marlissa Campbell, Ph.D., Private Consultant, Pacifica, California;
2.	 F. Peter Guengerich, Ph.D., Director, Center in Molecular Toxicology, Professor of
Biochemistry, Vanderbilt University, School of Medicine, Nashville, Tennessee; and
3.	 Thomas Zoeller, Ph.D., Professor, Department of Biology, University of Massachusetts at
Amherst, Amherst, Massachusetts;
These experts collectively have knowledge of phenol’s physical and chemical properties, toxicokinetics, 
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans.  All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
content.  The responsibility for the content of this profile lies with the ATSDR.
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1.  PUBLIC HEALTH STATEMENT 
 
This public health statement tells you about phenol and the effects of exposure to it. 
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  Phenol has been found in at least 595 of the 1,678 current or former NPL 
sites.  Although the total number of NPL sites evaluated for this substance is not known, the possibility 
exists that the number of sites at which phenol is found may increase in the future as more sites are 
evaluated.  This information is important because these sites may be sources of exposure, and exposure to 
this substance may be harmful. 
 
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
 
If you are exposed to phenol, many factors will determine whether you will be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health. 
 
1.1   WHAT IS PHENOL? 
 
Description  Phenol is a colorless-to-white solid when pure.  Commercial phenol is a 
liquid that evaporates more slowly than water. 
 
Phenol has a distinct odor that is sickeningly sweet and tarry. 
 
Uses 
 • Manufacturing 
 
 
 • Consumer 
products 
 
Phenol is both a manufactured chemical and produced naturally.  Large 
amounts of phenol are produced in the United States.   
 
Phenol is used to make plastics.  Phenol is also used as a disinfectant in 
household cleaning products and in consumer products such as:  
 • mouthwashes 
 • gargles 
 • throat sprays 
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For more information on the physical and chemical properties of phenol, and its production, disposal and 
use, see Chapters 4 and 5. 
 
1.2   WHAT HAPPENS TO PHENOL WHEN IT ENTERS THE ENVIRONMENT? 
 
Sources  Phenol can be found in air and water after release from the manufacture, use, 
and disposal of products containing phenol.  Phenol in soil is likely to move to 
groundwater.  
 
Break down  
 • Air 
 
 • Water 
 
 • Soil 
 
Phenol is quickly broken down in the air, usually within 1–2 days. 
 
Phenol may persist in water for a week or more. 
 
Phenol that remains in soil may be broken down by bacteria or other 
microorganisms. 
 
 
For more information on phenol in the environment, see Chapter 6. 
 
1.3   HOW MIGHT I BE EXPOSED TO PHENOL? 
 
Air The primary way you can be exposed to phenol is by breathing air 
containing it.  Releases of phenol into the air occur from:  
 • industries using or manufacturing phenol  
 • automobile exhaust  
 • cigarette smoke, and 
 • wood burning 
 
Recent data on levels of phenol in air are lacking. 
 
Water and soil Phenol has been detected in surface waters, rainwater, sediments, drinking 
water, groundwater, industrial and urban runoff, and at hazardous waste 
sites.  Phenol in soil is likely to move to groundwater. 
 
Workplace Workers in the following industries may be exposed to phenol: 
 
 • petroleum industry 
 • manufacture of nylon, epoxy resins and polycarbonates, herbicides, wood 
preservatives, hydraulic fluids, heavy-duty surfactants, lube-oil additives, 
tank linings and coatings, and intermediates for plasticizers and other 
specialty chemicals 
 
Exposure occurs through breathing and dermal contact with contaminated 
air or by skin contact with products containing phenol. 
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Food Low levels of phenol have been found in foods such as smoked summer 
sausage, smoked pork belly, mountain cheese, fried bacon, fried chicken, 
and black fermented tea.   
 
Consumer 
products 
Dermal contact can occur through the use of general disinfectants and 
ointments containing phenol. 
 
Ingestion can occur through the use of products such as throat lozenges or 
sore throat sprays that contain phenol. 
 
For more information on human exposure to phenol, see Chapter 6. 
 
1.4   HOW CAN PHENOL ENTER AND LEAVE MY BODY? 
 
Enter your body 
 
 • Inhalation 
 
 
 • Ingestion 
 
 
 • Dermal contact 
 
 
When you breathe air containing phenol, most of the phenol will rapidly 
enter your body through your lungs.   
 
Phenol in food or water may also rapidly enter your body through the 
digestive tract.   
 
A significant amount may enter through your skin when you come into 
contact with phenol vapor, liquid phenol or liquids containing phenol. 
 
Leave your body  Once in your body, phenol is transformed into other chemicals called 
metabolites.  Most of these other chemicals leave your body in the urine 
within few days.   
 
 
For more information on how phenol enters and leaves the body, see Chapter 3. 
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1.5   HOW CAN PHENOL AFFECT MY HEALTH? 
 
This section looks at studies concerning potential health effects in animal and human studies. 
 
Workers 
 • Inhalation/ 
dermal 
 
Long-term exposure to phenol at work has been associated with 
cardiovascular disease, but the workers were also exposed to other 
chemicals at the same time.     
 
General 
population 
 • Oral 
Ingestion of liquid products containing concentrated phenol can cause 
serious gastrointestinal damage and even death.   
General 
population 
 • Dermal 
Application of concentrated phenol to the skin can cause severe skin 
damage. 
Laboratory 
animals  
 • Inhalation  
Short-term exposure to high levels of phenol has caused irritation of the 
respiratory tract and muscle twitching in animals. 
 
Longer-term exposure to high levels of phenol caused damaged to the 
heart, kidneys, liver, and lungs in animals.    
 
Laboratory 
animals  
 • Oral 
 
Drinking water with extremely high concentrations of phenol has caused 
muscle tremors, difficulty walking, and death in animals. 
Laboratory 
animals 
 • Dermal 
 
Short-term application of phenol to the skin has produced blisters and burns 
in animals. 
Cancer There is no evidence that phenol causes cancer in humans. 
 
The International Agency for Research on Cancer (IARC) and the EPA 
determined that phenol is not classifiable as to human carcinogenicity. 
 
 
Further information on the health effects of phenol in humans and animals can be found in 
Chapters 2 and 3. 
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1.6   HOW CAN PHENOL AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age. 
 
Effects in children  Vomiting and lethargy were the main symptoms observed in children 
following accidental ingestion of a disinfectant containing phenol.  We do not 
know whether children would be more sensitive than adults to the effects of 
phenol. 
 
Birth defects Two studies of women exposed to phenol and other chemicals during 
pregnancy did not provide evidence of birth defects.   
 
Some birth defects have been observed in animals born to females exposed 
to phenol during pregnancy.  This generally occurred at exposure levels that 
were also toxic to the mothers. 
 
Breast milk 
 
There is no information on levels of phenol in human breast milk. 
 
1.7   HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PHENOL? 
 
Tobacco smoke Phenol is a component of tobacco smoke.  Avoid smoking in enclosed 
spaces like inside the home or car in order to limit exposure to children and 
other family members. 
 
Consumer 
products 
Household products and over-the-counter medications containing phenol 
should be stored out of the reach of young children to prevent accidental 
poisonings and skin burns.  
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1.8   IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
PHENOL? 
 
Detecting 
exposure  
Phenol can be measured in blood and urine.  Phenol is a normal constituent 
of human urine. 
 
Measuring 
exposure 
A higher-than-normal concentration of phenol in the urine may suggest 
recent exposure to phenol or to substances that are converted to phenol in 
the body. 
 
The detection of phenol and/or its metabolites in your urine cannot be used 
to predict the kind of health effects that might develop from that exposure.  
 
 
Information about tests for detecting phenol in the body is given in Chapters 3 and 7. 
 
1.9   WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
 
The federal government develops regulations and recommendations to protect public health.  Regulations 
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels.  These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value.  This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors. 
 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it. 
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Some regulations and recommendations for phenol include the following: 
 
Drinking water  The EPA has determined that exposure to phenol in drinking water at a 
concentration of 6 milligrams per liter (mg/L) for up to 10 days is not 
expected to cause any adverse effects in a child. 
 
The EPA has determined that lifetime exposure to 2 mg/L phenol in drinking 
water is not expected to cause any adverse effects.   
 
Bottled water  The FDA has determined that the phenol concentration in bottled drinking 
water should not exceed 0.001 mg/L.   
 
Workplace air  OSHA set a legal limit of 5 parts per million (ppm) phenol in air averaged 
over an 8-hour work day. 
 
 
For more information on regulations and advisories, see Chapter 8. 
 
1.10   WHERE CAN I GET MORE INFORMATION? 
 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may 
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:  
 
  Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
  1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
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Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
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2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PHENOL IN THE UNITED 
STATES 
Phenol is a naturally occurring and manufactured chemical that is widely distributed in the environment.  
It is found in various consumer products including throat lozenges, mouthwashes, and antiseptic lotions.  
The most likely route of exposure to phenol is through dermal contact either in the work environment or
at home using ointments and other household products containing phenol.
Phenol is a product of combustion of coal wood and municipal solid waste; therefore, residents near coal
and petroleum fueled facilities as well as residents near municipal waste incinerators may have increased 
exposure to phenol.  Phenol is also a product of auto exhaust, and therefore, areas of high traffic likely
contain increased levels of phenol.  Recent data on concentrations of phenol in air are lacking; it was
found at a median concentration of 30 parts per trillion (ppt) in 7 samples from one U.S. urban/suburban 
site in 1974 and at a median concentration of 5,000 ppt in 83 samples from seven sites between 1974 and 
1978. The individual medians of the seven source sites ranged from 520 to 44,000 ppt.  Higher phenol
concentrations may occur when there is smog or in highly contaminated air.
Phenol has been detected in surface waters, rainwater, sediments, drinking water, groundwater, industrial
effluents, urban runoff, and at hazardous waste sites.  Levels of up to 1 ppb have been detected in
unpolluted groundwater and concentrations ranging from 0.01 to 1 ppb were detected in unpolluted rivers.
Phenol has been detected in Lake Huron water at 3–24 ppb and industrial rivers in the United States at 0– 
5 ppb.
Phenol generally does not adhere very strongly to soils and tends to filter rapidly through soil, which may
account for the lack of monitoring data, since any phenol released to soils is likely to move to 
groundwater.  In addition, phenol is readily biodegraded under both aerobic and anaerobic conditions,
which is expected to attenuate its levels in soil. 
Phenol is degraded rapidly in air (half-life of approximately 15 hours), but may persist in water for a 
somewhat longer period.  In soil, phenol will biodegrade rapidly; the half-life in soil is generally <5 days.
Although low levels of phenol have been detected in certain foods and tap water, these levels do not
constitute major sources of exposure for most people.  Phenol has been reported at concentrations of
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7 and 28.6 ppm in smoked summer sausage and smoked pork belly, respectively, and was identified but
not quantified in mountain cheese, fried bacon, fried chicken, and black fermented tea.
Since plants can metabolize phenol readily, exposure through eating food derived from plants grown in 
phenol-containing soil is probably minimal.  Due to rapid biodegradation in water and soil, this
contamination should be limited.  People with contaminated tap water can be exposed from drinking the
water or eating foods prepared with it.  In addition, inhalation can occur during showering, bathing, and 
cooking with contaminated water.  People can also be exposed to phenol through dermal contact due to 
bathing or showering with contaminated water.  
There are no known unique sources of exposure to children.  No reports of phenol in breast milk or baby
foods were found.  Children are likely to be exposed to phenol through inhalation of contaminated air
from wood, coal, and waste incineration as well as from second-hand smoke.  Nonsmokers who live with 
smokers may be exposed to 6–14 µg/day of phenol.  
2.2  SUMMARY OF HEALTH EFFECTS 
Information about the health effects of phenol in humans is derived from studies of workers and members 
of the general population following inhalation, oral, and dermal exposure.  These studies indicate that
phenol is an irritating and corrosive substance, making the skin and mucosal membranes targets of
toxicity, but other effects have also been reported.  However, the data for humans exposed to phenol by
inhalation or ingestion are inadequate to establish concentration-response relationships, which are needed 
to identify adverse effects levels.  Fatalities due to ingestion or contact with a significant area of the skin 
have been reported.  A minimal lethal oral dose of approximately 70 mg/kg has been estimated in adults.  
Other estimates indicate that an oral dose as low as 1,000 mg could be fatal in humans, but patients
occasionally survived doses as high as 65,000 mg.  Postmortem examination typically showed serious
mucosal alterations in the gastrointestinal tract.  Other than the skin and mucosal membranes, the liver
and cardiovascular system might by considered targets for phenol toxicity.  In an epidemiological study of
workers from the rubber industry exposed to multiple chemicals (phenol among them), phenol showed the
strongest association with mortality due to ischemic heart disease.  Electrocardiographic alterations have 
been reported following acute oral and dermal exposure to phenol, as well as vomiting and lethargy.  
Studies of populations whose drinking water was contaminated with phenol found increased incidences of
nausea and diarrhea, but exposure to chlorophenols may have also occurred.  Also, liver effects, as judged 
by increased serum activities of alanine aminotransferase (ALT) and aspartate amino transferase (AST), 
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were reported in a case of prolonged inhalation exposure to phenol and in workers in an oil-refining plant, 
but exposure to other solvents could not be ruled out in the latter case.  An increased incidence of
headaches was reported among people who used drinking water contaminated with phenol and probably
chlorophenols also.  There is no evidence that phenol is a reproductive or developmental toxicant in 
humans.  The Development and Reproductive Toxicant Identification Committee of the California EPA’s
Office of Environmental Health Hazard Assessment examined the weight of evidence on the reproductive 
toxicity of phenol and concluded that phenol had not been clearly shown to cause reproductive toxicity.
There is only one modern study of inhalation exposure of animals to phenol.  The rest of the inhalation 
database for phenol is outdated and not useful for risk assessment, although it serves to identify some 
targets for phenol toxicity.  However, no single especially sensitive target emerged from these studies.  
Short-term (5 minutes) exposure of mice to phenol caused respiratory irritation, as judged by the animals’
reflex reduction in respiratory rate; a lowest-observed-effect level (LOEL) was not defined; but the 
exposure concentration that reduced the respiratory rate by 50% was 166 ppm.  In rats exposed nose-only
intermittently to concentrations up to 25 ppm for 2 weeks, phenol caused no gross or microscopic
alterations in major tissues and organs, including the nasal cavity, but some rats showed an increased 
incidence in a red nasal discharge possibly due to the irritating properties of phenol.  Phenol caused 
pneumonia, necrosis of the myocardium, centrilobular degeneration, and necrosis of the liver and renal
lesions in rabbits and guinea pigs, but not in rats, exposed whole-body intermittently to 26 ppm phenol for
intermediate durations.  In yet another study in rats, continuous whole-body exposure to 26 ppm phenol
for 15 days caused signs of neurological impairment including muscle tremors, twitching, and gait
disturbances during the first 3–5 days of exposure.  At termination, serum transaminases were elevated 
suggesting liver damage, but no histological examination was conducted.  Neurological effects, including
loss of coordination and tremors, were also observed in rats exposed to 234 ppm phenol for 8 hours.  In 
summary, inhaled phenol can affect several organs and tissues and produce neurological effects, but few
generalizations can be made from the available studies due to the different exposure protocols used (i.e., 
nose-only vs. whole-body; intermittent vs. continuous) and incomplete reporting.  Toxicokinetics
information indicates that phenol is readily absorbed through the skin of humans and animals, so that
whole-body exposure may result in considerably more absorbed phenol than in nose-only exposures. 
Application of phenol to the skin of animals has caused edema, erythema, necrosis, and death; the cause 
of death was not provided in the studies available.  The effects of phenol on the skin are due to its 
property to impair the stratum corneum and produce coagulation necrosis by denaturing and precipitating
proteins.  Lethality is influenced by the surface area exposed as well as the concentration of the applied 
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solution.  Systemic effects also have been described in animals following dermal exposure to phenol.  
Rabbits that received a dose of phenol of 24 mg/cm2/kg suffered cardiac arrhythmia.  Tremors leading to 
convulsions were reported in rats following application of 107 mg/kg of phenol to an unspecified surface
area.
In contrast to the limited inhalation database, there is an extensive database of oral studies in animals; yet, 
it is not easy to characterize the toxicity of orally administered phenol.  A key factor contributing to the
inability to do so is that phenol administered by oral gavage is much more toxic than when it is
administered in the drinking water, a phenomenon that is related to the toxicokinetics of phenol.  Studies
have shown that the toxicity of phenol is correlated with peak blood concentration rather than with total
dose, such as the area under the blood concentration curve (AUC).  Thus, end points that appear sensitive
to phenol administered by oral gavage are not affected by the same total daily dose given via the drinking
water. 
Results from a 28-day drinking water study in mice provided the lowest effect levels in the oral database 
for phenol and suggested that hematological, neurochemical, and immunological end points may be
particularly sensitive to phenol toxicity.  However, since the effects reported in that study occurred at
dose levels much lower than in any other study available, these findings should be interpreted with 
caution until supporting results are available.  In one study, phenol induced a significant decrease in red 
blood cell counts in mice at ≥1.8 mg/kg/day.  While this finding could have been due to macrocytosis, the 
study did not provide enough information to evaluate this possibility.  Only two additional studies
provided information on hematological parameters after phenol exposure.  In pregnant mice, a single 
gavage dose of 265 mg/kg of phenol (only dose tested) on gestation day (GD) 13 induced a reduction in 
the ratio of poly/normochromatic erythrocytes in the bone marrow, whereas phenol administered to rats in 
doses of up to 320 mg/kg/day in the drinking water for 10 weeks did not significantly affect a 
comprehensive number of hematological parameters monitored.  Other long-term drinking water studies
in rats and mice did not evaluate hematological parameters.
The neurochemical effects caused by phenol in a study also occurred at ≥1.8 mg/kg/day and consisted of
alterations in the levels of neurotransmitters in various brain areas.  This is difficult to interpret in light of
the absence of clinical signs and lack of supporting evidence from other studies.  Phenol, however, did 
induce neurological effects in other studies.  Short-term oral gavage administration of doses 
≥120 mg/kg/day of phenol caused muscle twitching and tremors in rats and mice, but no effects were 
observed at <40 mg/kg/day.  Decreased motor activity was reported in female rats dosed with 
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360 mg/kg/day of phenol in the drinking water for 13 weeks, but no effects were seen at 107 mg/kg/day.  
No neurochemical evaluations were conducted in these studies.  Other long-term drinking water studies in 
rats and mice that used much higher doses of phenol did not observe significant changes in gross or
microscopic appearance of the brain of the animals, but no neurological tests or neurochemical
evaluations were conducted in these studies.  
Phenol caused a significant decrease in antibody response to immunization with sheep red blood cells 
(SRBC) in mice at ≥6.2 mg/kg/day in a drinking water study.  Lymphoproliferative responses to T and 
B cell mitogens were also significantly suppressed at 33.6 mg/kg/day.  A study in which the plaque-
forming cell assay to SRBC (but not the antibody titer) and lymphoreticular organs of rats exposed to up 
to 321 mg/kg/day of phenol in the drinking water for 10 weeks were evaluated found no significant
alterations.  In another study, a single dose of 224 mg/kg of phenol administered to rats by oral gavage
caused necrosis or atrophy of the spleen or thymus, but no other immunological end point was evaluated.
Long-term drinking water studies in rats and mice did not report any significant gross and histological
alteration in lymphoreticular organs and tissues at phenol doses >1,000 mg/kg/day.
Other effects of phenol observed in oral studies include renal tubular necrosis in rats treated with a single
gavage dose of 224 mg/kg or with 40 mg/kg/day for 14 days.  However, long-term drinking water studies
in rats and mice that received much higher doses of phenol do not suggest that the kidney is a particularly 
sensitive target for phenol. Phenol also induced decreases in body weight in rats and mice in 13-week
and 2-year drinking water studies that were associated with significant reductions in water consumption 
due probably to poor palability.  Phenol reduced body weight gain in pregnant mice treated by oral
gavage with 280 mg/kg/day, a dose level that also caused frank neurotoxicity.  Doses of 120 mg/kg/day of
phenol administered to pregnant rats during GDs 6–15 using a divided dosing protocol to minimize the
adverse effects of a bolus dose caused a significant reduction in weight gain in the dams; the no-observed­
adverse-effect level (NOAEL) was 60 mg/kg/day.  The latter findings suggest that weight gain during
pregnancy is a sensitive end point for phenol toxicity and the dose of 120 mg/kg/day was the lowest
LOAEL in acute-duration oral studies in which no overt signs of toxicity (other than reduced maternal
weight gain) were observed following administration of phenol.  
Phenol has induced developmental effects in rodents, but, with one exception, it appears that this occurs
at dose levels that also affect the mothers.  In one study, doses of 120 mg/kg/day of phenol on GDs 6–15 
produced a 7% decrease in average fetal body weight in the absence of maternal effects.  In the study that
used the divided dosing protocol mentioned above, there were no developmental effects at
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120 mg/kg/day, but decreased ossification sites were seen at the highest dose level, 360 mg/kg/day.  In a
two-generation reproductive study in which the parental generation received doses of up to 301– 
321 mg/kg/day of phenol via the drinking water, decreased pup weight and percent live pups on postnatal
day 4 was reported at a dose level that also significantly decreased maternal water consumption, including
during gestation and lactation.  In pregnant mice, doses of 280 mg/kg/day on GDs 6–15 produced a
significant decrease in fetal weight and also caused tremors and ataxia in the dams.  
A study of phenol-exposed wood industry workers reported a small, nonsignificant excess of respiratory
cancers and a study of phenol production workers reported a small, non-significant excess of Hodgkin’s 
disease and of lung, esophageal, rectal, and kidney cancers.  However, the interpretation of these findings
is complicated due to lack of dose-response and potential for confounding.  Phenol has been tested for
carcinogenicity in long-term drinking water bioassays in rats and mice.  Statistically significant increased 
incidences of pheochromocytomas of the adrenal gland and leukemia or lymphomas were observed in 
male rats exposed to the low dose of phenol, but not to the high dose of phenol.  No significant effects
were seen in female rats or in mice.  Phenol has consistently been found to be a promoter in initiation-
promotion studies in mouse skin.  Based on inadequate evidence in humans and in animals, EPA assigned 
phenol to Group D, not classifiable as to human carcinogenicity.  Under updated guidelines, the data
regarding carcinogenicity of phenol are: “inadequate for an assessment of human carcinogenic potential.”
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for phenol.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
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or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
An acute-duration inhalation MRL was not derived for phenol due to inadequacies of the limited database
available.  The database includes a few animal studies of limited scope (Aranyi et al. 1986; De Ceaurriz et
al. 1981; Flickinger 1976) and a well-conducted study that used modern methodology to evaluate a
number of relevant end points (Hoffman et al. 2001).  No relevant human studies were located.  In the
animal studies, a target for phenol toxicity was not clearly defined; however, for an irritant substance such 
as phenol, it is reasonable to assume that portals of entry, such as the respiratory tract, could be potential
targets.  Of the studies mentioned above, only Hoffman et al. (2001) conducted a careful evaluation of the
respiratory tract.  Hoffman et al. (2001) exposed rats to various exposure levels for 2 weeks and evaluated 
a number of end points including histopathology, hematology, and clinical chemistry and reported no
adverse effects.  De Ceaurriz et al. (1981) exposed mice to various concentrations of phenol in air for
5 minutes and determined an RD50 (concentration that reduced the respiratory rate by 50%, a protective
reflex response in rodents) of 166 ppm.  Aranyi et al. (1986) also exposed mice to 5 ppm phenol
3 hours/day for 5 days and reported no significant changes in susceptibility to airborne bacterial agents
relative to mice exposed to filtered air.  Flickinger (1976) observed loss of coordination and tremors in 
rats exposed to 234 ppm phenol for 8 hours; a 1-hour exposure was without effect.  No other exposure
concentration was tested and no control group was used.  Fourteen days later, the rats were sacrificed and 
subjected to gross necropsy.  Flickinger (1976) indicated that no gross lesions were observed, but the 
scope of the examination was not specified.  Of all the studies available, the one conducted by Hoffman et
al. (2001) is the most complete, better-reported, and used modern methodology, but, as indicated above, 
because no adverse effects were reported, it is not a suitable basis for an MRL.  
An intermediate-duration inhalation MRL was not derived for phenol due to lack of adequate data.  No 
relevant human data were located and the available animal studies had numerous limitations including
poor control of exposure levels, unclear scope of the evaluations, and limited reporting.  The
intermediate-duration database consists of only three studies (Dalin and Kristoffersson 1974; Deichmann 
et al. 1944; U.S. Air Force 1961).  Dalin and Kristoffersson (1974) exposed a small number of rats to 0 or
26 ppm phenol continuously for 15 days and reported mild motor disorders (impaired balance, abnormal
gait, muscle twitching) during the first few days of exposure.  At termination, the activities of serum
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transaminases were significantly increased indicating liver damage, but no histopathology examination 
was conducted.  Because the exposure chamber was not of modern design, there is some uncertainty as to 
the actual exposure levels.  Deichmann et al. (1944) exposed guinea pigs, rats, and rabbits intermittently
for 6–12 weeks to a concentration of phenol in air that apparently could not be controlled with any
precision, but could have ranged from 26 to 52 ppm.  No controls were used and no actual data were
presented; the paper contains only a narrative of the results.  Exposure to phenol caused serious
histological alterations in the lungs, heart, liver, and kidneys in rabbits and guinea pigs, but no significant
changes were reported in rats.  U.S. Air Force (1961) exposed monkeys, rats, and mice continuously to 
0 or 5 ppm phenol for 90 days.  No information was provided regarding the frequency of monitoring the
test atmosphere, but the concentration of phenol was reported to remain in the range of 4.5–5.5 ppm after 
the first few days of the experiment.  Although the report indicates that there were no significant
histological alterations in organs and tissues, incomplete reporting of the results suggests that there may
have been some lung, liver, and kidney pathology.  In addition, no data were presented to support the
assertion that there were no effects on hematology (three species), blood chemistry (monkeys only), 
urinalysis (three species), and kidney function tests (monkeys and rats).  
A chronic-duration inhalation MRL for phenol was not derived due to lack of data for this duration. 
Occupational studies in humans are limited by lack of exposure data and simultaneous exposure to 
multiple chemicals.  No chronic inhalation study in animals was located.
Oral MRLs
No reliable human data were located for derivation of oral MRLs for phenol.  As mentioned in 
Section 2.2, effects of phenol administered to animals by oral gavage are different than those observed in 
drinking water studies.  Administration of phenol by oral gavage, as was done in almost all acute-duration 
oral studies, results in adverse effect levels that are much lower than those identified in drinking water
studies.  For example, tremors were reported in rats administered a single gavage dose of 120 mg/kg
(Berman et al. 1995) and in pregnant mice administered 140 mg/kg/day during gestation (NTP 1983b), 
but no adverse neurological signs were reported in rats administered 360 mg/kg/day in the drinking water
for 13 weeks (Beyrouty 1998) or in rats or mice administered phenol in the drinking water in doses
exceeding 700 mg/kg/day for up to 103 weeks (NCI 1980).  This differential toxicity is related to the
toxicokinetics of phenol.  A study by Hiser et al. (1994) showed that the toxicity of phenol is correlated 
with peak blood concentration rather than with total dose, such as the AUC.  Hiser et al. (1994) observed 
that rats given phenol by oral gavage developed a cluster of behaviors that the investigators termed 
   
 
   
 
 
 
 
 
 
 
 
     
     
  
 
    
   
  
   
 
     
  
  
 
   
 
 
 
  
  
    
  
   
    
  
   
 
    
   
   
   
   
 
  
PHENOL	 17
2. RELEVANCE TO PUBLIC HEALTH
“phenol twitching behavior” consisting of tremors, sudden jerks, hyper-reactivity to stimulus, and 
excessive blinking, none of which occurred in groups dosed via the drinking water.  Hiser et al. (1994)
also noticed that the twitching behavior developed almost immediately after gavage dosing, a time that
also coincided with peak blood levels of phenol, and disappeared by 37 minutes after dosing.  Also, for a
given daily dose, peak levels of phenol in blood were much higher following gavage dosing than 
following continuous administration in the drinking water.  Additional information that supports the idea
of toxicity being associated with peak blood levels of phenol was provided by experiments done by NTP
(1983a).  These investigators treated pregnant rats with phenol by gavage in different volumes during
GDs 6–15.  In a group dosed with 125 mg/kg/day in a volume of 1 mL/kg, 7 of 10 rats died.  Deaths were 
preceded by dose-related signs of toxicity, including tremors, convulsions, and respiratory distress, and 
necropsy revealed mottled liver and congested lungs.  However, in a group treated with 160 mg/kg/day in 
a volume of 5 mL/kg only one of six rats died, as a larger dosing volume would be expected to decrease
the absorption rate.  Based on the information discussed in this paragraph, only drinking water studies and 
divided dose gavage studies were considered appropriate for MRL derivation. 
•	 An MRL of 1 mg/kg/day has been derived for acute-duration oral exposure (1–14 days) to 
phenol.
All of the acute-duration oral studies available administered phenol to the animals by gavage.  As
indicated in the preceding paragraph, dosing volume in oral gavage studies is important in the
manifestation of phenol toxicity.  Acute-duration studies that used a relatively low dosing volume of
1 mL/kg are those by Berman et al. (1995), Moser et al. (1995), and Narotsky and Kavlock (1995).  These
studies were not considered for MRL derivation even though they identified adverse effects at dose levels 
lower than studies that used divided gavage dosing or drinking water studies.  The remaining database is 
essentially limited to two developmental studies, which were considered for MRL derivation.  In one of
these studies, rats were gavaged with phenol in doses of up to 120 mg/kg/day in a dosing volume of
5 mL/kg during GDs 6–15 (NTP 1983a).  There was no maternal toxicity, but mean fetal body weight at 
this dose level was approximately 7% lower than controls.  However, since historical control data showed 
that the concurrent control fetal weight for the CD rat was much higher (22%) than the historical control
weight and a larger litter size in the high-dose group may have contributed to the smaller fetal weight in 
the high-dose group, the dose of 120 mg/kg/day can be considered an equivocal LOAEL for
developmental effects; the NOAEL was 60 mg/kg/day.  In the other developmental study, which used a
divided dosing protocol and a dosing volume of 10 mL/kg, there was a dose-related decrease in maternal
body weight gain during treatment days and beyond, which achieved statistical significance at
120 mg/kg/day (York 1997).  Maternal body weight was also reduced, but differences with control
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achieved statistical significance only at 360 mg/kg/day (see details below).  No fetal toxicity was seen at
120 mg/kg/day.  The decrease in maternal body weight gain during gestation was the most sensitive end 
point and the dose level of 120 mg/kg/day is considered a LOAEL; the NOAEL is 60 mg/kg/day.  Since
the York (1997) study identified the most sensitive end point and utilized a dosing protocol that resembles 
more closely a potential environmental exposure scenario to phenol, it was selected as the principal study
for the derivation of an acute-duration oral MRL for phenol. 
In the York (1997) study, groups of pregnant Sprague-Dawley rats (25/dose group) were dosed 3 times 
daily with 0, 20, 40, or 120 mg phenol/kg in water (total daily doses of 0, 60, 120, or 360 mg/kg) by
gavage on GDs 6–15; the dosing volume was 10 mL/kg.  Maternal end points evaluated included clinical
signs, body weight, and food consumption.  Dams were also observed for abortions and premature
deliveries.  Dams were sacrificed on GD 20 and a gross necropsy was conducted. The uterus was 
examined for pregnancy, number and distribution of implantations, live and dead fetuses, and early and 
late resorptions.  Fetuses were weighed and examined for sex and gross external alterations.  Half of the
fetuses were examined for soft tissue alterations and the remaining fetuses were examined for skeletal
alterations.  One dam in the 360 mg/kg/day group died on GD 11 and the death was attributed to phenol
treatment.  Clinical signs considered treatment-related included excess salivation and tachypnea in rats 
exposed to 360 mg/kg/day.  Gross necropsy of the dams did not reveal any treatment-related alterations.  
In the 120 mg/kg/day group, maternal body weight gain was significantly reduced for GDs 6–16 (11%)
and for GDs 12–16 (19%), whereas in the 360 mg/kg/day group, body weight gain was reduced 38% for
GDs 6–16.  Maternal final body weight in the 360 mg/kg/day group was reduced, but <10% relative to 
controls.  Food consumption was reduced in the 360 mg/kg/day group by 16% for GDs 6–20 and by 15%
for GDs 0–20; in the 120 mg/kg/day group, food consumption for GDs 6–16 was reduced 11%.  Fetal
body weight at the 360 mg/kg/day level was reduced 5–7% relative to controls.  There was a significant
decrease in ossification sites on the hindlimb metatarsals in the 360 mg/kg/day group, which was
considered of minimal biological significance.  At the 120 and 360 mg/kg/day dose levels, there were
increases in litters with fetuses with "any alteration" and with "any variation", but neither reached 
statistical significance and there were no clear dose-response relationships.  There were no significant
effects on corpora lutea, implantations, litter sizes, live fetuses, early and late resorptions, or percent
resorbed conceptuses.  Based on decreased fetal body weight and delayed ossification, the dose of
360 mg/kg/day is a LOAEL for developmental effects; the NOAEL is 120 mg/kg/day.  Based on 
decreased weight gain during gestation, the dose of 120 mg/kg/day is a LOAEL for decreased maternal
body weight gain; the NOAEL is 60 mg/kg/day.  
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Data from York (1997) were analyzed using the BMD approach for MRL derivation.  BMD models in the
EPA Benchmark Dose Software (BMDS version 2.0) (linear, polynomial, power, and Hill models) were
fit to the maternal body weight gain data to determine potential points of departure for the MRL (details
of the modeling are presented in Appendix A).  The linear model with homogeneous variance (which was
identical to the power model), was selected because it was the simplest model and provided the best fit. 
In the absence of a clear criteria as to what level of change in weight gain during pregnancy should be
considered adverse, the BMR was defined as a change in mean body weight gain equal to one standard 
deviation from the control mean (EPA 2000c). The corresponding BMD was 152 mg/kg/day; the
corresponding benchmark dose limit (BMDL) was 125 mg/kg/day.  Applying an uncertainty factor of 100 
(10 for animal to human extrapolation and 10 for human variability) to the BMDL results in an acute-
duration oral MRL of 1 mg/kg/day.  
An intermediate-duration oral MRL for phenol was not derived.  Several studies are available that provide
information on the effects of phenol following intermediate-duration exposure and all of them used 
drinking water to administer the test material.  With the exception of one study (Hsieh et al. 1992, see
below), doses tested in intermediate-duration oral studies were higher than doses tested in acute-duration 
oral studies.  A 13-week drinking water study in rats and mice evaluated clinical signs and gross and 
microscopic appearance of a number of organs and tissues and found little evidence of toxicity (NCI
1980).  Reduction in body weight gain was observed in both rats and mice at the highest dose levels
tested (1,556 mg/kg/day in rats, 2,468 mg/kg/day in mice), which was most likely due to significant
decreases in water consumption.  Also available is a two-generation reproduction study that found no 
evidence of reproductive effects in male and female rats (301 and 321 mg/kg/day, respectively), but
reported decreased pup weight and reduced viability at 301/321 mg/kg/day (Ryan et al. 2001).  
Significantly reduced water consumption was also reported in the Ryan et al. (2001) study, particularly in 
the 301/321 mg/kg/day males and females.  A specialized 13-week neurotoxicity study in rats reported 
decreased motor activity in females dosed with 360 mg/kg/day, but not with 107 mg/kg/day (Beyrouty 
1998).  However, the most significant findings among the intermediate-duration database were reported in 
a 28-day study in mice (Hsieh et al. 1992).  These investigators found hematological and neurochemical
effects in mice at 1.8 mg/kg/day and immunological effects at ≥6.2 mg/kg/day.  Hsieh et al. (1992) dosed 
CD-1 mice (five per dose group) with phenol in the drinking water for 28 days.  At termination, there was 
a dose-related decrease in red cell counts, statistically significant at all dose levels.  The hematocrit was 
decreased only at the highest dose level.  In the absence of a change in hematocrit, the decrease in red
blood cells may have been due to macrocytosis, but the study did not provide sufficient information to 
evaluate this possibility.  Ryan et al. (2001), in a two-generation study, conducted a comprehensive
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evaluation of hematological parameters in rats exposed to up to 321 mg/kg/day for 10 weeks and found 
no significant alterations.  Similarly, in the inhalation experiments of U.S. Air Force (1961) in mice
exposed continuously for 90 days, no hematological alterations were observed.  Hsieh et al. (1992) also 
reported significant dose-related alterations in various neurotransmitters in the brain (i.e., dopamine, 
norepinephrine).  In the absence of clinical effects, this is difficult to interpret.  Beyrouty (1998) exposed 
rats to doses of 308 mg/kg/day of phenol for 13 weeks and found no significant neurological alterations, 
although neurochemical evaluations were not conducted.  Hsieh et al. (1992) also found a significant
decrease in antibody response to immunization with SRBCs at ≥6.2 mg/kg/day, detected by two different
assays (plaque-forming cell assay and antibody titer).  At the highest dose level tested, 33.6 mg/kg/day, 
lymphoproliferative responses to T and B cell mitogens were also significantly suppressed.  Ryan et al. 
(2001) also conducted the plaque-forming cell assay to SRBC (but not the antibody titer) and evaluated 
lymphoreticular organs of rats in the two-generation study and found no significant alterations, although it
is not uncommon to find differences in immune responses between rats and mice.  The Hsieh et al. (1992)
study was not used for derivation of an intermediate-duration oral MRL largely due to the unconfirmed 
nature of findings observed at relatively very low doses and because only five mice comprised each dose 
group.  Hsieh’s findings need to be replicated before the data can be used for risk assessment. 
A chronic-duration oral MRL for phenol was not derived.  The only chronic-duration animal studies are
the NCI (1980) 103-week studies in rats and mice.  NCI (1980) evaluated clinical signs, organ weights, 
and gross and microscopic appearance of organs and tissues.  The lowest doses tested were 
322 mg/kg/day in rats and 590 mg/kg/day in mice.  Under the conditions of the study, phenol showed 
essentially no systemic toxicity, but neither hematology nor clinical chemistry tests were conducted.  The
only reported effect was a significant decrease in body weight in male ( ≥322mg/kg/day) and female 
(≥721 mg/kg/day) rats associated with significant decreases in water intake; food consumption was 
comparable among all groups.  It would not be appropriate to use the LOAEL of 322 mg/kg/day as the
basis for an MRL since the effect (reduced final body weight) was likely due to decreased water intake. 
An additional reason for not deriving a chronic-duration oral MRL for phenol is the intermediate data 
from Hsieh et al. (1992) suggesting that immunosuppression may be the most sensitive effect, which 
leaves open the possibility that it could do the same in longer-term studies.  Tests of immunocompetence 
were not conducted in the standard 2-year bioassays available.
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of phenol.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
It should be noted that phenol is the simplest form, or parent compound, of the class of chemicals
commonly referred to as phenols or phenolics, many of which are natural substances widely distributed 
throughout the environment.  There is some confusion in the literature as to the use of the term ‘phenol’;
in some cases, it has been used to refer to a particular phenolic compound that is more highly substituted 
than the parent compound (Doan et al. 1979), whereas in other cases, it has been used to refer to the class
of phenolic compounds (Beveridge 1997). This chapter, however, addresses only those health effects that
can be directly attributable to the parent compound, monohydroxybenzene, or phenol.  As Deichmann and
Keplinger (1981) note:  “It cannot be overemphasized that the structure-activity relationships of phenol
and phenol derivatives vary widely, and that to accept the properties of individual phenolic compounds as
being those of phenol is a misconception and leads to error and confusion.”
A glossary and list of acronyms, abbreviations, and symbols can be found in Appendix C at the end of
this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that
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evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
3.2.1.1  Death 
A cohort mortality study of workers in five formaldehyde-resin manufacturing facilities was conducted to 
evaluate whether excess mortality could be attributed to occupational exposure to phenol (Dosemeci et al. 
1991).  Workers (exposed and non-exposed) had a mortality rate, from all causes, similar to that of the
general U.S. population.  Compared to either the general population or unexposed workers, exposed
workers had small statistically non-significant excesses in mortality due to Hodgkin’s disease 
(standardized mortality ratio [SMR], 1.7; 95% confidence interval [CI], 0.8–3.1) and esophageal (SMR, 
1.6; 95% CI, 0.9–2.6), renal (SMR, 1.3; 95% CI, 0.7–2.1), and rectal (SMR, 1.4; 95% CI, 0.8–2.2)
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cancers.  They also had small reductions in mortality due to: cancer of the stomach, testes, pancreas, 
buccal cavity/pharynx and brain; lymphosarcoma; liver cirrhosis; emphysema; diseases of the
cardiovascular, circulatory, and digestive systems; motor vehicle accidents; and all accidents.  The 
ambiguity of these data, as well as the fact that dose-related trends occurred only for those diseases 
showing reductions in mortality, makes it difficult to assess the impact on mortality of long-term 
occupational exposure to phenol. 
Deichmann et al. (1944) exposed guinea pigs, rabbits, and rats to phenol vapor at levels ranging from
26 to 52 ppm for 28–88 days.  After 28 days of exposure, 5 of 12 guinea pigs died, but no deaths occurred 
in rabbits or rats.  Since only a range was given for the exposure level, the exact level of phenol in air that
resulted in death of guinea pigs was not established and may be as low as 26 ppm or as high as 52 ppm.  
Interpretation of this study is further complicated by an apparent lack of controls. However, since the
effects observed in guinea pigs and rabbits (described in subsequent sections in Chapter 3) were so 
severe, it is difficult to ascribe the mortality to any source other than the phenol exposure.  The lower
limit of the exposure range, 26 ppm, is recorded as a serious LOAEL in Table 3-1 and plotted in 
Figure 3-1.  No deaths were reported in Rhesus monkeys, rats, or mice exposed to 5 ppm phenol
continuously for 90 days (U.S. Air Force 1961).
3.2.1.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
Respiratory Effects. Slight increases in mortality associated with respiratory cancers were seen in 
two epidemiological studies of workers exposed to phenol (Dosemeci et al. 1991; Kauppinen et al. 1986).  
However, after adjusting for smoking-related behavior, these increases became nonsignificant in the
Kauppinen et al. (1986) study, and neither study showed a dose-related trend; thus, the relevance of these 
findings to respiratory disease per se is somewhat uncertain.  Indeed in the latter study, there were slight, 
yet nonsignificant reductions in mortality associated with emphysema among exposed workers, leading
the investigators to suggest that exposure to phenol could have a protective effect for diseases involving
free radical damage.  
A case-control study of office workers was conducted by Baj et al. (1994) to evaluate the risks of
chronic exposures to “inhaled formaldehyde, phenol, and isomers of organic chlorohydrocarbons from
Ksylamit™ ...” which is a widely used liquid wood preservative.  It should be noted that in the report, 
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Table 3-1 Levels of Significant Exposure to Phenol - Inhalation 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Systemic 
1 Rat 
(Fischer- 344) 
2 wk 
5 d/wk 
6 hr/d 
System 
Resp 
NOAEL 
(ppm) 
25 
Less Serious 
(ppm) 
LOAEL 
Serious 
(ppm) 
Reference 
Chemical Form 
Hoffman et al. 2001 
Comments 
NOAELs are for organ 
weights and 
histopathology. 
Hemato 25 
Hepatic 
Renal 
25 
25 
Bd Wt 25 
2 Mouse 
(Swiss OF1) 
5 min 
Resp 166 M (50% decrease in 
respiration rate) 
De Ceaurriz et al. 1981 
Immuno/ Lymphoret 
3 Rat 
(Fischer- 344) 
2 wk 
5 d/wk 
6 hr/d 
25 Hoffman et al. 2001 NOAEL is for 
histopathology of the 
spleen. 
4 Mouse 
(CD-1) 
5 d 
3 hr/d 5 F 
Aranyi et al. 1986 NOAEL is for no 
change in susceptibility 
to infectious agents. 
Neurological 
5 Rat 
Harlan-
Wistar 
1 hr 
234 F Flickinger 1976 NOAEL is for no 
adverse neurological 
signs. 
P
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E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
24
2
234
065
26
106
5
5
5
5
5
145
26
26
26
Table 3-1 Levels of Significant Exposure to Phenol - Inhalation (continued) 
a 
Key to 
Figure 
Species 
(Strain) System 
Exposure/ 
Duration/ 
Frequency 
(Route) 
NOAEL 
(ppm) 
Less Serious 
(ppm) 
LOAEL 
Comments 
Serious 
(ppm) 
Reference 
Chemical Form 
6 Rat 
(Harlan-
Wistar) 
8 hr Flickinger 1976234 F (loss of coordination and 
tremors) 
INTERMEDIATE EXPOSURE 
Death 
7 Gn Pig 
(NS) 
6 wk 
5 d/wk 
7 hr/d 
Systemic 
8 RespMonkey 
(Rhesus) 
90 d 
24 hr/d 5 M 
Deichmann et al. 194426 (5/12 deaths) 
NOAELs are for organ 
histopathology. 
U.S. Air Force 1961 
Hemato 
Hepatic 
Renal 
Bd Wt 
5 M 
5 M 
5 M 
5 M 
9 HematoRat 
(White) 
15 d 
24 hr/d 26 
Dalin and Kristoffersson 1974 
Hepatic 26 (serum activities of ALT, 
AST, LDH, and GLDH 
increased 2-6-fold; 
increased serum 
magnesium) 
Bd Wt 26 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
25
064
26
26
26
26
107
5
5
5
5
5
108
5
5
5
5
5
Table 3-1 Levels of Significant Exposure to Phenol - Inhalation (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(ppm) 
Less Serious 
(ppm) 
LOAEL 
Serious 
(ppm) 
Reference 
Chemical Form Comments 
10 Rat 
(NS) 
10 wk 
5 d/wk 
7 hr/d 
Resp 26 Deichmann et al. 1944 NOAELs are for 
histopathology of 
tissues. 
Cardio 
Hepatic 
Renal 
26 
26 
26 
11 Rat 
(Sprague-
Dawley) 
90 d 
24 hr/d Resp 5 M 
U.S. Air Force 1961 NOAELs are for 
histopathology of 
tissues. 
Hemato 
Hepatic 
Renal 
Bd Wt 
5 M 
5 M 
5 M 
5 M 
12 Mouse 
(NS) 
90 d 
24 hr/d Resp 5 M 
U.S. Air Force 1961 NOAELs are for 
histopathology of 
tissues. 
Hemato 
Hepatic 
Renal 
Bd Wt 
5 M 
5 M 
5 M 
5 M 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
26
068
26
26
26
26
Table 3-1 Levels of Significant Exposure to Phenol - Inhalation (continued) 
Exposure/ LOAEL 
Duration/ 
a 
Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (ppm) (ppm) (ppm) Chemical Form Comments 
13 Gn Pig 
(NS) 
6 wk 
5 d/wk 
7 hr/d 
Resp 26 Deichmann et al. 1944(acute lobular pneumonia 
with occasional 
abscesses and vascular 
damage) 
Cardio 26 (necrosis of the 
myocardium, extensive 
reactive inflammation) 
Hepatic 26 (fatty changes, 
centrolobular 
degeneration and 
necrosis) 
Renal 26 (edema of the convoluted 
tubules, slightly 
advanced focal cortical 
lesions, glomerular 
degeneration) 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
27
063
26
26
26
26
224
5
146
26
Table 3-1 Levels of Significant Exposure to Phenol - Inhalation (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(ppm) 
Less Serious 
(ppm) 
LOAEL 
Serious 
(ppm) 
Reference 
Chemical Form Comments 
14 Rabbit 
(NS) 
12 wk 
5 d/wk 
7 hr/d 
Resp 26 (confluent lobular 
pneumonia, chronic 
purulent bronchitis, 
hyperplastic peribronchial 
tissue, degenerative 
changes in pulmonary 
vessels) 
Deichmann et al. 1944 
Cardio 26 (myocardial 
degeneration, necrosis of 
muscle bundles, 
interstitial fibrosis, 
lymphocytic infiltration) 
Hepatic 26 (centrilobular 
degeneration and 
necrosis) 
Renal 26 (edema of the convoluted 
tubules, focal cortical 
lesions, glomerular 
degeneration) 
Neurological 
15 Monkey 
(Rhesus) 
90 d 
24 hr/d 5 M 
U.S. Air Force 1961 
16 Rat 
(White) 
15 d 
24 hr/d 26 (mild motor disorders 
during the first 4 days of 
exposure, 4.4 degrees 
decrease in sliding angle) 
Dalin and Kristoffersson 1974 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
28
226
5
228
5
154
26
Table 3-1 Levels of Significant Exposure to Phenol - Inhalation (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(ppm) 
Less Serious 
(ppm) 
LOAEL 
Serious 
(ppm) 
Reference 
Chemical Form Comments 
17 Rat 
(Sprague-
Dawley) 
90 d 
24 hr/d 5 M 
U.S. Air Force 1961 NOAEL is for brain 
histopathology and 
results of a swimming 
test. 
18 Mouse 
(NS) 
90 d 
24 hr/d 5 M 
U.S. Air Force 1961 NOAEL is for brain 
histopathology and 
results of a swimming 
test. 
19 Gn Pig 
(NS) 
6 wk 
5 d/wk 
7 hr/d 
26 (hindlimb paralysis) Deichmann et al. 1944 
P
H
E
N
O
L
a The number corresponds to entries in Figure 3-1. 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; Gastro = 
gastrointestinal; GLDH = glutamate dehydrogenase; Gn pig = guinea pig; Hemato = hematological; hr = hour(s); Immuno = immunological; LDH = lactate dehydrogenase; LOAEL = 
lowest-observed-adverse-effect level; M = male; min = minute(s); NOAEL = no-observed-adverse-effect level; NS = not specified; Resp = respiratory; wk = week(s); yr = year(s) 
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Figure 3-1 Levels of Significant Exposure to Phenol - Inhalation
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Ksylamit™ is indicated to consist of “...a mixture of chlorinated benzenes, pentachlorophenol, 
alpha-chloronaphthalene, chloroparaffin and kerosene...”, and that the authors provide no discussion of
how phenol and formaldehyde are produced through the use of such a mixture.  Twenty-two workers
(18 women and 4 men) exposed for at least 6 months were the cases, and 29 non-exposed, nonsmoking
volunteers matched for age, sex, and place of residence were the controls.  The investigators indicate that
all exposed workers developed chronic complaints, among them cough and sore throat, but that no 
remarkable increase in morbidity was found during the 6 months of exposure to Ksylamit™ nor during
the 3-year follow-up study (details of which were not provided).  The investigators attribute these
symptoms to the irritant effect of the inhaled Ksylamit™ probably (based on the references provided) due
to the formaldehyde vapor they assert emanates from the wood-preserving liquid.
In laboratory animals, phenol is a respiratory irritant.  De Ceaurriz et al. (1981) reported a dose-response 
function for reflex apnea, an index of respiratory irritation, in mice exposed to phenol vapor.  From the
log dose-response function for decreased breathing rate, the RD50 (RD designates respiratory depression), 
or level of phenol in air that resulted in a 50% decrease in breathing rate during a 5-minute head-only
exposure, was established as 166 ppm.  Based on the RD50, the study authors estimated that a
concentration of 17 ppm (0.1xRD50) would be a LOAEL for respiratory irritation in humans, and a
concentration of 2 ppm (0.01xRD50) would be a NOAEL.
In a study in which female Harlan Wistar rats were exposed for 1 hour to a phenol aerosol at a
concentration of 234 ppm, then held for 2 weeks postexposure, Flickinger (1976) observed signs of nasal
irritation during exposure.  However, all animals exhibited normal behavior by postexposure day 1, and 
no abnormal lesions were observed upon gross autopsy.  No histopathology was performed; thus, this
study is not presented as a LOAEL for rats.  A more recent study in which rats were exposed 
intermittently nose-only to up to 25 ppm phenol for 2 weeks found no significant gross or microscopic 
alterations in the respiratory tract, including the nasal turbinates (Hoffman et al. 2001).  
Inflammation, cellular infiltration, pneumonia, bronchitis, endothelial hyperplasia, and capillary
thrombosis occurred in guinea pigs exposed by inhalation to 26–52 ppm phenol for 41 days (Deichmann 
et al. 1944).  Rabbits exhibited qualitatively similar but less severe effects after 88 days of similar
exposure.  Rats exposed similarly showed no gross or microscopic alterations in the respiratory tract.
Since only a range was given for the exposure level (26–52 ppm), the exact level of phenol in air that
resulted in respiratory effects was not established and may be as low as 26 ppm or as high as 52 ppm.  
Interpretation of this study is further complicated by an apparent lack of controls. However, the lung
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pathology was so severe, particularly in the guinea pigs, that it is difficult to ascribe the effects to any
source other than the phenol exposure.  The lower limit of the exposure range, 26 ppm, can be considered 
a LOAEL for respiratory effects in guinea pigs and rabbits and a NOAEL for rats. 
No significant histological abnormalities of the lungs were detected in Rhesus monkeys, rats, or mice 
exposed to 5 ppm phenol continuously for 90 days (U.S. Air Force 1961).
Cardiovascular Effects. In a cohort mortality study of workers in a large rubber and tire
manufacturing plant, Wilcosky and Tyroler (1983) found a significant increase in mortality from ischemic
heart disease in phenol exposed workers.  Of the 25 solvents used in the plant, phenol exposure showed 
the strongest association with mortality from heart disease, greater even than that observed for exposure
to carbon disulfide, the only known occupational cause of atherosclerosis.
In a cohort-mortality study of workers from five phenol-formaldehyde resin plants, Dosemeci et al. 
(1991) found a slight reduction in mortality due to heart disease.  These investigators hypothesized a
protective effect of phenol exposures; however, these results clearly conflict with those of Wilcosky and 
Tyroler (1983).  As a consequence, without more definitive studies, it is difficult to assess the
cardiovascular risk to humans, if any, posed by occupational exposure to phenol.
Myocardial injury was reported in guinea pigs exposed to 26–52 ppm for 41 days, rabbits exhibited
qualitatively similar but less severe effects after 88 days of similar exposure, and rats showed no 
significant alterations after 54 exposures (Deichmann et al. 1944).  The injury was characterized by
myocardial inflammation, degeneration, and necrosis, interstitial fibrosis, and lymphocyte infiltration.  
Since only a range was given for the exposure level (26–52 ppm), the exact level of phenol in air that
resulted in myocardial injury was not established and may be as low as 26 ppm or as high as 52 ppm.  
Interpretation of this study is further complicated by an apparent lack of controls. However, the heart
pathology was so severe that it is difficult to ascribe the effects to any source other than the phenol
exposure.  The lower limit of the exposure range, 26 ppm, can be considered a LOAEL for myocardial
injury in guinea pigs and rabbits and a NOAEL for rats.
Gastrointestinal Effects. Historical information in a case report (Merliss 1972) indicates that
‘carbol marasmus’ was a common occupational disorder of physicians and their assistants during the mid­
19th Century when carbolic acid sprays (1:40 phenol in water) were commonly used for antisepsis in 
operating rooms.  Among the characteristics of this disorder was anorexia leading to progressive weight
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loss and excess production of saliva.  Similar gastrointestinal effects were observed in one of the author’s 
patients who was involved in the daily distillation of phenol over a 13.5-year period.  Exposed both via
inhalation of the vapors and dermally from frequent spills, the patient’s symptoms included both loss of
appetite and weight loss.
A cohort mortality study of workers in five phenol-formaldehyde resin manufacturing plants found that
exposed workers showed a slight reduction in death rate due to cancers of the digestive system as 
compared to both non-exposed workers and the general population (Dosemeci et al. 1991). 
In a study of rats exposed continuously for 15 days to 26 ppm phenol vapor, Dalin and Kristoffersson
(1974) noted the absence of alterations in the digestive system and attributed this to the relatively low
exposure levels (as compared to studies using oral dosing), but no further discussion was provided.
Hematological Effects. A case-control study of office workers was conducted by Baj et al. (1994) to 
evaluate the risks of chronic exposures to “inhaled formaldehyde, phenol and isomers of organic chloro­
hydrocarbons from Ksylamit™” which is a widely used liquid wood preservative.  It should be noted that
in the report, Ksylamit™ is indicated to consist of “a mixture of chlorinated benzenes, pentachlorophenol, 
alpha-chloronaphthalene, chloroparaffin and kerosene,” and that the authors provide no discussion of how
phenol and formaldehyde are produced through the use of such a mixture.  Twenty-two workers
(18 women and 4 men) exposed for at least 6 months were the cases, and 29 non-exposed, nonsmoking
volunteers matched for age, sex, and place of residence were the controls.  Using blood and urine samples
drawn after 6 months of exposure, cases and controls were compared on a variety of biochemical, 
hematological, and immunological parameters.  The exposed group showed no differences in any of the
blood chemistry parameters examined, serum bilirubin, alanine, and aspartate aminotransferase activity, 
but had about a 30% increase in eosinophils, a 25% increase in monocytes, and a 70% decrease in 
erythrocytes.  Measurement of the office air at the end of the 6-month period revealed a level of phenol of
0.34 ppm.  Although the authors contend that their observations support the concern that chronic exposure
to phenol could adversely affect the hematopoietic system, it is important to consider not only that other
volatile chemicals, chlorinated organics, were present in the wood-preserving liquid, but also that the
chemical composition provided for Ksylamit™ opens up the possibility that the effects being evaluated 
result from exposure to pentachlorophenol rather than to phenol.  This is particularly true since it was not
possible to determine from the information presented if the analytical methods used would differentiate
between phenol and pentachlorophenol.
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Workers (n=20) at an oil-refining plant in Egypt exposed to a time-weighted mean concentration of
5.4 ppm of phenol in air for a mean exposure period of 13.15 years showed small but significant increases 
in hemoglobin, hematocrit, mean corpuscular hemoglobin, and mean corpuscular volume, but red blood 
cell counts were not significantly altered relative to a group of 30 unexposed controls (Shamy et al. 1994). 
Other small, but significant changes relative to controls included increased basophils and neutrophils, 
decreased monocytes, and increased clotting time.
Hematocrit and hemoglobin concentrations were not affected in rats exposed to 26 ppm phenol in air
continuously for 15 days (Dalin and Kristoffersson 1974).  Detailed hematological evaluations including
red and white blood cell, reticulocyte, and platelet counts; white cell differential; hemoglobin and 
sulfhemoglobin, and red cell fragility tests, as well as corpuscular volume, corpuscular hemoglobin, and 
corpuscular hemoglobin concentrations, did not reveal any effects in Rhesus monkeys, rats, or mice 
exposed continuously to 5 ppm phenol in air for 90 days (U.S. Air Force 1961).  Comprehensive
hematology testing of rats exposed nose-only to up to 25 ppm of phenol 6 hours/day, 5 days/week for 
2 weeks showed no significant exposure-related deviations from control values (Hoffman et al. 2001).
Musculoskeletal Effects. A case of muscle pain and weakness was described in an individual after
intermittent chronic inhalation and dermal exposure to vapors and solutions of phenol, cresol, and xylenol
for >10 years (Merliss 1972).  The symptoms lessened when the subject was removed from exposure.  
Although the exposure concentrations were not reported, the study author stated that the patient often
detected heavy odors, and that phenol was often spilled on his clothes resulting in skin irritation.  Since
phenol is absorbed readily from the skin, dermal absorption of phenol may have contributed to the
systemic effects that were observed.  The above symptoms may represent neurological effects rather than 
injury to the muscle tissue.
Hepatic Effects. Enlarged liver and elevated serum levels of hepatic enzymes indicative of liver
injury (lactate dehydrogenase, 2 times above normal; aspartate aminotransferase (AST), 21 times above 
normal; alanine aminotransferase (ALT), 100 times above normal) were observed in an individual
following chronic daily exposure to vapors and spills of phenol for >10 years (Merliss 1972).  The
symptoms lessened when the individual was removed from the site of exposure.  Although the exposure
concentrations were not reported, the study author stated that the patient often detected heavy odors and 
that phenol was often spilled on his clothes resulting in skin irritation.  Since phenol is absorbed readily
from the skin, dermal absorption may have contributed to the systemic effects that were observed.  A 
study of 20 workers at an oil-refining plant in Egypt exposed to a time-weighted average concentration of
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phenol of 5.4 ppm for a mean exposure duration of 13.15 years found small, but significant increases in 
ALT and AST activities (approximately 65 and 54%, respectively) in serum collected at the end of the
shift of the last working day of the week relative to 30 unexposed controls (Shamy et al. 1994).
No effects on activities of liver enzymes (ALT, AST, γ-glutamyltranspeptidase, alkaline phosphatase) in 
the serum or changes in serum bilirubin or ceruloplasmin were noted in 22 workers exposed for 6 months
to vapors from a wood-treatment liquid containing phenol, formaldehyde, and organic chlorohydro­
carbons (Baj et al. 1994). Although the study authors considered a significant increase in serum iron to 
reflect an adverse effect on the liver that they attributed to phenol exposure, it is important to consider not
only that other volatile chemicals, chlorinated organics, were present in the wood-preserving liquid, but
also that the chemical composition provided for Ksylamit™ opens up the possibility that the effects being
evaluated result from exposure to pentachlorophenol rather than phenol.  Dosemeci et al. (1991) saw a
dose-related decrease in mortality from liver cirrhosis in a cohort of workers occupationally exposed to 
phenol during their employment at five phenol-formaldehyde resin plants. These findings are 
complicated by the fact that workers were also exposed to other chemicals; however, the authors 
hypothesize that exposure to phenol could have a protective effect for diseases involving free radical
damage.  
Centrilobular degeneration and necrosis of the liver were reported in guinea pigs exposed intermittently
by inhalation to 26–52 ppm phenol for 41 days, rabbits exhibited qualitatively similar but less severe 
effects after 88 days of similar exposure, whereas rats showed no significant alterations after 54 exposures
(Deichmann et al. 1944).  Since only a range was given for the exposure level (26–52 ppm), the exact
level of phenol in air that resulted in hepatic injury was not established and may be as low as 26 ppm or as
high as 52 ppm.  Interpretation of this study is further complicated by an apparent lack of controls.  
However, the liver pathology was so severe, particularly in the guinea pigs, that it is difficult to ascribe
the effects to any source other than the phenol exposure.
Elevated activities of liver enzymes (lactate dehydrogenase, AST, ALT, glutamate dehydrogenase) were 
found in the serum of rats exposed continuously to 26 ppm phenol vapor for 15 days (Dalin and 
Kristoffersson 1974).  Increased concentration of these enzymes in serum is often associated with liver
injury, but is not conclusive evidence for the type or severity of injury.  Therefore, 26 ppm can be
considered a less serious LOAEL in rats.  Serum levels of magnesium were also increased in these rats, an
effect the study authors suggested may also be a sign of liver injury.  In a more recent study, rats exposed 
nose-only to up to 25 ppm of phenol 6 hours/day, 5 days/week for 2 weeks showed no evidence of liver
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effects as monitored by clinical chemistry tests and histopathological examination of the liver (Hoffman 
et al. 2001). No significant histological abnormalities were detected in the livers of Rhesus monkeys, 
rats, or mice exposed continuously to 5 ppm phenol in air for 90 days (U.S. Air Force 1961).
Renal Effects. In a case of chronic phenol poisoning, dark urine and glucose in the urine were noted 
in a man following intermittent exposure to vapors and solutions of phenol (Merliss 1972).  The urine
tested negative for protein and urobilinogen.  The urine cleared 2–3 months after removal from exposure.  
Although the exposure concentrations were not reported, the study author stated that heavy odors were
often detectable, and that phenol was often spilled on the patient’s clothes resulting in skin irritation.  
Since phenol is absorbed readily from the skin, dermal absorption may have contributed to the systemic
effects that were observed.
Renal proximal tubule and glomerular injury was reported in guinea pigs exposed intermittently by
inhalation to 26–52 ppm phenol for 41 days, and rabbits exhibited qualitatively similar but less severe 
effects after 88 days of similar exposure; rats exposed similarly for 54 days showed no significant effects
(Deichmann et al. 1944).  Since only a range was given for the exposure level (26–52 ppm), the exact
level of phenol in air that resulted in renal injury was not established and may be as low as 26 ppm or as 
high as 52 ppm.  Interpretation of this study is further complicated by an apparent lack of controls.  
However, the kidney pathology was so severe, particularly in the guinea pigs, that it is difficult to ascribe
the effects to any source other than the phenol exposure.  The lower limit of the exposure range, 26 ppm, 
can be considered a LOAEL for renal injury in guinea pigs and rabbits.  No significant histological
abnormalities were detected in the kidneys of Rhesus monkeys, rats, or mice exposed continuously to 
5 ppm phenol in air for 90 days (U.S. Air Force 1961). No kidney pathology was reported in a study in 
rats exposed intermittently nose-only to up to 25 ppm of phenol for 2 weeks (Hoffman et al. 2001);
specific end points monitored included kidney histopathology, blood urea nitrogen (BUN), and serum
creatinine and electrolytes.
Dermal Effects. Historical information in a case report (Merliss 1972) indicates that ‘carbol
marasmus’ was a common occupational disorder of physicians and their assistants during the mid-19th 
Century.  Among the characteristics of this disorder was an odd form of pigmentation, which commonly
occurred in the urine, but also occasionally colored the sclera of the eyes, the skin over the nose, and the
cheek bones.  NIOSH (1983) conducted a survey in an Oregon hospital in response to concerns about
respiratory problems and contact dermatitis in housekeeping staff members who were exposed frequently
to germicidal solutions containing phenol and other solvents (formaldehyde, cellosolve, ethanolamine).  
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According to the survey, the housekeeping staff reported significantly more symptoms of cough, itching, 
sinus problems, and dermatitis than other employees.  Air concentrations of phenol in the work areas were 
below the limit of detection (<0.01 ppm).  Urinary phenol levels in housekeeping staff were not
significantly different from those of other employees.  Thus, while it is likely that the employees came 
into contact with irritants, the cause of the reported symptoms could not be assigned to phenol or any
other specific substance in the work environment.
No studies were located regarding dermal effects in animals following inhalation exposure to phenol.
Ocular Effects. A case-control study of office workers was conducted by Baj et al. (1994) to evaluate
the risks of chronic exposures to “inhaled formaldehyde, phenol and isomers of organic
chlorohydrocarbons from Ksylamit™” which is a widely used liquid wood preservative reported to
consist of “a mixture of chlorinated benzenes, pentachlorophenol, alpha-chloronaphthalene, 
chloroparaffin, and kerosene.” Twenty-two workers (18 women and 4 men) exposed for at least 6 months
were the cases, and 29 non-exposed, nonsmoking volunteers matched for age, sex, and place of residence 
were the controls.  The authors indicate that all of the exposed workers developed chronic complaints, 
among them burning eyes, but that no remarkable increase in morbidity was found during the 6 months of
exposure to Ksylamit™, nor during the 3-year follow-up study (details of which were not provided).  The
authors attribute these symptoms to the irritant effect of the inhaled Ksylamit™ probably (based on the
references provided) due to the formaldehyde vapor they assert emanates from the wood-preserving
liquid.
In a study in which female Harlan Wistar rats were exposed for 1 hour to a phenol aerosol at a
concentration of 234 ppm, then held for 2 weeks postexposure, Flickinger (1976) observed signs of ocular
irritation during exposure.  However, all animals were normal by postexposure day 1, and no abnormal
lesions were observed upon gross autopsy.
Body Weight Effects. Historical information in a case report (Merliss 1972) indicates that ‘carbol
marasmus’ was a common occupational disorder of physicians and their assistants during the mid-19th 
Century.  Among the characteristics of this disorder were anorexia accompanied by progressive weight
loss. The author reported that his patient, a 44-year-old man involved in the daily distillation of phenol, 
showed many of the symptoms of this condition, including lack of appetite and severe weight loss, 
probably due to his daily workplace exposures to phenol vapors.  Although the exposure concentrations
were not reported, the report indicated that the patient often detected heavy odors, and that phenol was 
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often spilled on his clothes resulting in skin irritation.  Since phenol is absorbed readily from the skin, 
dermal absorption may have contributed to the systemic effects that were observed.
Body weight effects were not observed in adult female Harlan Wistar rats exposed to an aerosol
containing 234 ppm phenol for 8 hours (Flickinger 1976), in rats exposed continuously to 26 ppm phenol
in air for 15 days (Dalin and Kristoffersson 1974), in Rhesus monkeys, rats, or mice exposed 
continuously to 5 ppm phenol in air for 90 days (U.S. Air Force 1961), or in rats exposed intermittently
nose-only for 2 weeks to up to 25 ppm of phenol vapor (Hoffman et al. 2001).
Metabolic Effects. Dalin and Kristoffersson (1974) reported elevated serum concentrations of
potassium and magnesium in rats exposed to 26 ppm phenol vapor continuously for 15 days.  While not
necessarily adverse, this effect may be related to the muscle tremors and neurological effects observed 
following inhalation exposure to phenol (see Section 3.2.1.4).  No further information was located 
regarding metabolic effects of inhaled phenol in animals.
3.2.1.3  Immunological and Lymphoreticular Effects
A case-control study of office workers was conducted by Baj et al. (1994) to evaluate the risks of chronic
exposures to “inhaled formaldehyde, phenol and isomers of organic chlorohydrocarbons from
Ksylamit™” which is a widely used liquid wood preservative. Twenty-two workers (18 women and 
4 men) exposed for at least 6 months were the cases, and 29 non-exposed, nonsmoking volunteers
matched for age, sex, and place of residence were the controls.  Using blood samples drawn after
6 months of exposure, cases and controls were compared on a variety of immunological parameters.  The
exposed group showed significantly decreased (p<0.05) levels of the CD3+, CD4+, and CD8+ subsets of
T-lymphocytes, a significant decrease (p<0.001) in lymphocyte responsiveness to the mitogen 
phytohemagglutinin (PHA), a significant decrease (p<0.05) in natural killer (NK) cell cytotoxicity, and a
significant decrease (p<0.0001) in the mixed lymphocyte response assay.  Measurement of the office air
at the end of the 6-month period revealed a level of phenol of 0.34 ppm.  Although the authors contend 
that their observations support the concern that chronic exposure to phenol could adversely affect the
immune system, it is important to consider not only that other volatile chemicals, chlorinated organics, 
were present in the wood-preserving liquid, but also that the chemical composition provided for
Ksylamit™ opens up the possibility that the effects being evaluated resulted from exposure to 
pentachlorophenol rather than phenol.  This is particularly true since it was not possible to determine from
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the information presented if the analytical methods used would differentiate between phenol and 
pentachlorophenol.
An increased susceptibility to Streptococcus zooepidemicus aerosol was not observed in mice exposed to 
5 ppm phenol for 3 hours, or for 5 daily 3-hour periods (Aranyi et al. 1986).  Neither did the phenol
exposures affect pulmonary bactericidal activity towards Klebsiella pneumonia. Although tests for
vulnerability to infectious agents do not represent a comprehensive evaluation of immunological
competence, the 5-ppm level can be considered a NOAEL for this specific immunological effect, and is
recorded in Table 3-1 and plotted in Figure 3-1.  Gross and microscopic examination of the spleen of rats
exposed nose-only to up to 25 ppm phenol intermittently for 2 weeks did not reveal any significant
exposure-related alterations (Hoffman et al. 2001).  This exposure concentration is listed as a NOAEL for
lymphoreticular effects in Table 3-1. 
3.2.1.4  Neurological Effects 
Historical information in a case report (Merliss 1972) indicates that ‘carbol marasmus’ was a common 
occupational disorder of physicians and their assistants during the mid-19th Century.  Among the
characteristics of this disorder were anorexia, headache, and vertigo.  The author reported that his patient, 
the subject of the case report, showed many of the symptoms of this condition, although his chief
complaints were weakness and muscle pain in his arms and legs, progressive weight loss, and excess 
production of saliva.  The symptoms lessened when the subject was removed from the site of exposure.  
Although it is possible that these symptoms resulted from injury to the muscle, it is more likely that they
represent a neurological effect.  No information on exposure concentrations was presented; however, the
report indicated that the patient often detected heavy odors and that phenol was often spilled on his
clothes resulting in skin irritation.  Since phenol is absorbed readily from the skin, dermal absorption may
have contributed to the systemic effects that were observed.
A case-control study of office workers was conducted by Baj et al. (1994) to evaluate the risks of chronic
exposures to “inhaled formaldehyde, phenol and isomers of organic chlorohydrocarbons from
Ksylamit™” which is a widely used liquid wood preservative.  Twenty-two workers (18 women and 
4 men) exposed for at least 6 months were the cases, and 29 non-exposed, nonsmoking volunteers 
matched for age, sex, and place of residence were the controls. The workers complained of a variety of 
chronic symptoms, among them headache and fatigue.  Measurement of the office air at the end of the
6 month period revealed a level of phenol of 0.34 ppm.  Although these symptoms could be a sign that
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chronic inhalation exposure to phenol could adversely affect the neurological system, it is important to 
consider not only that other volatile chemicals, chlorinated organics, were present in the wood-preserving
liquid, but also that the chemical composition provided for Ksylamit™ opens up the possibility that the
effects being evaluated resulted from exposure to pentachlorophenol rather than phenol.  This is
particularly true since it was not possible to determine from the information presented if the analytical
methods used would differentiate between phenol and pentachlorophenol.
Female Harlan Wistar rats exposed for 1 or 8 hours to 234 ppm phenol delivered in an aerosol
demonstrated no neurological effects at 1 hour, a slight loss of coordination with spasm of the muscle
groups at 4 hours, and frank tremors leading to a severe loss of coordination by 8 hours (Flickinger 1976).  
All animals were normal by postexposure day 1, and no abnormal lesions were observed upon gross
autopsy performed at the end of a 14-day observation period.  These exposure levels are recorded in 
Table 3-1 and are plotted in Figure 3-1 as a NOAEL, a less serious LOAEL, and a serious LOAEL.
Rats exposed continuously to 26 ppm showed numerous symptoms and signs of neurological impairment, 
including muscle tremors, twitching, and disturbances in walking rhythm and posture during the first 3– 
5 days of exposure, and impaired performance (4.4° decrease in sliding angle) on a tilting plane test after
15 days of exposure (Dalin and Kristoffersson 1974).  These effects are indicative of neurological
impairment.  Because the tremors did not last during the whole exposure period, the effects were not
considered severe.
Hindlimb paralysis was reported in guinea pigs exposed to 26–52 ppm phenol for 41 days (Deichmann et
al. 1944).  Rabbits and rats exhibited no overt neurological effects after 88 and 74 days of similar
exposure, respectively.  Since only a range was given for the exposure level (26–52 ppm), the exact level
of phenol in air that resulted in hindlimb paralysis was not established and may be as low as 26 ppm or as
high as 52 ppm.  Interpretation of this study is further complicated by an apparent lack of controls.  
However, the neurological effect was so severe in the guinea pigs that it is difficult to ascribe the effects 
to any source other than the phenol exposure.  The lower limit of the exposure range, 26 ppm, is recorded 
in Table 3-1 and plotted in Figure 3-1 as a LOAEL for serious neurological effects in guinea pigs.  Since
the presence or absence of overt neurological effects such as paralysis is not a sensitive end point for
detecting neurological effects, 26–52 ppm is not considered a reliable NOAEL for neurological effects in 
rats and rabbits.  
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3. HEALTH EFFECTS
There are several differences in the experimental designs of the Dalin and Kristoffersson (1974) and 
Deichmann et al. (1944) studies that may account for the different results regarding neurological effects in
rats.  Dalin and Kristoffersson (1974) reported subtle effects that may have been overlooked in the
Deichmann et al. (1944) study.  Furthermore, Dalin and Kristoffersson (1974) subjected the rats to a
specific test for neurological impairment, the tilting plane test.  Although exposure concentrations were
the same in both studies, Dalin and Kristoffersson (1974) exposed rats continuously, while Deichmann et
al. (1944) exposed rats intermittently.  Because phenol is metabolized quite rapidly (see Section 3.4.3), 
rats exposed intermittently may not develop neurological effects.
Histopathological changes in the brain were not observed in Rhesus monkeys, rats, or mice exposed 
continuously to 5 ppm phenol in air for 90 days (U.S. Air Force 1961).
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species for acute and intermediate-duration exposure are recorded in Table 3-1 and plotted in 
Figure 3-1.
3.2.1.5  Reproductive Effects
The only relevant information located is that from a retrospective study of pregnancy outcome among
university laboratory employees in Sweden (Axelsson et al. 1984).  No significant increase in the rate of
miscarriage was found in a group of 576 women exposed to organic solvent relative to 576 unexposed 
pregnancies.  Specific mention of phenol was reported in only five cases, all of which were normal
deliveries.  No relevant information was found in animal inhalation studies.
3.2.1.6  Developmental Effects 
Neither perinatal death rates nor prevalence of malformations were significantly increased in the study of 
laboratory workers conducted by Axelsson et al. (1984) mentioned above.  An abstract by Hernberg et al.
(1983) on data from personal interviews of 1,047 Finnish mothers exposed to disinfectants (including
phenol) during early pregnancy did not indicate significant associations between exposure to disinfectants
and the occurrence of congenital defects.  No further relevant information in humans was located.  No 
developmental inhalation studies in animals were located.   
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3. HEALTH EFFECTS
3.2.1.7  Cancer
In a nested case-control study of cancers associated with chemical exposures in the wood industry, 
Kauppinen et al. (1986) found a significantly increased risk of respiratory system cancer associated with 
exposure to phenol and phenol in wood dust.  As is often the case in occupational settings, these
exposures were confounded by smoking and exposures to other materials like pesticides; in addition, 
information on direct phenol measurements was not provided.  The increased risk observed for exposure
to phenol was almost 5-fold (odds ratio of 4.94), but showed no dose-related increase.  This risk dropped 
to 4-fold with adjustments for smoking history, and <3-fold (and non-significant) when workers exposed 
to both phenols and pesticides were excluded from the analysis.
Similar to the findings of Kauppinen et al. (1986), a large (14,861) cohort mortality study of workers in 
the phenol-formaldehyde resin manufacturing industry found nondose-related increases in the risk of 
several respiratory system cancers in workers exposed to phenol (Dosemeci et al. 1991).  The authors 
develop a semiquantitative exposure assessment by assigning exposure levels (none, low, medium, and 
high) to each job category.  The increased risks were small; for instance, for cancer of the larynx or lung, 
standard mortality ratios (SMRs) of 1.1 were less than those found for non-exposed workers.  For a
number of other cancers, including those of the esophagus, rectum, bladder, kidney, and Hodgkin’s
disease, the SMRs found for phenol-exposed workers were slightly elevated, but none of the increases 
were statistically significant when compared with those in the general population.  Furthermore, none of
these increases had dose-response relationships with cumulative exposure to phenol.
No studies were located regarding cancer in animals following inhalation exposure to phenol.
3.2.2 Oral Exposure
3.2.2.1  Death 
There have been numerous reports of suicide or suicide attempts involving ingestion of large amounts of
phenol.  However, the lack of accurate documentation of dose levels in these cases makes it difficult to 
identify a minimal dose at which lethality occurs.  Deichmann and Keplinger (1981), in summarizing the
literature, indicated that an oral dose as low as 1 g could be fatal in humans, but that occasionally patients
had survived doses as high as 65 g.  Assuming that these patients were male with an average weight of
70 kg, the lower limit on the dose for death would be 14 mg/kg and the upper limit would be
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3. HEALTH EFFECTS
approximately 930 mg/kg.  In a review of the toxicology of phenol, Bruce et al. (1987) summarized 
human oral lethality data from numerous case reports and estimated 140 mg/kg to be the minimal dose at
which death occurs.  Stajduhar-Caric (1968) reported a case in which a woman ingested ≈10–20 g of
phenol and died within hours.  The lower limit of the ingested dose was converted to 172 mg/kg, 
assuming a 58 kg body weight, to derive a dose for death, which is recorded in Table 3-2 and plotted in 
Figure 3-2.  Boatto et al. (2004) described the case of a male who ingested a solution containing phenol
and cresol and died approximately 30 minutes after ingestion.  Toxicology tests revealed that the stomach 
content, blood, and urine of the individual contained 115.0, 58.3, and 3.3 μg/mL of phenol, respectively.  
Similar blood concentrations (56–130 μg/mL) were measured in fatal cases reported by Tanaka et al. 
(1998), Soares and Tift (1982), and Lo Dico et al. (1989).
The oral LD50 has been determined in rats treated by gavage with phenol in water; the LD50 was found to 
decrease with increasing concentration of phenol in the gavage fluid.  The reported LD50 values were 
340 mg/kg in rats gavaged with a solution of 200,000 ppm phenol and 530 mg/kg in rats gavaged with a
solution of 20,000 ppm phenol (Deichmann and Witherup 1944).  After rats were treated by gavage with 
600 mg/kg in a 5% solution, 9 of 30 5-week-old rats, 18 of 20 10-day-old rats, and 12 of 20 adult rats died 
indicating that the 10-day-old rat is more sensitive to phenol than rats in the other age groups tested 
(Deichmann and Witherup 1944).  In pregnant rats treated on gestation days (GDs) 6–15, 7 of 10 rats died 
at a dose of 125 mg/kg/day when treated with a volume of 1 mL/kg, while 1 of 6 rats died at a dose of
160 mg/kg/day when treated with a volume of 5 mL/kg (NTP 1983a).  In a 1-day dosing regimen study, 
female rats were given 0, 12, 40, 120, or 224 mg/kg in order to determine a single-dose oral LD50 of
400 mg/kg (Berman et al. 1995).  Mortality was observed only at the highest dose where two of eight rats
treated died.  All female rats treated for 14 days with a dose of 120 mg/kg/day died (Berman et al. 1995;
Moser et al. 1995).  In a 14-day dosing regimen with the same doses (except the 224 mg/kg), all animals
died at the dose of 120 mg/kg.
The oral LD50 of phenol has been estimated as 300 mg/kg in mice (von Oettingen and Sharpless 1946).  
Five of 10 rabbits treated with an oral dose of 420 mg/kg died (Deichmann and Witherup 1944).  In 
pregnant mice treated on GDs 6–15, four of 35 mice died at a dose of 280 mg/kg/day (NTP 1983b).
Flickinger (1976) gave male Harlan-Wistar albino rats single doses of 0, 200, 398, 795, and 1,580 mg/kg
phenol by gavage and held the animals for 14 days postdosing in order to determine an oral LD50. No 
animals died following the 0, 200, or 398 mg/kg doses; four of five animals died the first day following
059
172
115
400
119
120
073
340
166
125
100
280
104
300
075
420
Table 3-2 Levels of Significant Exposure to Phenol - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Human once 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
172 F (death) 
Reference 
Chemical Form 
Stajduhar-Caric 1968 
Comments 
2 Rat 
(Fischer- 344) 
once 
(GW) 
400 F (LD50) Berman et al. 1995 
3 Rat 
(Fischer- 344) 
14 d 
1 x/d 
(GW) 
120 F (8/8 died) Berman et al. 1995 Dosing volume was 1 
mL/kg. 
4 Rat 
(Wistar) 
once 
(GW) 
340 (LD50) Deichmann and Witherup 1944 
5 Rat 
(CD) 
10 d 
Gd 6-15 
1 x/d 
(GW) 
125 F (7/10 maternal deaths) NTP 1983a Dosing volume was 1 
mL/kg. 
6 Mouse 
(CD-1) 
10 d 
Gd 6-15 
1 x/d 
(GW) 
280 F (4/35 maternal deaths) NTP 1983b Dosing volume was 10 
mL/kg. 
7 Mouse 
(NS) 
once 
(GO) 
300 M (5/10 deaths) Von Oettingen and Sharpless 
1946 
8 Rabbit 
(White) 
once 
(GW) 
420 (5/10 deaths) Deichmann and Witherup 1944 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
46
117
224
120
224
120
224
224
120
40
12
40
40
40
195
40
40
Table 3-2 Levels of Significant Exposure to Phenol - Oral	 (continued) 
Exposure/ 
Duration/ 
a 
Key to Species Frequency 
Figure (Strain) (Route) 
P
H
E
N
O
L
Systemic 
9 Rat once 
(Fischer- 344) (GW) 
10 Rat	 14 d 
1 x/d(Fischer- 344) 
(GW) 
11 Rat	 14 d 
Gd 6-19(Fischer- 344) 
(GW) 
System 
Hepatic
 
Renal
 
Endocr
 
Bd Wt
 
Hepatic
 
Renal 
Endocr 
Bd Wt 
Resp 
Bd Wt 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
224 F Berman et al. 1995 Dosing volume was 1 
mL/kg. 
120 F 224 F (renal tubular necrosis, 
protein casts, papillary 
hemorrhage) 
120 F 224 F (unspecified changes in 
the adrenal gland) 
224 F 
40 F Berman et al. 1995 Dosing volume was 1 
mL/kg. 
12 F 40 F (renal tubular necrosis, 
protein casts, papillary 
hemorrhage in 3/8) 
40 F 
40 F 
40 F (dyspnea, rales) Narotsky and Kavlock 1995 Dosing volume was 1 
mL/kg. 
40 F (20% decrease in 
maternal body weight 
gain) 
3.  H
E
A
LTH
 E
FFE
C
TS
47
168
120
120
257
60
120
140
265
171
280
140
280
118
120
224
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
12 Rat 
(CD) 
10 d 
Gd 6-15 
1 x/d 
(GW) 
Hepatic 120 F NTP 1983a Dosing volume was 5 
mL/kg. 
Bd Wt 120 F 
13 Rat 
(Sprague-
Dawley) 
10 d 
Gd 6-15 
3 x/d 
(GW) 
Bd Wt 
b 
60 F 120 F (11% reduced maternal 
body gain on Gd 6-16) 
York 1997 Dosing volume was 10 
mL/kg. 
14 Mouse 
(Swiss CD-1) 
once 
Gd 13 
(GW) 
Hemato 265 F (30-60% reduction in the 
ratio of poly/normo 
chromatic erythrocytes in 
the bone marrow of 
pregnant dams) 
Ciranni et al. 1988 
15 Mouse 
(CD-1) 
10 d 
Gd 6-15 
1 x/d 
(GW) 
Hepatic 280 F NTP 1983b Dosing volume was 10 
mL/kg. 
Bd Wt 140 F 280 F (67% decrease in 
absolute maternal body 
weight gain) 
Immuno/ Lymphoret 
16 Rat 
(Fischer- 344) 
once 
(GW) 
120 F 224 F (necrosis or atrophy of 
the spleen or thymus) 
Berman et al. 1995 Dosing volume was 1 
mL/kg. 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
48
121
40
105
207
190
40
120
193
12 40
101
70
140 280
196
40
53.3
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
17 Rat 
(Fischer- 344) 
14 d 
1 x/d 
(GW) 
Berman et al. 199540 F NOAEL is for weight 
and histopathology of 
the spleen. 
Neurological 
18 Rat 
(Sprague-
Dawley) 
once 
(G) 
Liao and Oehme 1981207 M (muscle twitching, 
convulsions, coma) 
Dosing volume not 
reported. 
19 Rat 
(Fischer- 344) 
once 
(GW) 
Moser et al. 199540 F 120 F (mild-to-severe 
whole-body tremors, 
decreased motor activity) 
Dosing volume was 1 
mL/kg. 
20 Rat 
(Fischer- 344) 
14 d 
1 x/d 
(GW) 
Moser et al. 199512 F 40 F (increased rearing) Dosing volume was 1 
mL/kg. 
21 Mouse 
(CD-1) 
10 d 
Gd 6-15 
1 x/d 
(GW) 
Developmental 
22 Rat 
(Fischer- 344) 
14 d 
Gd 6-19 
(GW) 
NTP 1983b70 F 140 F (mild tremors on the first 
3 days of dosing) 
280 F (tremors, ataxia in 
pregnant dams) 
Narotsky and Kavlock 199540 F 53.3 F (significant decrease in 
the number of live-born 
pups, associated with 
severe respiratory effects 
in the dams) 
Dosing volume was 10 
mL/kg. 
Dosing volume was 1 
mL/kg. 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
49
103
60
120
254
120
360
046
140
280
Table 3-2 Levels of Significant Exposure to Phenol - Oral	 (continued) 
P
H
E
N
O
L
Exposure/ LOAEL 
Duration/ 
a FrequencyKey to Species	 NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
23 Rat 10 d 60 F 120 F (7% decrease in averageGd 6-15(CD) fetal body weight)1 x/d
 
(GW)
 
24 Rat 10 d 120 360 (decreased fetal weightGd 6-15(Sprague- and decrease ossification3 x/dDawley) sites)
(GW) 
25 Mouse 10 d 140 F	 280 FGd 6-15(CD-1) 
1 x/d
 
(GW)
 
(18% decreased fetal 
body weight, cleft palate 
8/214) 
Reference 
Chemical Form Comments 
NTP 1983a	 Dosing volume was 5 
mL/kg. 
York 1997	 Dosing volume was 10 
mL/kg. 
NTP 1983b	 Dosing volume was 10 
mL/kg. 
3.  H
E
A
LTH
 E
FFE
C
TS
50
198
1694
1694
1694
1694
1694
1694
1694
1694
467
508
1556 1694
251
321
321
321
Table 3-2 Levels of Significant Exposure to Phenol - Oral	 (continued) 
Exposure/ 
Duration/ 
a 
Key to Species Frequency 
Figure (Strain) (Route) 
P
H
E
N
O
L
INTERMEDIATE EXPOSURE 
Systemic 
26 Rat 13 wk 
ad lib(Fischer- 344) 
(W) 
27 Rat	 10 wk 
2-gen(Sprague-
ad libDawley) 
(W) 
System 
Resp 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Bd Wt 
Hemato 
Hepatic 
Renal 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
1694 F NCI 1980 NOAELs are for organ 
weight and 
histopathology. 
1694 F 
1694 F 
1694 F 
1694 F 
1694 F 
1694 F 
1694 F 
c 
467 M 
508 F 
1556 M (16% decrease in body 
weight gain associated 
with decreased water 
intake) 
1694 F (26% decrease in body 
weight gain associated 
with decreased water 
intake) 
321 F Ryan et al. 2001 NOAELs are for 
histopathology of liver 
and kidney. 
321 F 
321 F 
3.  H
E
A
LTH
 E
FFE
C
TS
51
161
33.6
33.6
1.8
33.6
33.6
33.6
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
28 Mouse 
(CD-1) 
28 d 
ad lib 
(W) 
Resp 33.6 M Hsieh et al. 1992 NOAELs are for 
histopathology. 
Cardio 33.6 M 
Hemato 1.8 M (32% decrease in RBC 
count) 
Hepatic 
Renal 
33.6 M 
33.6 M 
Bd Wt 33.6 M 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
52
203
2642
2642
2642
2642
2642
2642
2642
2642
741
2468
250
321
015
1.8
6.2
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
29 Mouse 
(B6C3F1) 
13 wk 
ad lib 
(W) 
Resp 2642 F NCI 1980 NOAELs are for organ 
weight and 
histopathology. 
Cardio 2642 F 
Gastro 2642 F 
Musc/skel 2642 F 
Hepatic 2642 F 
Renal 2642 F 
Endocr 2642 F 
Dermal 2642 F 
Bd Wt 741 M 2468 M (80% decrease in body 
weight gain associated 
with decreased water 
intake) 
Immuno/ Lymphoret 
30 Rat 
(Sprague-
Dawley) 
10 wk 
ad lib 
(W) 
321 F Ryan et al. 2001 NOAEL is for spleen 
and thymus histology 
and antibody 
production against 
immunization with 
SRBC. 
31 Mouse 
(CD-1) 
28 d 
ad lib 
(W) 
1.8 M 6.2 M (decreased antibody 
production response to 
SRBC) 
Hsieh et al. 1992 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
53
255
107
360
014
1.8
201
1556
1694
248
301
321
206
2468
2642
249
93
321
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Neurological 
32 Rat 
(Sprague-
Dawley) 
13 wk 
ad lib 
(W) 
Beyrouty 1998107 F 360 F (decreased motor activity 
on week 4) 
33 Mouse 
(CD-1) 
28 d 
ad lib 
(W) 
Hsieh et al. 19921.8 M (decreased levels of 
dopamine in the corpus 
striatum) 
Reproductive 
34 Rat 
(Fischer- 344) 
13 wk 
ad lib 
(W) 
NCI 1980
c 
1556 M 
1694 F 
NOAEL is for 
histopathology of 
reproductive organs. 
35 Rat 
(Sprague-
Dawley) 
10 wk 
2-gen 
ad lib 
(W) 
Ryan et al. 2001
c 
301 M 
321 F 
NOAEL is for P males 
sperm parameters and 
F1 reproductive organ 
histology. 
36 Mouse 
(B6C3F1) 
13 wk 
ad lib 
(W) 
NCI 1980
c 
2468 M 
2642 F 
NOAEL is for 
reproductive organ 
histopathology. 
Developmental 
37 Rat 
(Sprague-
Dawley) 
10 wk 
2-gen 
ad lib 
(W) 
Ryan et al. 200193 F 321 F (decreased pup weight 
and percent live on day 
4) 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
54
050
721
721
721
721
721
721
721
721
322
721
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
Exposure/ 
Duration/ 
a 
Key to Species Frequency 
Figure (Strain) (Route) 
P
H
E
N
O
L
CHRONIC EXPOSURE 
Systemic 
38 Rat 103 wk 
ad lib(Fischer- 344) 
(W) 
System 
Resp 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Bd Wt 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
721 F NCI 1980 NOAELs are for organ 
weight and 
histopathology. 
721 F 
721 F 
721 F 
721 F 
721 F 
721 F 
721 F 
c 
322 M (about 12% decrease in 
body weight associated 
with a 20% decrease in 
water intake) 
721 F (about 17% decrease in 
body weight associated 
with a 10% decrease in 
water intake) 
3.  H
E
A
LTH
 E
FFE
C
TS
55
212
1204
1204
1204
1204
1204
1204
1204
1204
1204
207
721
213
1204
208
721
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
Exposure/ 
Duration/ 
a 
Key to Species Frequency 
Figure (Strain) (Route) 
39 Mouse 103 wk 
(B6C3F1) ad lib 
(W) 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TSImmuno/ Lymphoret 
40 Rat 103 wk 
ad lib(Fischer- 344) 
(W) 
41 Mouse 103 wk 
(B6C3F1) ad lib 
(W) 
Neurological 
42 Rat 103 wk 
ad lib(Fischer- 344) 
(W) 
System 
Resp 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Endocr 
Dermal 
Bd Wt 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
1204 F NCI 1980 NOAELs are for organ 
weight and 
histopathology. 
1204 F 
1204 F 
1204 F 
1204 F 
1204 F 
1204 F 
1204 F 
1204 F 
721 F NCI 1980 NOAEL is for weight 
and histopathology of 
lymphoreticular organs 
and tissues. 
1204 F NCI 1980 NOAEL is for weight 
and histopathology of 
lymphoreticular organs. 
Immuno competence 
was not evaluated. 
721 F NCI 1980 NOAEL is for weight 
and histopathology of 
the brain. 
56
214
1204
209
721
215
1204
Table 3-2 Levels of Significant Exposure to Phenol - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
43 Mouse 
(B6C3F1) 
103 wk 
ad lib 
(W) 
1204 F NCI 1980 NOAEL is for weight 
and histopathology of 
the brain. 
Reproductive 
44 Rat 
(Fischer- 344) 
103 wk 
ad lib 
(W) 
721 F NCI 1980 NOAEL is for weight 
and histopathology of 
reproductive organs of 
males and females. 
Fertility was not 
assessed. 
45 Mouse 
(B6C3F1) 
103 wk 
ad lib 
(W) 
1204 F NCI 1980 NOAEL is for weight 
and histopathology of 
reproductive organs of 
males and females. 
Fertility was not 
assessed. 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
a The number corresponds to entries in Figure 3-2. 
b Used to derive an acute-duration oral MRL of 1 mg/kg/day; the MRL was derived by dividing the BMDL of 125 mg/kg/day by an uncertainty factor of 100 (10 for animal to human 
extrapolation and 10 for human variability). 
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; (G) = gavage; Gastro = gastrointestinal; gd = gestational day; gen = 
generation; Gn pig = guinea pig; (GO) = gavage in oil; (GW) = gavage in water; Hemato = hematological; hr = hour(s); Immuno = immunological; LD50 = lethal dose, 50% kill; LOAEL 
= lowest-observed-adverse-effect level; M = male; min = minute(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; RBC = red blood 
cell; Resp = respiratory; SRBC = sheep red blood cells; x = time(s); (W) = drinking water; wk = week(s); yr = year(s) 
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3. HEALTH EFFECTS
the 795 mg/kg dose, and five of five animals died within 2 hours following 1,580 mg/kg dose.  From
these data, the investigators estimated an oral LD50 of 650 mg/kg.
No effect on survival was observed in mice treated with phenol in the drinking water at doses up to 
33.6 mg/kg/day for 28 days (Hsieh et al. 1992).  Survival was not affected in rats and mice treated with 
phenol in drinking water for 13 or 103 weeks (NCI 1980).  Both species were treated with drinking water
concentrations up to 10,000 mg/L in the 13-week study (maximum doses in mg/kg/day:  1,694 for female 
rats, 1,556 for male rats; 2,643 for female mice, 2,468 for male mice), and up to 5,000 mg/L in the
103-week study (maximum doses in mg/kg/day:  721 for female rats, 645 for male rats; 1,204 for female 
mice, 1,180 for female mice).
In most studies, a specific cause of death was not reported, but common signs preceding death included 
convulsions, coma, and respiratory arrest. The LD50 values and doses resulting in death from each 
reliable study in each species in the acute-duration category are recorded in Table 3-2 and plotted in 
Figure 3-2.
3.2.2.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
Respiratory Effects. Stajduhar-Caric (1968) reported on a case in which a woman who ingested 
approximately 10–20 g of phenol, became comatose and died within a matter of hours.  During the course
of the poisoning and treatment, initially an increase in respiration was observed, then irregularities in 
breathing, and finally cessation of respiration.  An autopsy revealed marked hyperemia of the tracheal and 
bronchial mucous membranes, as well as pulmonary edema.  According to Deichmann and Keplinger
(1981), the progression of impacts on the respiratory system summarized above are typical of oral
poisonings in humans, although often the intermediate stages are characterized by a decrease in 
respiration rate and magnitude.  According to these authors, in acute intoxication, death usually results
from respiratory failure.  Pulmonary congestion and edema were reported in a man who died following
phenol poisoning (Soares and Tift 1982).  In another case of fatal ingestion of phenol, autopsy reported 
white froth in the nostrils, upper airway, trachea, and bronchi as well as edema and fluid in the lungs (Lo 
Dico et al. 1989). Inflammatory changes in the lungs also were observed in a more recent fatal case of
ingestion of phenol (Tanaka et al. 1998).
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Dyspnea and rales were observed in pregnant rats treated by gavage with phenol in water on GDs 6–19 
(Narotsky and Kavlock 1995).  The respiratory effects were observed at both 40 and 53.3 mg/kg/day.  
Gross pathological examinations did not reveal any adverse changes in the lungs of mice treated with 
phenol in drinking water at doses of 1.8, 6.2, or 33.6 mg/kg/day for 28 days (Hsieh et al. 1992).
In a study reported by the National Cancer Institute (NCI 1980), rats exposed to 16–1,694 mg/kg/day 
(100–10,000 mg/L) and mice exposed to 25–2,642 mg/kg/day (100–10,000 mg/L) phenol in drinking
water exhibited no indication of histopathological effects on the respiratory system after 13 weeks of 
exposure.  No histological abnormalities of the respiratory tract were observed in rats or mice exposed to 
2,500 or 5,000 ppm phenol in drinking water for 103 weeks (mg/kg/day doses:  322 or 645 for male rats;
360 or 721 for female rats; 590 or 1,180 for male mice; 602 or 1,204 for female mice) (NCI 1980).
Cardiovascular Effects. In a recent report on the clinical treatment of phenol poisoning, Langford 
et al. (1998) provide a summary of a case report in which a woman accidentally consumed an ounce of
89% phenol that had mistakenly been given to her in preparation for an in-office procedure.  Her
immediate reaction upon consuming the phenol was to clutch her throat and collapse, and within 
30 minutes, she was comatose and had gone into respiratory arrest.  Treatment was initiated with an 
endotracheal intubation.  Ventilation with a bag and mask led to the detection of a lamp oil odor.  Within 
an hour, she developed ventricular tachycardia, which responded to cardioversion; however, she
subsequently developed (in the first 24 hours) supraventricular and ventricular dysrhythmias, metabolic 
acidosis, and experienced a grand mal seizure.  After a 15-day hospital stay, she was completely
recovered with no evidence of impaired motility or compromised gastrointestinal or cardiovascular
systems.
Gross pathological examinations did not reveal any adverse changes in the hearts of mice treated with 
phenol in drinking water at doses of 1.8, 6.2, or 33.6 mg/kg/day for 28 days (Hsieh et al. 1992).  In a
study reported by the NCI (1980), rats exposed to 16–1,694 mg/kg/day (100–10,000 ppm) and mice 
exposed to 25–2,642 mg/kg/day (100–10,000 ppm) phenol in drinking water exhibited no indication of
histopathological effects on the heart after 13 weeks of exposure.  Histological abnormalities of the heart
were not evident in rats after 103 weeks of exposure to 322 or 645 mg/kg/day for males or 360 or
721 mg/kg/day for females (2,500 or 5,000 ppm) or in mice after exposure to 590 or 1,180 mg/kg/day for
males or 602 or 1,204 mg/kg/day for females (2,500 or 5,000 ppm).  Cardiovascular function was not
evaluated in these studies.
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Gastrointestinal Effects. In a study on the clinical treatment of phenol poisoning, Langford et al. 
(1998) provide a summary of a case report in which a woman accidentally consumed an ounce of 89%
phenol that had mistakenly been given to her in preparation for an in-office procedure.  Her immediate 
reaction upon consuming the phenol was to clutch her throat and collapse, and within 30 minutes, she was 
comatose and had gone into respiratory arrest.  Treatment was initiated with an endotracheal intubation, 
which revealed her mouth and hypopharynx to be white.  Esophagitis and upper gastrointestinal bleeding
occurred in the first week, and an examination of the esophagus on day 8 revealed hyperkeratosis,
erythema, and a friable mucosa.  After a 15-day hospital stay, she was completely recovered with no 
evidence of impaired motility or compromised gastrointestinal system. A male who ingested a solution 
containing phenol and cresol and eventually died did not show macroscopic lesions of the esophagus and 
stomach, but histological examination revealed exfoliation of the mucosa of the esophagus and 
coagulative necrosis of the gastric mucosa (Boatto et al. 2004).  Coagulation of the gastric mucosa was 
also reported in a fatal case of poisoning with phenol (Soares and Tift 1982).  Erosive duodenal gastritis
was also observed in a woman who ingested about 70 mL of a 42–52% phenol solution (Kamijo et al. 
1999). Other fatal cases have described mucous changes in the digestive organs (Tanaka et al. 1998) and 
crusted corrugated appearance of the stomach (Lo Dico et al. 1989).
In a retrospective study of 158 persons exposed to phenol in drinking water for several weeks following
an accidental spill of phenol, significantly (p<0.01) increased gastrointestinal symptoms (mouth sores, 
nausea, diarrhea) were reported by 17 of the 39 most highly-exposed individuals (Baker et al. 1978).  
Exposure concentrations for the most highly-exposed group were >0.1 mg/L, and the study authors
estimated phenol intake during this period as 10–240 mg/person/day (0.14–3.4 mg/kg/day assuming a 
70-kg body weight).  Symptom rates were not increased among 61 persons exposed to concentrations of
≤0.1 mg/L (0.003 mg/kg/day assuming 2 L water per day and a 70-kg body weight).  Dermal exposure
was not considered in these estimates of dose.  A similar study was conducted by Jarvis et al. (1985)
among 344 English households whose drinking water contaminated with phenol.  An unexposed group 
(250 households) served as control. The day of the contamination incident, the concentration of phenol in 
a high-exposure area (250 households) was estimated to be 10 µg/L, whereas in a low-exposure area
(94 households), the concentration was 4.7 µg/L.  The day after the incident, the phenol concentration in
the water from both areas was 4.7 µg/L, and 2 days after the incident, it was 0.9 µg/L.  Chlorophenols, 
which formed upon chlorination of the water, were detected at a higher concentration of phenol and 
followed a similar pattern as phenol.  Since the concentration of phenol and chlorophenols were similar in 
the two exposed areas, the two exposed areas were combined in the analysis.  Exposed individuals had
   
 
    
 
 
 
 
 
 
 
 
 
 
  
  
 
 
      
  
    
     
  
 
  
  
  
   
   
 
      
 
 
    
    
  
    
       
    
    
 
 
 
    
 
PHENOL 64
3. HEALTH EFFECTS
significantly higher incidences of gastrointestinal illness (i.e., diarrhea, nausea, vomiting, and abdominal
pain) than the unexposed group, and the onset of symptoms coincided with the period of elevated 
concentrations of phenol in the drinking water.  Moreover, stronger associations were observed among
those who reported drinking the water in the exposed areas than among those who reported not drinking
the water in the same areas.  The specific contribution of phenol to the adverse signs and symptoms 
reported is difficult to determine.
A case control study of 6,913 individuals living near a Korean river contaminated with 30 tons of 100%
phenol found nausea, vomiting, diarrhea, and abdominal pain among 1,824 exposed subjects compared to 
1,064 unexposed subjects (Kim et al. 1994).  The level of phenol measured in the two reservoirs that
served the community was 0.05 mg/L after the spill, while that in the chlorinated tap water was
0.0084 mg/L.  
In a study reported by the NCI (1980), rats exposed up to 1,694 mg/kg/day and mice exposed up to 
2,642 mg/kg/day phenol in drinking water exhibited no indication of histopathological effects on the
gastrointestinal system after 13 weeks of exposure.  No histological abnormalities of the gastrointestinal
tract were observed in rats or mice exposed to phenol in drinking water that provided doses of
approximately 720 and 1,200 mg/kg/day, respectively, for 103 weeks (NCI 1980).
Hematological Effects. No studies were located regarding hematological effects in humans
following oral exposure to phenol.
A 30–60% decrease in the ratio of polychromatic to normochromatic erythrocytes was observed in the
bone marrow of pregnant mice treated by gavage with a single dose of 265 mg/kg phenol in water on 
GD 13 (Ciranni et al. 1988).  Dose-related and significant decreases in red blood cell counts were 
observed in mice treated with phenol in the drinking water at doses of 1.8, 6.2, or 33.6 mg/kg/day for
28 days (Hsieh et al. 1992).  Red blood cell counts in cells x106/mm3 were 7.17 in controls, 4.9 at the low
dose, 4.64 at the middle dose, and 3.23 at the high dose.  A significant decrease in hematocrit was only
observed at the high dose (48% control, 44.1% high dose), and no changes were observed in leucocyte
numbers or leucocyte differentials.
No significant alterations in hematology parameters were observed in male or female rats dosed with up 
to 301 or 321 mg phenol/kg/day in the drinking water, respectively, for 10 weeks (Ryan et al. 2001).
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Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans
following oral exposure to phenol.
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day phenol in drinking water
exhibited no histological abnormalities of the bone after 13 weeks of exposure (NCI 1980).  No 
histological abnormalities of the bone were observed in rats or mice up to 721 or 1,204 mg/kg/day, 
respectively, of phenol in drinking water for 103 weeks. (NCI 1980).
Hepatic Effects. Serum markers of liver effects, bilirubin, glucose, cholesterol, and AST activity
were not affected in 39 persons exposed to phenol in the drinking water at an estimated dose of 0.14– 
3.4 mg/kg/day for several weeks (Baker et al. 1978).  Because these examinations were completed 
7 months after the spill, this study does not provide conclusive evidence that there was no reversible liver
damage.  Autopsy of a fatal case of ingestion of phenol revealed substantial toxic changes in the liver
including extension of sinusoid lumens and an increase in centrilobular increase of cytoplasmic 
eosinophility (Tanaka et al. 1998).
Serum markers of liver effects (lactic dehydrogenase, alkaline phosphatase, ALT, bilirubin) and
histopathological changes in the liver were observed in rats given single gavage doses of 224 mg/kg or
14 daily gavage doses of 40 mg phenol/kg in water (Berman et al. 1995).  Changes in liver weight were
not observed in pregnant rats treated by gavage with 120 mg/kg/day of phenol in water on GDs 6–15 
(NTP 1983a), or in pregnant mice treated by gavage with 280 mg/kg/day phenol in water on GDs 6–15 
(NTP 1983b).
Gross pathological examinations did not reveal any lesions in mice treated with phenol in the drinking
water at a dose of 33.6 mg/kg/day for 28 days (Hsieh et al. 1992).
In a study sponsored by the National Cancer Institute (NCI 1980), rats exposed up to 1,694 mg/kg/day 
and mice exposed up to 2,642 mg/kg/day phenol in drinking water exhibited no histological abnormalities
of the liver after 13 weeks of exposure. Similar observations were made in rats dosed with up to 301– 
321 mg phenol/kg/day in the drinking water for 10 weeks (Ryan et al. 2001).  No histological
abnormalities of the liver were observed in rats or mice exposed up to 721 or 1,204 mg/kg/day 
respectively, of phenol in drinking water for 103 weeks (NCI 1980). 
   
 
    
 
 
 
 
 
 
 
         
      
   
  
      
 
  
  
  
 
 
  
    
      
       
  
 
 
      
 
    
   
   
    
 
 
     
 
  
 
PHENOL 66
3. HEALTH EFFECTS
Renal Effects. Although not adverse, dark urine (as a result of oxidation products of phenol or a
result of hemoglobin or its breakdown products in the urine) is a common symptom observed in humans
exposed to phenol.  In persons exposed to about 0.14–3.4 mg/kg/day phenol in drinking water for several
weeks after an accidental spill, dark urine was reported by 17.9% of the most highly-exposed individuals, 
while only 3.4% of the controls reported the effect (Baker et al. 1978).  This difference was not
statistically significant.  A 3.3-fold increase in the prevalence of dark urine was reported by persons 
exposed to unspecified doses of phenol after an accidental spill in Korea (Kim et al. 1994).  Autopsy of an 
individual who ingested phenol showed interstitial edema and renal tubular hemorrhage (Tanaka et al. 
1998).  Extensive renal autolysis was also observed in a fatal case of poisoning with phenol (Soares and 
Tift 1982).
Renal tubular necrosis, protein casts, and papillary hemorrhage were not observed in rats treated with a
single gavage dose of 120 mg/kg phenol in water, but were seen in 60% of animals examined at the next
highest dose of 224 mg/kg (Berman et al. 1995). No histopathological changes in the kidney were
observed after 14 daily doses of 12 mg/kg/day, but were observed in 3 of 8 animals given 14 daily doses
of 40 mg/kg/day (Berman et al. 1995).
Gross pathological examinations did not reveal any adverse changes in the kidneys of mice treated with
phenol in drinking water at doses of 1.8, 6.2, or 33.6 mg/kg/day for 28 days (Hsieh et al. 1992).
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day of phenol in drinking water
exhibited no indication of histopathological effects on the kidney after 13 weeks of exposure (NCI 1980).  
Rats exposed to up to 301–321 mg phenol/kg/day in the drinking water for 10 weeks showed no 
significant histopathological effects in the kidneys (Ryan et al. 2001).
No compound-related histological changes in the kidneys were observed in rats or mice exposed up to 
721 or 1,204 mg/kg/day, respectively, of phenol in drinking water for 103 weeks (NCI 1980).  A higher
incidence of inflammation of the kidney was reported in male rats exposed to 624 mg/kg/day (96%) than 
in controls (74%); however, because of the high incidence of inflammation in the controls, it is impossible
to ascertain whether this was related to the exposure to phenol (NCI 1980).  A high age-related incidence 
of inflammation is expected in male rats of the Fischer-344 strain used in this study.  Kidney function, 
including glomerular filtration rate and glomerular sieving, however, was not evaluated in this study.  
Furthermore, histological examination was limited to standard light microscopic examinations which 
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would not have detected functionally significant glomerular abnormalities like disruption of the
glomerular basement membrane or immune complex deposition.
Endocrine Effects. Autopsy of a subject who died following ingestion of a solution containing
phenol showed interstitial hemorrhage in the pancreas and adrenal glands (Tanaka et al. 1998).  No 
further information regarding effects of phenol on endocrine-related end points was located.
Unspecified microscopic changes were observed in the adrenal glands of rats given a single gavage dose 
of 224 mg/kg phenol in water, but no changes were described in rats treated similarly with doses
≤120 mg/kg/day (Berman et al. 1995).  No adrenal gland effects were observed in rats 14 daily gavage
doses of 4, 12, or 40 mg/kg (Berman et al. 1995).
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day phenol in drinking water
exhibited no histopathological changes in the pancreas, pituitary, adrenal glands, thyroid, or parathyroid 
after 13 weeks of exposure (NCI 1980).  Exposure-related histopathological changes in the pancreas, 
pituitary, adrenal glands, thyroid, or parathyroid were also not observed in rats and mice exposed to 
2,500 or 5,000 ppm phenol in drinking water for 103 weeks (NCI 1980).  Estimated mg/kg/day doses
were 322 or 645 for male rats, 360 or 721 for female rats, 590 or 1,180 for male mice, and 602 or
1,204 for female mice.
Dermal Effects. Skin rash and mouth sores were reported in persons living near a site with 
contaminated well water resulting from an overturned tanker car carrying 37,900 L of 100% phenol
(Baker et al. 1978).  The level of phenol in the drinking water of this cohort was >0.1 mg/L, and while
substantial oral exposure probably occurred, dermal exposure cannot be ruled out.  Increases in the
prevalence of skin rashes and sore throats were reported by persons drinking water from a river
contaminated by an accidental spill of phenol (Kim et al. 1994).  Because the water was chlorinated 
before use, the effect may also have been a result of exposure to chlorophenol.  Perioral chemical burns
from phenol were observed in a woman who ingested approximately 70 mL of a 42–52% phenol solution 
(Kamijo et al. 1999).  Spiller et al. (1993) also reported oral and esophageal burns in 17 out of 52 patients 
following ingestion of a disinfectant containing 26% phenol. 
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day phenol in drinking water
exhibited no histopathological changes in the skin after 13 weeks of exposure (NCI 1980).  Exposure­
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related histopathological changes in the skin were also not observed in rats and mice exposed up to 721 or
1,204 mg/kg/day, respectively, phenol in drinking water for 103 weeks (NCI 1980).
Ocular Effects. No studies were located regarding ocular effects in humans or animals following oral
exposure to phenol.
Body Weight Effects. No effects on body weight were observed in rats treated with a single gavage 
dose of 224 mg/kg phenol in water or 14 daily gavage doses of 40 mg/kg (Berman et al. 1995; Moser et
al. 1995).  Maternal body weight gain was approximately 20% lower in rats treated by gavage with 40 or
53.3 mg/kg/day phenol in water on GDs 6–19 (Narotsky and Kavlock 1995).  Maternal body weight gain 
was 67% lower than controls in mice treated by gavage with 280 mg/kg/day phenol in water on GDs 6– 
15, with no effects on body weight gain observed at 140 mg/kg/day (NTP 1983b).  Body weight gain was
not affected in pregnant rats treated by gavage with 120 mg/kg/day phenol in water on GDs 6–15 (NTP
1983a).  Body weight gain was significantly reduced in pregnant rats dosed with 120 mg phenol/kg/day
on GDs 6–15 (11% for GDs 6–16 and 19% for GDs 12–16) (York 1997).  Doses of 360 mg/kg/day 
caused a reduction in body weight gain of 38% for GDs 6–16; the NOAEL for maternal weight gain in 
this study was 60 mg/kg/day.  The reduction in maternal body weight gain in rats during pregnancy
reported in the York (1997) study was used as the basis for derivation of an acute-duration oral MRL for
phenol.
Body weight was not affected in mice treated with phenol in drinking water at a dose of 33.6 mg/kg/day 
for 28 days (Hsieh et al. 1992).  During 13-week studies in rats and mice treated with phenol in drinking
water, decreased body weight gain was associated with dose-related decreases in water intake, 
presumably due to taste aversion (NCI 1980).  In rats provided with the highest concentration 
(10,000 ppm), body weight gain was decreased by 26% in females at 1,694 mg/kg/day, and by 16% in 
males at 1,556 mg/kg/day.  An effect on body weight gain was not observed in rats at 3,000 ppm
(467 mg/kg/day for males, 508 mg/kg/day for females).  In mice provided with the highest concentration
(10,000 ppm), body weight gain was decreased by 33% in females at 2,642 mg/kg/day, and by 80% in 
males at 2,468 mg/kg/day.  An effect on body weight gain was not observed in mice at 3,000 ppm
(741 mg/kg/day for males, 793 mg/kg/day for females).  A significant decrease in body weight gain 
associated with a significant decrease in water consumption was also observed in male and female rats 
dosed with 301–321 mg/kg/day phenol in the drinking water for 10 weeks (Ryan et al. 2001).
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Decreased mean body weight associated with decreased water intake was also observed in rats in a
103-week study (NCI 1980).  At the high concentration (5,000 ppm), body weight was 19% lower than 
controls in males (645 mg/kg/day) and 17% lower than controls in females (721 mg/kg/day).  At the low
concentration (2,500 ppm), body weight was 12% lower than controls in males (322 mg/kg/day) and 
within 10% of controls in females (360 mg/kg/day).  Body weight was not affected in mice treated with 
phenol in drinking water for 103 weeks at doses up to 1,180 for males and up to 1,204 mg/kg/day for
females (NCI 1980).
3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans following oral
exposure to phenol.
Necrosis or atrophy of the spleen or thymus was observed in four of six rats given a single gavage dose of
224 mg/kg of phenol in water, and one of seven rats given 120 mg/kg/day (Berman et al. 1995).  Based on 
this effect, which was not further described, the study authors considered 224 mg/kg to be a LOAEL for
immunological effects.  One of eight animals given 12 mg/kg/day, and two of eight given 40 mg/kg/day 
for 14 days showed these same effects.
Hsieh et al. (1992) conducted a 28-day study of the immunotoxicologic impact of phenol in which 
CD-1 mice were given drinking water that provided doses of phenol of approximately 0, 1.8, 6.2, or
33.6 mg/kg/day.  When challenged with sheep red blood cells (SRBC), a significant decrease was
observed in the splenic concentration of anti-erythrocyte antibody-forming cells and in the anti-
erythrocyte antibody titer at the two highest doses, while a significant decrease in the absolute number of
anti-erythrocyte antibody-forming cells present in the spleen was observed only at the top dose.  In 
contrast to the results of Hsieh et al. (1992), Ryan et al. (2001) reported no immunologic alterations in 
male rats in a drinking water study.  Rats were dosed for 10 weeks with up to 301 mg phenol/kg/day and 
then immunized intravenously with sheep red blood cells.  Eighteen hours later, splenocytes were 
prepared in cell culture medium for enumeration of plaque-forming cells.  Treatment with phenol had no 
significant effect on antibody-forming cells, and there were no significant effects on spleen or thymus
weight, spleen cellularity, or spleen and thymus histology.  
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day phenol in drinking water
exhibited no histopathological changes in the bone marrow, spleen, or lymph nodes after 13 weeks of
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exposure (NCI 1980).  Exposure-related histopathological changes in the bone marrow, spleen, or lymph 
nodes were also not observed in rats or mice exposed to estimated doses of up to 721 or 1,204 mg/kg/day, 
respectively, for 103 weeks (NCI 1980).
The highest NOAEL values and all LOAEL values from each reliable study for immunological and 
lymphoreticular effects in each species and duration category are recorded in Table 3-2 and plotted in 
Figure 3-2.
3.2.2.4  Neurological Effects 
Headaches were reported 6 times more frequently by persons using drinking water contaminated with 
phenol than by controls (Kim et al. 1994).  The water was used after chlorination; therefore, chlorophenol
may have contributed to the observed effects. Fine, rapid, rhythmic, perioral movements, as well as signs
of Parkinson’s syndrome were observed in a woman who ingested approximately 70 mL of a 42–52%
solution of phenol (Kamijo et al. 1999).  Central nervous system depression was described in 11 out of
52 patients who ingested amounts ranging from 2 to 90 mL of a disinfectant solution containing 26%
phenol (Spiller et al. 1993).
Acute oral phenol poisoning in rabbits and rats was characterized by muscular tremors in the head region, 
which eventually spread to other regions of the body, with the lower extremities being the last affected.  
Loss of coordination and convulsions preceded death at doses of 300–940 mg/kg (Deichmann and 
Witherup 1944).  Liao and Oehme (1981) described tremors of the muscles around the eyes, followed by
convulsions and coma, in rats after a sublethal oral dose of 207 mg/kg phenol.  Mild-to-severe whole-
body tremors and decreased motor activity were reported in rats given a single gavage dose of 120 mg/kg
phenol in water (Moser et al. 1995).  A dose of 40 mg/kg resulted in no neurological effects following a
single dose, while increased rearing was reported following 14 daily doses (Moser et al. 1995).  Pregnant
mice treated by gavage with phenol in water on GDs 6–15 exhibited tremors and ataxia at 280 mg/kg/day, 
mild tremors on the first 3 days of dosing at 140 mg/kg/day, and no adverse neurological effects at
70 mg/kg/day (NTP 1983b).  
In contrast with results from oral gavage studies, phenol administered in the drinking water was much less 
toxic.  For example, male rats exposed to up to 309 mg phenol/kg/day in the drinking water for 13 weeks 
showed no significant alterations in tests of motor activity or a functional observation battery conducted 
throughout the exposure period (Beyrouty 1998).  However, females dosed with 360 mg phenol/kg/day
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showed a significant reduction in motor activity on week 4 of the study; no significant alterations were
seen in females at 107 mg/kg/day.  Gross and microscopic evaluation of the brain, spinal cord, and 
peripheral nerves was unremarkable (Beyrouty 1998).
Mice exposed for 28 days to phenol in drinking water exhibited a significant reduction in dopamine level
in the corpus striatum at the 1.8 mg/kg/day dose, and significantly decreased levels of norepinephrine, 
serotonin, and 5-hydroxyindoleacetic acid in the hypothalamus at the 6.2 mg/kg/day dose (Hsieh et al. 
1992).  Levels of neurotransmitters in other brain regions were also significantly altered at higher doses of
phenol.
Rats exposed to 16–1,694 mg/kg/day and mice exposed to 25–2,642 mg/kg/day phenol in drinking water
exhibited no abnormal histology of the brain after 13 weeks of exposure (NCI 1980).  Histopathological 
changes in the brain were not evident after 103 weeks of exposure to 322 or 645 mg/kg/day in male rats, 
360 or 721 mg/kg/day in female rats, 590 or 1,180 mg/kg/day in male mice, and 602 or 1,204 mg/kg/day 
in female mice (NCI 1980).  However, this study did not include tests for neurological impairment or
histopathological examinations of tissues in the nervous system other than the brain.
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans following oral exposure to phenol.
No evidence of impaired reproduction was found in rats exposed to phenol in drinking water at
<5,000 ppm (estimated 571 mg/kg/day) for three generations or at <1,000 ppm (estimated 
114 mg/kg/day) for five generations (Heller and Pursell 1938).  Data regarding breeding habits, controls, 
and the methods used to evaluate the rats for reproductive impairment were not reported in sufficient
detail to establish reliable NOAELs or LOAELs for presentation in Table 3-2 and Figure 3-2.
Rats exposed up to 1,694 mg/kg/day and mice exposed up to 2,642 mg/kg/day of phenol in drinking water
exhibited no histopathological changes in the prostate, testes, uterus, or ovaries after 13 weeks of 
exposure (NCI 1980).  Exposure-related histopathological changes in the prostate, testes, uterus, or
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ovaries were also not observed in rats or mice exposed up to 721 or 1,204 mg/kg/day, respectively, phenol
in drinking water for 103 weeks (NCI 1980). 
In a two-generation study in which rats were administered phenol in the drinking water (up to 301– 
321 mg/kg/day), there was a significant decrease in absolute seminal vesicle weight in parental males at
301 mg/kg/day and in absolute ovaries weight in parental females at 321 mg/kg/day, but were no 
significant alterations in gross or microscopic appearance of the reproductive organs of males and females 
from the parental and F1 generations (Ryan et al. 2001).  In addition, there were no significant effects on 
estrus frequency, testicular sperm count, or sperm motility or morphology.  Significant reductions in 
prostate and uterine weights in all F1 treated groups were not considered adverse effects of phenol by
Ryan et al. (2001) on the basis of the absence of histological alterations and functional reproductive
effects, and based on the fact that only a few animals had organ weights outside the range of concurrent
control values.
Information on the effects of exposure to phenol on the genetic material of germinal cells is presented in 
Section 3.3, Genotoxicity.
The highest NOAEL values from each reliable study for reproductive effects in each species and duration 
category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans following oral exposure to phenol.
In a multi-generational study of the effect of various levels of phenol administered orally in water, Heller
and Pursell (1938) saw no effect on growth, reproduction, and normal rearing of young over 5 generations 
of rats given concentrations of ≈1,000 mg/L phenol in drinking water (estimated dose of 114 mg/kg/day)
nor over three generations of rats given concentrations of ≈5,000 ppm (estimated dose 571 mg/kg/day).  
Phenol in water was administered to pregnant rats by gavage (5 mL/kg) at dose levels of 0, 30, 60, or
120 mg/kg/day on GDs 6–15 (NTP 1983a).  A dose-related decrease in fetal body weight with increasing
dose was observed, with 60 mg/kg/day established as the NOAEL and 120 mg/kg/day as the LOAEL.  
The mean reduction in fetal body weight relative to controls was approximately 7%.  Concurrent controls
provide the most appropriate comparison for experimental data; however, it is worth noting that the
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weights of control fetuses in this study were 22% higher than those of historical controls.  As litter size is
 
known to influence fetal weight, it is possible that a larger litter size in the high-dose group may have
 
contributed to the smaller fetal weights in that group.  The data were not specifically analyzed for that
 
potential effect.  Teratogenic effects were not observed and no signs of maternal toxicity were observed at
 
any dose level.  In a preliminary range-finding study conducted by NTP (1983a), a decrease in maternal
 
weight gain and an increased incidence of maternal mortality were observed at >160 mg/kg.  Tremors, a
 
typical symptom of phenol toxicity, were also observed.
 
In a study of the developmental toxicity of phenol and structurally-related chemicals, Kavlock (1990)
 
examined the effects of 0, 100, 333, 667 and 1,000 mg/kg phenol given by gavage on day 11 of gestation.  

Phenol was administered in a 4:4:1:1 mixture of water, Tween 20, propylene glycol, and ethanol.  

Five variables were examined:  maternal weight change (at 24 and 72 hours postdosing), litter size
 
(postnatal day [PND] 1 and 6), perinatal loss, pup weight (on PND 1 and 6), and litter biomass (in g on 

PND 1 and 6). 

Within these five parameters, a significant decrease in maternal weight gain was seen at the two highest
 
doses.  At these same doses, malformations involving the limbs and tail were seen.  At a dose of
 
667 mg/kg, pups in 21% of the litters were affected.  At a dose of 1,000 mg/kg, pups in 27% of the litters
 
were affected.  The effect on tails was one of shortening or crimping (i.e., ‘kinky’ tails).  The hindlimb 

effect consisted of paralysis and/or palsy.  In animals with palsy, the limb function would alternate
 
between normal strides and several, second-long period of tetany.  Because limb function matures
 
postnatally, this effect was not evident in the newborn but required 7–10 days to become obvious.  

In a subsequent study, Narotsky and Kavlock (1995) found a significant decrease in the number of
 
liveborn pups associated with severe respiratory effects in pregnant rats treated by gavage with 

53.3 mg/kg/day phenol in water on GDs 6–19.  In addition, in one high-dose litter, two of four surviving
pups had kinked tails; this finding was not analyzed for significance but was consistent with earlier
observations (Kavlock 1990).  Developmental effects were not significant at 40 mg/kg/day.
Phenol in water was administered to pregnant mice by gavage (10 mL/kg) at dose levels of 0, 70, 140, or
280 mg/kg/day on GDs 6–15 (NTP 1983b).  Decreased maternal weight gain, tremors, and increased 
maternal mortality were observed at 280 mg/kg/day.  In the fetuses, growth retardation, decreased 
prenatal viability, abnormal structural development, and an increased incidence of cleft palate were 
observed at 280 mg/kg/day.  Developmental effects were not observed at 140 mg/kg/day.  In pregnant
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mice that received 265 mg/kg phenol by gavage on GD 13, Ciranni et al. (1988) found no evidence of
fetal cellular toxicity, as measured by a ratio polychromatic erythrocyte/normochromatic erythrocyte.
York (1997) conducted a study in which phenol was administered in three daily gavage doses in water to 
Sprague-Dawley pregnant rats in dosing volumes of 10 mL/kg on GDs 6–15.  The total daily doses were
0, 60, 120, or 360 mg phenol/kg/day.  Maternal end points evaluated included clinical signs, body weight, 
and food consumption.  Dams were also observed for abortions and premature deliveries.  Dams were 
sacrificed on GD 20 and a gross necropsy was conducted.  The uterus was examined for pregnancy, 
number and distribution of implantations, live and dead fetuses, and early and late resorptions.  Fetuses
were weighed and examined for sex and gross external alterations.  Half of the fetuses were examined for 
soft tissue alterations and the remaining fetuses were examined for skeletal alterations.  In the mid-dose
group, maternal body weight gain was reduced 11% for GDs 6–16 and 19% for GDs 12–16, whereas in 
the high-dose group, body weight gain was reduced 38% for GDs 6–16.  Maternal final body weight in 
the high-dose group was reduced, but <10% relative to controls.  Dose-related decreases in food 
consumption were also observed during the dosing period.  Mean fetal weight in the high-dose group was
reduced 5–7% relative to controls.  In addition, there was a significant decrease in ossification sites on the
hindlimb metatarsals in the high-dose group, which the investigators considered of minimal biological
significance.  At the mid- and high-dose levels, there were increases in litters with fetuses with “any
alteration” and with “any variation”, but neither reached statistical significance and there were no clear
dose-response relationships.  No significant effects were seen regarding corpora lutea, implantations, litter
sizes, live fetuses, early and late resorptions, and percent resorbed conceptuses.  Based on the reduced 
fetal weight and delayed ossification in the high-dose group, the dose of 360 mg/kg/day is a
developmental LOAEL; the developmental NOAEL is 120 mg/kg/day. Based on the reduction in body
weight gain, the maternal LOAEL is 120 mg/kg/day and the NOAEL is 60 mg/kg/day.
In a two-generation reproduction study, administration of phenol in the drinking water to the parental
generation (301–321 mg/kg/day) resulted in a significant reduction in F1 pup weight (30% by PND 21 
relative to controls) and F2 pup weight (37% by PND 21 relative to controls) (Ryan et al. 2001). There
was also a decrease in percent live pups on day 4 in both generations and for days 7–21 in the F2 
generation at the high-dose level.  In addition, preputial separation and vaginal patency were significantly
delayed at the high dose in F1 males and females, respectively.  In this study, water consumption was 
significantly reduced at the high dose, including in females during gestation and lactation, and this was
accompanied by reduced food consumption and body weight gain.  A LOAEL of 321 mg/kg/day can be
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defined in this study for developmental toxicity; the NOAEL for developmental toxicity was
93 mg/kg/day. 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species in the acute-duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.7  Cancer
No studies were located regarding carcinogenicity in humans following oral exposure to phenol.
The carcinogenicity of orally administered phenol was examined in rats and mice in a study reported by
the NCI (1980).  Rats and mice received 0, 2,500, or 5,000 ppm in drinking water for 103 weeks.  
Calculated intakes for rats were 322 and 645 mg/kg/day for males and 360 and 721 mg/kg/day for
females.  Calculated intakes for mice were 590 and 1,180 mg/kg/day for males and 602 and
1,204 mg/kg/day for females.  Statistically significant increased incidences of pheochromocytomas of the
adrenal gland and leukemia or lymphomas were observed in male rats exposed to 322 mg/kg/day 
(2,500 ppm), but not in male rats exposed to 645 mg/kg/day (5,000 ppm).  No significant effects were 
seen in female rats or mice of either sex exposed to either exposure level.  Since cancer occurred only in 
males of one of the two species tested and a positive dose-response relationship could not be established, 
these results are inconclusive regarding the carcinogenic potential of orally administered phenol.
3.2.3 Dermal Exposure 
3.2.3.1  Death 
Application of phenol to the skin can be lethal.  Death occurred within 10 minutes after ≈25% of an 
individual's body surface was exposed to liquid phenol (Griffiths 1973).  The cause of death was reported 
to be respiratory depression and cardiac arrest.  In another report, an individual died after being painted 
with a brush that had been soaked in a solution of phenol and thoroughly washed before use (Lewin and 
Cleary 1982).  In neither case was the dose known with sufficient accuracy to establish a lethal dose.  
A 10-year-old boy who was hospitalized with serious burns was treated dermally with 7.5 L of an 
antiseptic solution containing 2% phenol for 2.5 days.  During this period his urine became dark and his
respiration became labored, fell into a coma, and died. Postmortem analysis of urine showed the presence 
of 200 mg/L of conjugated phenol (Cronin and Brauer 1949).  Soares and Tift (1982) described two fatal
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cases attributed to absorption of phenol through intact skin.  One was a 17-year-old male who died within 
30 minutes of splattering a solution containing 30% phenol over portions of his face, neck, and right
trunk.  The other case was a 4-week-old female who was mistakenly treated with undiluted Castellani’s
paint (a mixture of phenol, basic fuchsin, resorcinol, acetone, ethanol, and water) to treat seborrheic
dermatitis and died 5 hours later. 
Lethality associated with dermal exposure to phenol is greatly influenced by the surface area exposed as 
well as the concentration of the applied solution.  Mortality can vary depending on concentration; a dose
of 100% phenol may be less toxic than the same dose of phenol given as a diluted solution.  When an 
undiluted dose of 0.5 mL/kg was applied to the shaved backs of groups of five rats; one rat died, a 
1/3 dilution killed three rats, a 1/2 dilution killed four rats, and a 2/3 dilution killed all five rats (Conning
and Hayes 1970).  Conning and Hayes (1970) speculated that an undiluted solution may produce a
coagulative necrosis, which would slow further penetration of phenol resulting in a smaller number of
deaths than with more diluted solutions.  In rats treated with 3,000 mg/kg phenol in a 6% solution over
1/6 of the total body surface, all 22 treated animals died (Deichmann and Witherup 1944).  Increased
lethality with decreased concentration has also been observed in rabbits treated dermally with 
2,000 mg/kg; 95% phenol resulted in the death of 53% of treated rabbits, while 10% phenol in water
resulted in the death of 100% of treated rabbits (Deichmann and Witherup 1944).  The cause of death was
not stated in these studies.
In rats given a single treatment of 5% phenol in water to achieve a dose of 3,000 mg/kg, 10-day-old rats
were more sensitive than 5-week-old rats or adult rats (Deichmann and Witherup 1944).  Within 2– 
14 hours after dosing, 13 of 20 10-day-old rats died; 5 of 20 5-week-old rats died 2–3 hours after dosing, 
and 9 of 20 adult rats died 30–180 minutes after dosing.
The dermal LD50 of undiluted phenol in rats was reported to be 669 mg/kg (Conning and Hayes 1970).  
The LD50 of an unspecified concentration of phenol in rabbits was reported to be 1,400 mg/kg (Vernot et
al. 1977).  Flickinger (1976) determined a dermal LD50 by exposing male albino rabbits to 0, 252, 500, 
1,000, or 2,000 mg/kg phenol which was placed “in contact” with “abraded and intact skin for a
maximum period of 24 hours.”  No animals died in the 0, 252, or 500 mg/kg groups whereas three of
four in the 1,000 mg/kg group and all in the 2,000 mg/kg group died the first day following dosing.  From
these data, the authors estimated a “single dose skin penetration LD50" of 850 mg/kg.
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Among pigs treated with a single dose of 500 mg/kg of undiluted phenol on 35–40% of the total body
surface (about 1,136 cm2; 0.44 mg/cm2/kg), two of three died (Pullin et al. 1978).  The study authors
reported that a general state of lethargy, cyanosis, convulsions, and coma were observed 5–7 minutes
before death.
No effects on survival were observed in mice treated dermally with an unspecified volume of 5% phenol
(3 times/week) or 10% phenol (2 times/week) in acetone for 12 months (Wynder and Hoffmann 1961).  
Pretreatment with a single dose of 7,12-dimethylbenz[a]anthracene (7,12-DMBA) followed by phenol
resulted in increased skin tumors and decreased survival.
All LOAEL and LD50 values from each reliable study are recorded in Table 3-3.
3.2.3.2  Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-3.
Respiratory Effects. Pulmonary edema was observed in two fatal cases of dermal poisoning with 
phenol (Soares and Tift 1982).  A 79-year-old man who mistakenly instilled into his nose 0.5–10 mL of a
89% phenol solution (approximately 0.4–9 g) showed erythema and sloughing of the nasal mucosa 3 days 
after the accident (Durback-Morris and Scharman 1999).  No further relevant information was located 
regarding respiratory effects in humans following dermal exposure to phenol.
Dyspnea was reported in pigs treated with a single dose of 500 mg/kg of undiluted phenol over 35–40%
of the total body surface area (0.44 mg/cm2/kg) (Pullin et al. 1978).  This treatment resulted in the death 
of two of the three treated pigs.
Cardiovascular Effects. There have been several reports of cardiac arrhythmias associated with 
application of phenol solutions to the skin in connection with the surgical procedure of skin peeling
(Gross 1984; Truppman and Ellenby 1979; Warner and Harper 1985).  In this procedure, a mixture of
phenol (≈50% w/v), hexachlorophene, and croton oil is applied to the skin while the patient is under
anesthesia.  In a series of 54 patients in which the whole face was peeled in 1 day, cardiac arrhythmias 
were reported in 39%, while in a series of patients in which half the face was treated on 1 day, and the
second half was treated 24 hours later, cardiac arrhythmias were reported in 22% (Gross 1984).  The
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Table 3-3 Levels of Significant Exposure to Phenol - Dermal 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
(Alderly Park) 
Rat 24 hr 
System NOAEL Less Serious 
LOAEL 
669.4 F 
mg/cm²/d 
Serious 
(LD50) 
Reference 
Chemical Form 
Conning and Hayes 1970 
Comments 
(Wistar) 
Rat once 
3000 
mg/cm²/d 
(13/20 deaths 
10-day-old, 5/20 deaths 
5-week-old, 9/20 deaths 
adult) 
Deichmann and Witherup 1944 
(New 
Zealand) 
Rabbit NS 
1400 F 
mg/cm²/d 
(LD50) 
Vernot et al. 1977 
(Mixed breed) 
Pig 24 hr 
0.44 F 
mg/cm²/d 
(2/3 died) 
Pullin et al. 1978 
Systemic 
Human 1 hr Cardio 75 M 
mg/cm²/d 
(cardiac arrhythmia) 
Warner and Harper 1985 
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Table 3-3 Levels of Significant Exposure to Phenol - Dermal (continued) 
Exposure/ LOAEL
 
Duration/
 
Frequency Reference
Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
(Alderly Park) 
Rat 24 hr Renal 107.1 F 
mg/cm²/d 
(severe hemoglobinuria, 
hematin casts in the 
tubules) 
Conning and Hayes 1970 
Dermal 107.1 F 
mg/cm²/d 
(severe edema, 
coagulative necrosis, 
erythema) 
(B6C3F1) 
Mouse 
(ICR) 
Mouse 
(NS) 
once 
once 
Dermal 
Dermal 12 F 
mg/cm²/d 
329 F 
mg/kg 
15 F 
mg/cm²/d 
(skin inflammation) 
(skin irritation indicated 
by thickening of treated 
ear) 
Murray et al. 2007 
Patrick et al. 1985 
(NS) 
Rabbit once Cardio 23.8 M 
mg/cm²/d 
(cardiac arrhythmias, 
ventricular tachycardia) 
Wexler et al. 1984 
P
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L
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A
LTH
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FFE
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TS
79
220
mg/cm²/d
220
mg/cm²/d
143
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221
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Table 3-3 Levels of Significant Exposure to Phenol - Dermal (continued) 
Exposure/ LOAEL
 
Duration/
 
Frequency Reference
Species 
(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
(Mixed breed) 
Pig 24 hr Resp 0.44 F 
mg/cm²/d 
(dyspnea) 
Pullin et al. 1978 
Dermal 0.44 F 
mg/cm²/d 
(necrosis of the skin) 
Neurological 
(Alderly Park) 
Rat 24 hr 
107.1 F 
mg/cm²/d 
(severe muscle tremors, 
marked twitching, 
generalized convulsions, 
loss of consciousness 
and prostration) 
Conning and Hayes 1970 
(Mixed breed) 
Pig 24 hr 
0.44 F 
mg/cm²/d 
(twitching, tremors) 
Pullin et al. 1978 
P
H
E
N
O
L
3.  H
E
A
LTH
 E
FFE
C
TS
Cardio = cardiovascular; d = day(s); F = Female; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = 
no-observed-adverse-effect level; NS = not specified; Resp = respiratory 
80
   
 
    
 
 
 
 
 
 
 
   
 
 
 
   
       
 
     
 
   
   
 
 
      
  
     
    
  
    
 
 
 
 
      
  
 
  
   
  
 
      
   
PHENOL 81
3. HEALTH EFFECTS
study author also indicated that the arrhythmias were less severe in the patients treated over a longer
period of time.
Cardiac arrhythmia and bradycardia were reported in a man that splashed an unspecified concentration of
a phenol-water solution over his face, chest wall, hand, and both arms (Horch et al. 1994).  The cardiac 
effects were noted during the first 6 hours after exposure.  The serum levels of phenol in μg/L were
11,400 after 1 hour, 17,400 after 4 hours, and 6,000 after 8 hours.  Premature heartbeats and arterial
fibrillation were reported in a male who experienced a 4.5-hour occlusive exposure to 90% phenol
(Bentur et al. 1998); the concentration of phenol in serum reached a peak of 21.6 mg/L.
Cardiac arrhythmia has also been noted in rabbits treated with 2 mL of a 50% phenol solution on a
15-cm2 area (23.8 mg/cm2/kg) (Wexler et al. 1984).  Reducing plasma concentrations of phenol by forced 
diuresis or a longer application time reduced the cardiac effects.
Gastrointestinal Effects. During the first few days after a man splashed a phenol-water solution 
(concentration not stated) on his face, chest wall, hand, and both arms, he complained of nausea and 
vomited twice (Horch et al. 1994).  A worker who was partially immersed for only a few seconds in a
shallow vat containing a mixture of 40% phenol in dichloromethane, collapsed after showering and was
taken to a hospital where he was found to have burns over 50% of his body.  Initial observations were
stable; however, after drinking fluids, he developed nausea and vomiting (Foxall et al. 1989).
No studies were located regarding gastrointestinal effects in animals following dermal exposure to
phenol.
Hematological Effects. No studies were located regarding hematological effects in humans
following dermal exposure to phenol.
Hemoglobinuria and hematin casts were reported in the renal tubules of rats treated dermally with 
108 mg/kg phenol (Conning and Hayes 1970).  These observations are indicative of red blood cell
hemolysis; however, this was not confirmed with hematological examinations.
Musculoskeletal Effects. Muscle pain in the arms and legs was reported in a case of chronic phenol
poisoning (Merliss 1972).  The man worked in a laboratory for 13.5 years where he distilled phenol
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several times a day.  During the process, heavy odors were detectable, phenol was often spilled on his
clothes, and he noted skin irritation.  The man recovered after 2–3 months away from the exposure.
No studies were located regarding musculoskeletal effects in animals following dermal exposure to
phenol.
Hepatic Effects. Two days after a man was splashed with a phenol-water solution over his face, chest
wall, hand, and both arms, serum bilirubin increased 2-fold (Horch et al. 1994). After 5 days, serum
bilirubin returned to normal.  An enlarged and tender liver and increased liver transaminase activity in the
serum were reported in a case of chronic phenol poisoning (Merliss 1972).  Lactate dehydrogenase was
about 2-fold greater than normal, AST was about 21-fold greater than normal, and ALT was about
100-fold greater than normal.  The man worked in a laboratory for 13.5 years where he distilled phenol
several times a day.  During the process, heavy odors were detectable, phenol was often spilled on his 
clothes, and he noted skin irritation.
No studies were located regarding hepatic effects in animals following dermal exposure to phenol.
Renal Effects. Renal tubule cell vacuolization was described in a fatal case of dermal poisoning with 
phenol (Soares and Tift 1982). A case of acute renal failure was reported by Foxall et al. (1989) in a
worker who accidentally fell into a shallow vat containing a mixture of phenol (40%) in dichloromethane.  
The worker was partially immersed for only a few seconds and avoided ingesting any of the solution.  He
showered immediately, subsequently collapsed and was admitted to the hospital with surface burns over
50% of his body (involving the face, chest, genitals, and both legs).  Following admission he became
anuric and plasma creatinine levels rose.  He was transferred to the regional renal unit where he was 
diagnosed with phenol- induced burns, acute tubular necrosis, and fluid overload.  For the first 2 weeks, 
the patient demonstrated amino aciduria, glycosuria, and lactic aciduria consistent with renal cortical
necrosis.  This was followed by a period of polyuria revealing a biochemical pattern consistent with renal
papillary damage.  Treatment consisted of administration of a diuretic intravenously and hemodialysis
daily for a week followed by an additional 18 days of hemodialysis at gradually increasing intervals.  The 
patient was discharged 42 days after admission once renal clinical chemistry values had return to normal, 
although nuclear magnetic resonance (NMR) spectroscopic analysis still revealed abnormalities consistent
with renal papillary damage.  One year after the incident, the patient was still polyuric.
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Dark urine was reported in a case of chronic phenol poisoning (Merliss 1972).  The man worked in a
laboratory for 13.5 years where he distilled phenol several times a day.  During the process, heavy odors 
were detectable, phenol was often spilled on his clothes, and he noted skin irritation.  The study authors
indicated that the urine was so dark that it suggested hemoglobinuria.  Glucose was present in the urine, 
although the urine was negative for homogentistic acid (a substance whose presence can cause urine to 
darken upon standing) and urobilinogen.  The urine cleared 2–3 months after the subject was removed
from phenol exposure.  Dark urine was also observed in a man who spilled 90% phenol over an occluded 
area of the skin and kept the area unattended for 4.5 hours (Bentur et al. 1998).
Hemoglobinuria and hematin casts in the distal convoluted tubules and tubular lumens located in the
medulla and papilla were reported in rats after a single dermal exposure to 107 mg/kg liquid phenol
(Conning and Hayes 1970).  These phenomena are probably related to red blood cell lysis and increased 
glomerular filtration of hemoglobin.  Hemoglobinuria is characteristic of lethal or near-lethal exposures
by the dermal route.
Dermal Effects. Application of phenol to the skin of humans results in dermal inflammation and 
necrosis (Horch et al. 1994; Merliss 1972; Truppman and Ellenby 1979).  Data concerning minimal
effective exposure levels in humans were not found.  NIOSH (1983) conducted a survey in an Oregon 
hospital in response to concerns about respiratory problems and contact dermatitis in housekeeping staff
members who were exposed frequently to germicidal solutions containing phenol and other solvents
(formaldehyde, cellosolve, ethanolamine).  The housekeeping staff reported significantly more symptoms
of cough, itching, sinus problems, and dermatitis than did other employees.  Air concentrations of phenol
in the work areas were below the limit of detection (<0.01 ppm).  Urinary phenol levels in the
housekeeping staff members were not significantly different from those of the other employees.  Thus, 
while it is likely that the employees came into contact with irritants, the cause of the reported symptoms 
could not be attributed to phenol or any other specific substance in the work environment.  Therefore, this
study is not recorded in Table 3-3.
Application of 0.1 mL of molten phenol/kg (≈100 mg/kg) (Brown et al. 1975) or 107 mg/kg (Conning and 
Hayes 1970) to the skin of rats for 24 hours (surface area not reported) produced severe edema, erythema, 
and necrosis.  In pigs, application of 500 mg/kg molten phenol to 35–40% of the body surface
(0.44 mg/cm2/kg) resulted in skin discoloration after 20–30 minutes of exposure and severe necrosis after
8 hours of exposure. Two of three pigs died within 95 minutes after exposure (Pullin et al. 1978).  
Necrosis, hyperemia of superficial dermal vessels, and dense perivascular infiltration of lymphocytes and 
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neutrophils were noted in the skin of pigs treated dermally with an unspecified amount of 89% phenol
(Hunter et al. 1992).  The dose-effect relationship and time course for skin irritation and inflammation 
have been studied in mice (Patrick et al. 1985).  The end point examined was swelling (increased 
thickness) of the ear after dermal application to the ear pinna.  Application of 12 mg/cm2/kg of phenol to 
the ear resulted in swelling in four of nine mice within 1 hour after application.  Severity of skin irritation
increased as the concentration of the applied phenol solution increased.  Swelling persisted for 6 weeks 
after application of 18 mg/cm2/kg.  Swelling was observed in only one of eight mice treated with
12 mg/cm2/kg phenol.  Application of 3.5 mM phenol/kg to a 3-cm2 shaved dorsal area from mice 
resulted in inflammation, as evidenced by an increase in skin bi-fold thickness and recruitment of
inflammatory cells (Murray et al. 2007).  This was accompanied by oxidation of glutathione and protein 
thiols and decreased vitamin E and total antioxidant reserves in the skin.  Application of an unspecified 
amount of a 1:6 or 1:9 phenol:water solution to the skin of guinea pigs for 1 minute resulted in erythema 
and increased skin vascular permeability indicated by dye permeability (Steele and Wilhelm 1966).  
Skin crusts were reported on mice exposed repeatedly to 5 mg phenol as a 5% (w/v) solution for
32 weeks, whereas skin ulceration was observed in mice exposed to 5 mg phenol as a 20% (w/v) solution 
(Salaman and Glendenning 1957).  The skin ulceration healed in 4 weeks after the end of the exposure.  
In a 52-week study, mice were exposed 2 times each week to 42 or 83 mg/kg of phenol in a 5 or 10%
solution in benzene (Boutwell and Bosch 1959).  Severe skin damage was reported after 36 weeks in the
mice exposed to 83 mg/kg.  Skin papillomas were reported in mice exposed at 42 mg/kg.  Because phenol
was applied in benzene which is also a skin irritant, this study is not presented in Table 3-3.
Direct application of phenol to the inner ear of rats has resulted in external otitis, inner ear damage 
(Schmidt et al. 1990), and inflammation of the tympanic membrane (Schmidt and Hellström 1993).  
These studies were conducted because phenol has been used as a topical anesthetic in infected ears.
Ocular Effects. No studies were located regarding ocular effects in humans following dermal
exposure to phenol. 
A modified Draize test was used to assess ocular damage resulting from application of 5% phenol to the
center of the cornea in New Zealand rabbits (Murphy et al. 1982).  The eyes of one group of rabbits were
irrigated with water 30 seconds after exposure, while the eyes of another group were unirrigated.  
Conjunctivitis developed in all treated groups and lasted through the 7 days of observation.  Corneal
opacities became apparent in four of nine rabbits 24 hours after phenol application in unirrigated eyes, but
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only 1 hour after application in four of nine rabbits receiving irrigation.  The opacities lasted through the
7-day observation period in the unirrigated eyes, but were cleared by day 7 in the irrigated eyes.  Based 
on these observations, phenol was designated as a severe eye irritant in unirrigated eyes, and as a 
moderate eye irritant in irrigated eyes (Murphy et al. 1982).
Body Weight Effects. A man chronically exposed to phenol at a laboratory where he distilled it
several times a day was 71.5 inches tall, weighed 135 pounds, and was described as emaciated (Merliss 
1972).  Loss of appetite and a slow weight loss were symptoms that the subject reported during the
13.5 years he worked at the laboratory.  During the distillation process, heavy odors were detectable, 
phenol was often spilled on his clothes, and he noted skin irritation.
No studies were located regarding body weight effects in animals following dermal exposure to phenol.
3.2.3.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans or animals 
following dermal exposure to phenol.
3.2.3.4  Neurological Effects 
Fatal dermal exposure to an 80% phenol solution in a 24-year-old man being treated for skin rash was
characterized by severe convulsions prior to death (Lewin and Cleary 1982).  A child who suffered 
accidental dermal poisoning with phenol became listless and developed seizures before death (Soares and 
Tift 1982).  Seizures were also reported in a young adult who splattered a solution containing 30% of
phenol over portions of his face, neck, and right trunk and later died (Soares and Tift 1982).  A man who 
spilled 90% phenol over his foot and shoe had hypalgesia and hypoesthesia of the affected area in 
addition to confusion, vertigo, and faintness (Bentur et al. 1998).
Muscle tremors and convulsions are characteristic effects of acute dermal phenol toxicity in laboratory
animals.  Tremors that developed into convulsions and prostration were reported in rats exposed to 
107 mg/kg liquid phenol; application surface areas were not reported (Conning and Hayes 1970).  In pigs, 
application of 500 mg/kg over 35–40% of the body surface (0.44 mg/cm2/kg) resulted in muscular
tremors in the head region within 3–5 minutes of exposure (Pullin et al. 1978).  This was followed by
dilation of the pupils, loss of coordination, and excess salivation and nasal discharge within 5 minutes of
exposure.  It was followed by convulsions, coma, and death 5–7 minutes after exposure in two of three
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pigs.  Direct application of a dose of 38 mg/kg phenol to the inner ear resulted in a reduced threshold for
auditory brainstem response (Schmidt et al. 1990).
No studies were located regarding the following health effects in humans or animals after dermal
exposure to phenol:
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
No studies were located regarding cancer in humans following dermal exposure to phenol.
In a study of the promoting effects of phenol, mice were exposed to 9,10-dimethyl-1,2-benzanthracene
(9,10-DMBA) (300 μg) followed by weekly dermal exposure to 5 mg phenol in either a 5 or 20% phenol
solution in acetone for 32 weeks (Salaman and Glendenning 1957).  Exposure to 9,10-DMBA followed 
by phenol (5 or 20%) resulted in a significantly greater incidence of tumors, including carcinomas, than 
exposure to 20% phenol alone; tumors, but no carcinomas, resulted from exposure to 20% phenol, and no 
tumors resulted from exposure to 5% phenol.  Application of 5% phenol alone resulted in skin "crusting"
at the site of application, whereas 20% phenol resulted in skin ulceration.  The study authors concluded 
that phenol was an effective tumor promoter after a single application of 9,10-DMBA.  Although this
study did not include a group of animals that had been exposed to 9,10-DMBA alone, the authors 
indicated that previous work done in their laboratory provided the data from such animals and that it was
thus the comparison between such historical information and the information from this study which led to 
their conclusion about the promotional effects of phenol.
A similar promoting activity was observed when an unspecified volume of 10% phenol in acetone was
placed on the backs of mice 2 times/week for 12 months and when 5% phenol in acetone was placed on 
the backs of mice 3 times/week for 12 months (Wynder and Hoffmann 1961).  
Additional studies indicate that phenol applied to the skin is a cancer promoter and possibly a complete
carcinogen (i.e., promoter and initiator) in mice.  Boutwell and Bosch (1959) examined the carcinogenic
effects of phenol in several strains of mice.  Mice were exposed to a single dermal application of
9,10-DMBA (75 mg) followed by repeated dermal applications of a 5 or 10% phenol solution in benzene
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(42 or 83 mg/kg/treatment), twice each week for 52 weeks.  Two other experimental groups of mice were 
exposed to 9,10-DMBA alone or phenol alone.  Severe skin damage, decreased body weight, and 
increased mortality were observed in phenol-treated animals.  Sutter strain mice (inbred for 
three generations for susceptibility to the initiator 9,10-DMBA) treated with 9,10-DMBA followed by
10% phenol developed papillomas (95% in 13 weeks) and carcinomas (43% in 42 weeks) at a much 
higher incidence than mice treated with 9,10-DMBA alone (14% with papillomas at 42 weeks; no 
carcinomas), or phenol alone (36% with papillomas at 52 weeks; no carcinomas).  One fibrosarcoma was 
observed after 52 weeks of exposure to phenol alone.  An elevated incidence of papilloma was also 
observed in CAF1, C3H, and Holtzmann mice exposed to 9,10-DMBA followed by phenol, and in
Holtzmann mice exposed to 10% phenol alone. The promoting effect of phenol was dose related;
application of 5% phenol (41.7 mg/kg) following 9,10-DMBA treatment resulted in fewer tumors than a 
similar protocol using 9,10-DMBA followed by 10% phenol (83.3 mg/kg).  Phenol elicits skin tumors in 
mice even without treatment with 9,10-DMBA.  Ten out of 30 albino mice treated twice weekly for 
12 weeks with a 20% phenol solution in dioxane developed papilloma of the skin; also, 8 out of 30 mice 
treated with 10% phenol solution in benzene for 15 weeks developed papilloma, and 3 developed 
carcinoma of the skin (Boutwell and Bosch 1959).  Because the phenol was administered in benzene or
dioxane, both of which are skin irritants and/or de-fatting agents, this study is not presented in Table 3-3.
The effect of phenol on benzo[a]pyrene (B[a]P) carcinogenicity has been examined (Van Duuren and 
Goldschmidt 1976; Van Duuren et al. 1971, 1973).  Dermal application of 3 mg phenol in acetone
simultaneously with 5 μg B[a]P resulted in significantly fewer tumors than application of B[a]P alone.  
Application surface areas were not reported and could not be estimated from the description of the
application procedure.  Mice treated dermally with B[a]P followed by dermal application of brewed tea
on alternate days over a period of 55 days developed epithelial cell carcinoma or exhibited various stages
of squamous cell tumors (Kaiser 1967).  The brewed tea contained an unspecified level of phenol, the
presumed cancer promoter in this experiment, as well as cresols and dimethylphenols.
3.3  GENOTOXICITY
Phenol has been evaluated for genotoxicity in both in vivo (Table 3-4) and in vitro (Table 3-5) test
systems.  End points evaluated in in vivo mammalian test systems include chromosomal aberrations, 
micronucleus, and deoxyribonucleic acid (DNA) synthesis.  Several different cell types have been 
monitored, including bone marrow, liver, and renal cell.  Both positive and negative results have been 
reported for in vivo genotoxicity tests.  In vitro studies have been conducted in prokaryotic and eukaryotic
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Table 3-4.  Genotoxicity of Phenol In Vivo
Species (test system) End point Results Reference
Mammalian cells:
Mouse bone marrow Chromosomal aberration – Barale et al. 1990; Chen and 
Eastmond 1995a; Pashin et al.
1987
Mouse bone marrow Chromosomal aberration + Shelby and Witt 1995
Mouse spermatocytes Chromosomal aberration + Bulsiewicz 1977
Bone marrow from pregnant Micronucleus + Ciranni et al. 1988
mice
Mouse fetal liver cells Micronucleus – Ciranni et al. 1988
Mouse bone marrow Micronucleus + Li et al. 2005; Shelby and Witt
1995
Mouse bone marrow Micronucleus – Barale et al. 1990; Gocke et al.
1981
Mouse tubular renal and liver DNA synthesis + Amlacher and Rudolph 1981
epithelial
Rat testes DNA synthesis – Skare and Schrotel 1984
Rat liver DNA synthesis – Miyagawa et al. 1995
Insects:
Drosophila Micronucleus – Gocke et al. 1981; Sturtevant
1952
+ = positive response; – = negative response; DNA = deoxyribonucleic acid
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Table 3-5.  Genotoxicity of Phenol In Vitro
Results
With Without
Species (test system) End point activation activation Reference
Prokaryotic organisms:
Salmonella typhimurium
S. typhimurium
 
Escherichia coli
 
E. coli
Eukaryotic organisms:
Aspergillus
V79 Chinese hamster
cells
Chinese hamster ovary
cells
Chinese hamster ovary
cells (DNA strand breaks)
Crucian (goldfish)
erythrocytes
Mouse lymphoma (DNA
strand breaks)
Mouse spermatocytes
Rat liver mitochondria
Syrian hamster embryo
cells
Syrian hamster embryo
cells
Syrian hamster embryo
cells
Syrian hamster embryo
cells
Human lymphocytes
Human lymphocytes
Human lymphocytes
Human lymphocytes
Gene mutation
Gene mutation
Gene mutation
Gene mutation
Chromosomal
aberration
Gene mutation
Micronuclei
Chromosomal
aberration
DNA damage
Chromosomal
aberration
DNA damage
DNA synthesis
Gene mutation
Chromosomal
aberration
Sister chromatid 
exchanges
Unscheduled DNA
synthesis
Sister chromatid 
exchanges
Sister chromatid 
exchanges
Sister chromatid 
exchanges
DNA damage
–
+
–
No data
No data
+
+
No data
No data
No data
No data
No data
No data
No data
No data
No data
+
No data
No data
No data
–
–
–
+
+
–
+
–
+
–
+
–
+
+
+
+
+
–
+
+
Florin et al. 1980;
Haworth et al. 1983;
Kubo et al. 2002; Pool
and Lin 1982
Gocke et al. 1981
Nagel et al. 1982
Demerec et al. 1951
Crebelli et al. 1987
Paschin and Bahitova 
1982
Miller et al. 1995
Sze et al. 1996
Li et al. 2005
Pellack-Walker and 
Blumer 1986
Li et al. 2005
Schwartz et al. 1985
Tsutsui et al. 1997
Tsutsui et al. 1997
Tsutsui et al. 1997
Tsutsui et al. 1997
Morimoto and Wolff
1980; Morimoto et al.
1983
Jansson et al. 1986
Erexson et al. 1985
Li et al. 2005
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Table 3-5.  Genotoxicity of Phenol In Vitro
Species (test system) End point
Human diploid fibroblasts DNA synthesis
HeLa cells DNA synthesis
Results
With
activation 
Without
activation 
No data +
+ No data
Reference
Poirier et al. 1975
Painter and Howard 
1982
+ = positive response; – = negative response; DNA = deoxyribonucleic acid
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test systems. Results for various end points (gene mutation, chromosomal aberration, micronuclei, DNA
damage, sister chromatid exchanges, and unscheduled DNA synthesis) have been both positive and 
negative.  The mixed results in both the in vivo and in vitro assays indicate that under certain conditions, 
especially at higher doses, phenol has the potential to be genotoxic.  However, at the exposure levels 
likely to occur near hazardous waste sites, phenol is not anticipated to be genotoxic.
Positive and negative results have been reported for phenol in in vivo chromosomal aberration tests. 
Increases in chromosomal aberrations have been reported in bone marrow (Shelby and Witt 1995) and in
spermatocytes (Bulsiewicz 1977) from mice treated with phenol.  Chromosomal aberrations were
reported in the bone marrow of male B6C3F1 mice exposed to phenol through intraperitoneal injection 
(Shelby and Witt 1995).  Bulsiewicz (1977) also reported results of a five-generation study with Porton 
strain inbred mice.  Chromosomal aberrations were monitored in spermatogonia and spermatocytes of
gavage treated mice.  Dose dependent increases in aberrations were observed with succeeding
generations.  The investigator attributed the observed chromosomal effects to interactions of phenol with 
the spindle apparatus.  Other studies have not observed chromosomal aberrations in bone marrow from
mice treated with phenol (Barale et al. 1990; Chen and Eastmond 1995a; Pashin et al. 1987).  In tests of
feeding and injection exposures of Drosophila to phenol, results were negative in sex-linked recessive 
lethal assays (Gocke et al. 1981; Sturtevant 1952).    
Positive (Ciranni et al. 1988; Li et al. 2005; Shelby and Witt 1995) and negative (Barale et al. 1990;
Gocke et al. 1981) results were reported for in vivo micronucleus assays in bone marrow isolated from
mice treated with phenol.  Bone marrow micronucleus tests were positive for male B6C3F1 mice exposed 
to phenol through intraperitoneal injection (Shelby and Witt 1995).  In a study of pregnant CD-1 mice 
receiving doses of phenol, maternal bone marrow micronuclei were studied.  Pregnant mice were treated 
by gavage with a single dose of 265 mg/kg of phenol on GD 13.  Observed effects included an increase in 
bone marrow micronuclei and cytotoxicity.  Micronuclei were not observed in fetal liver tissue (Ciranni et
al. 1988).  Bone marrow of Kunming mice exposed to concentrations of 20, 40, or 80 mg/kg of phenol
through intraperitoneal injection showed increased frequency of micronuclei at dose levels of 40 and 
80 mg/kg (Li et al. 2005). However, exposures of male CD-1 mice to maximum intraperitoneal injections
of 160 mg/kg resulted in negative micronucleus tests (Barale et al. 1990).  Results were also negative for 
micronucleus assays in male and female NMRI mice dosed twice by intraperitoneal injections of 
188 mg/kg of phenol (Gocke et al. 1981). 
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Phenol increased DNA synthesis in tubular renal and liver epithelial cells from mice (Amlacher and
Rudolph 1981).  Skare and Schrotel (1984) reported the results of experiments where Sprague-Dawley
rats were dosed with single intraperitoneal injections of 79 mg/kg or five daily intraperitoneal injections
of 39.5 mg/kg/day.  Single strand breaks were not observed in testicular cells.  A DNA synthesis test in 
male B6C3F1 mice dosed by gavage with concentrations of 0, 300, and 600 mg/kg of phenol also was
negative (Miyagawa et al. 1995).
In vitro tests with phenol for gene mutations in microorganisms have yielded both negative (Florin et al. 
1980; Haworth et al. 1983; Kubo et al. 2002; Nagel et al. 1982; Pool and Lin 1982) and positive
(Demerec et al. 1951; Gocke et al. 1981) results.  Negative results have been reported in Salmonella 
typhimurium strains TA98, TA100, TA1535, TA1537, and TA1538 with and without S9 activation 
(Haworth et al. 1983; Kubo et al. 2002; Pool and Lin 1982).  However, increased mutagenicity was
observed in S. typhimurium TA98, with S9 activation (Gocke et al. 1981).  Paschin and Bahitova (1982)
also reported positive results at the HGPRT locus of V79 for mutagenicity studies involving exposures of
Chinese hamster ovary (CHO) cells, with S9 activation.  Studies of Syrian hamster embryos (SHE) were 
also positive for mutagenicity (Tsutsui et al. 1997).
In vitro studies regarding chromosomal aberrations in eukaryotic cells have been positive in Aspergillus
(Crebelli et al. 1987), and in SHE cells (Tsutsui et al. 1997), and negative in mouse lymphoma cells 
(Pellack-Walker and Blumer 1986) and CHO cells (Sze et al. 1996).  Tsutsui et al. (1997) reported dose-
dependent increases in the frequencies of chromosome aberrations in SHE cells exposed to phenol. 
Single strand breaks were not observed in mouse lymphoma L5178YS cells (Pellack-Walker and Blumer
1986).
The report of an in vitro micronucleus study with CHO cells was positive with and without S9 activation, 
with stronger results observed with S9 activation (Miller et al. 1995).
Results of in vitro sister chromatid exchange tests were reported as positive and negative.  Phenol
produced dose-related increases in sister chromatid exchanges in human lymphocytes at doses of
≥500 μM (Erexson et al. 1985).  In contrast, sister chromatid exchanges were not observed in human 
lymphocytes incubated with 0–2,000 μM phenol (Jansson et al. 1986).  Incubation of human lymphocytes
with 1,000,000 μM, but not 200,000 μM phenol for 72 hours resulted in an increase in sister chromatid 
exchanges (Morimoto and Wolff 1980).  Exposures of human lymphocytes to 3,000 μM phenol with S9 
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activation also resulted in an increase in sister chromatid exchanges (Morimoto et al. 1983).  Phenol
induced sister chromatid exchanges in SHE cells at doses of 1,000 and 3,000 μM (Tsutsui et al. 1997).  
In vitro assays for DNA synthesis have been negative in rat liver mitochondria (Schwartz et al. 1985), and 
positive in human fibroblasts (Poirier et al. 1975) and HeLa cells (Painter and Howard 1982).  However, 
unscheduled DNA synthesis was induced to the same degree in SHE cells incubated with phenol in 
concentrations ranging from 1 to 30 μM (Tsutsui et al. 1997). 
An in vitro study of DNA damage using the comet assay indicated that phenol induced DNA damage in 
human lymphocytes, mouse spermatocytes, and crucian erythrocytes.  In these tissues, amounts of DNA
damage increased in conjunction with increasing doses.  Observed DNA damage to mouse spermatocytes
and crucian erythrocytes was more significant than DNA damage to human lymphocytes (Li et al. 2005).  
3.4  TOXICOKINETICS
Phenol is readily absorbed and widely distributed following inhalation, oral, and dermal exposure.  The
distribution of phenol is thought to be dependent on blood flow.  Conjugates with glucuronic acid and 
sulfate are the major metabolites of phenol, although small amounts of the hydroxylation products
catechol and hydroquinone are also produced.  Sulfotransferase and glucuronyltransferases are present in 
most tissues, although the major sites of phenol conjugation are the gastrointestinal tract, liver, lung, and 
kidney.  Because of the large capacity of the intestines and liver to conjugate phenol, the fact that the
first-pass effect occurs following oral exposure but not following dermal exposure may contribute to the
greater potential for phenol to result in adverse effects following dermal exposure.  Phenol and its
conjugates are predominantly excreted in the urine.
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
Phenol is absorbed readily after inhalation exposure.  Eight subjects were exposed to phenol vapors (1.6– 
5.2 ppm) for 8 hours (Piotrowski 1971).  Subjects were exposed through a face mask in order to eliminate
the possibility of percutaneous absorption.  The concentration of phenol in inhaled and exhaled air was
determined, and urine was analyzed for total phenol (phenol and phenol conjugates).  Steady-state 
appeared to be achieved within 3 hours after initiating exposure; steady-state retention was 60–88%.  
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Urinary recovery of phenol that had been retained in the lungs was 99±8% within 24 hours after initiating
exposure.  
Total urinary phenol was determined at about 7 hours into an 8-hour shift in Bakelite workers exposed to 
airborne phenol at 0.16–32 ppm (Ohtsuji and Ikeda 1972).  Daily urinary excretion of total phenol was
99% of the estimated amount inhaled indicating that phenol is readily absorbed.  However, lung retention
was not measured, and the contribution of percutaneous absorption to urinary phenol could not be
evaluated in this study.
Rats exposed by intratracheal instillation to [14C]-labeled phenol also demonstrated rapid absorption 
kinetics, with most of the radioactivity being excreted within 72 hours (Hughes and Hall 1995).  Rats
exposed for 6 hours nose-only to 25 ppm [14C]-labeled phenol demonstrated rapid absorption.  Greater
than 90% of phenol-derived radioactivity was measured in the urine 30 minutes after initiation of
exposure (Hiser et al. 1994).
3.4.1.2  Oral Exposure
Based on the rapid excretion of phenol and its metabolites in urine, it has been concluded that phenol is
readily absorbed by the oral route in humans (Capel et al. 1972) and a variety of mammalian species 
including monkeys (Capel et al. 1972), rodents (Capel et al. 1972; Edwards et al. 1986; Hughes and Hall
1995; Kao et al. 1979; Kenyon et al. 1995), dogs (Capel et al. 1972), rabbits (Capel et al. 1972), cats
(Capel et al. 1972; French et al. 1974), and pigs (Capel et al. 1972; Kao et al. 1979). 
In three men given a single oral dose of 0.01 mg/kg [14C]-labeled phenol in food or drink, about 90%
(range 85–98%) of the dose was excreted in the urine in 14 hours (Capel et al. 1972).  In this same study, 
urinary recovery of orally administered [14C]-labeled phenol was determined in 18 other mammalian 
species; mean 24-hour recoveries of 14C ranged from 95% in the rat to 31% in the squirrel monkey.  Rats
exposed orally to radiolabeled phenol demonstrated rapid absorption and excretion, with most of the
radioactivity being excreted within 72 hours (Hughes and Hall 1995).  The gastrointestinal absorption of
phenol has also been studied in rats with in situ preparations.  The absorption kinetics of [14C]-labeled 
phenol administered directly into the small intestines of rats were described as first-order, with a rate
constant for intestinal absorption of 0.127±0.003 minute-1 (or half-life of 5.5±0.5 minutes from
t½=0.693k) (Humphrey et al. 1980).  Two hours after [14C]-labeled phenol was injected into the small 
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intestines of anesthetized rats, recoveries in the urine were 77.9±2% after a 12.5-mg/kg dose, and 
76.9±5.8% after a 25-mg/kg dose (Kao et al. 1979).  
Hiser et al. (1994) reported results of the kinetics of oral doses of phenol in rats.  Exposures included
single and multiple bolus and drinking water doses of different concentrations.  Peak blood concentrations
of free phenol of 0.02 μg/g blood in rats receiving 1.5 mg/kg bolus dose were reached 1–3 minutes after
receiving the dose.  A terminal half-life of about 8 minutes was calculated for phenol following low
doses.  Peak blood concentrations of phenol of 46.4 μg/g blood in rats receiving 150 mg/kg bolus dose
were reached 1 minute after receiving the dose.  Since the doses were separated by only a factor of
100 and the blood peak concentration by a factor of 2,320, these results suggest saturated absorption or
saturated metabolism and excretion.  After 24 hours, concentrations of administered [14C]-radioactivity
were >90% in the urine, regardless of the dosing method or concentration.
3.4.1.3  Dermal Exposure 
Phenol is readily absorbed through the skin, and the skin is considered the primary route of entry during
occupational exposure (ACGIH 2005).  Whole-body skin exposures studies were conducted in volunteers
lightly clothed and unclothed (Piotrowski 1971).  The subjects were exposed to phenol vapor (35%
humidity, 26 °C) at concentrations of 1.3, 2.6, or 6.5 ppm for 6 hours.  Fresh air was supplied to the
subjects through a face mask in order to prevent absorption of phenol through the lungs.  The total
amount of phenol excreted in urine during and after exposure (minus baseline excretion) was used as a
measure of absorption.  Absorption increased proportionately with exposure level.  Percutaneous
clearance (mg phenol absorbed through the skin per hour/mg phenol per m3 of air) was estimated to be 
0.35 m3/hour.  Thus, an amount of phenol equivalent to that contained in 0.35 m3 of air was absorbed 
through the skin each hour.
The data reported by Piotrowski (1971) provide a basis for comparing the relative contributions of lung
and percutaneous absorption during exposures to phenol vapor.  Assuming a ventilation rate for the
human of 0.8 m3/hour (EPA 1986a) and a steady-state lung retention of inhaled phenol of 0.7 m3/hour
(Piotrowski 1971), clearance of airborne phenol through the lung is ≈0.6m3/hour.  Thus, an amount of
phenol equivalent to that contained in 0.6 m3 of air was absorbed through the lungs each hour.  It can be
concluded that at any given exposure level within the range of 5–25 mg/m3 (1.3–6.4 ppm), percutaneous
absorption (0.35 m3/hour) will be about half that of absorption through the lungs (0.6 m3/hour).
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Percutaneous absorption of phenol applied in solution directly to the forearm (15.6 cm2) of volunteers has
been measured (Baranowska-Dutkiewicz 1981).  Absorption rate from a 2-mL reservoir of an aqueous 
phenol solution (2.5, 5.0, or 10.0 g/L) was constant for 60 minutes (0.08 mg/cm2/hour) and increased 
proportionately with applied concentration.  Approximately 13% of the applied dose was absorbed in 
30 minutes, of which 80% (range 58–98%) was recovered in the urine within 24 hours.
When human skin was treated in vitro with 0.0013–0.0027 mg/cm2 [14C]-labeled phenol and left 
unoccluded, 20% of the radioactivity was absorbed when analyzed 72 hours later, while 7% remained on 
the skin surface (Hotchkiss et al. 1992).  Covering the skin with a teflon cap resulted in the absorption of
47%, with 3% recovered in the skin. When rat skin was subjected to the same exposure regime in this 
study, 72 hours later, 24% of the radioactivity was absorbed with 22% recovered in the skin when the skin 
was unoccluded, and 36% was absorbed with 3–4% recovered in the skin when the skin was occluded.
In rats in which a 0.03-mg/kg dose of [14C]-labeled phenol was placed on the skin, only 1–5% of the dose
remained in the body 72 hours later (Hughes and Hall 1995).  The dermal absorption of phenol was also 
studied in three pigs in which undiluted phenol was placed on the skin for 1 minute, and the peak plasma 
level was determined (Pullin et al. 1978).  Plasma levels were not measurable in one pig treated with a
dose of 90 mg/kg over a surface area of 91.6 cm2. In pigs treated with a dose of 500 mg/kg over surface 
areas of 91.6 and 1,135.5 cm2, peak plasma levels of 0.9 and 30.5 ppm were reported, respectively.
Permeability coefficients for phenol in isolated skin patches from nude mice have been determined (Behl
et al. 1983).  The permeability coefficient increased as the concentration of the applied aqueous phenol
solution increased; doubling the concentration from 20 to 40 g/L resulted in a 12-fold increase in mean 
permeability coefficient (0.007–0.085 cm/hour).  The value obtained for the permeability coefficient
when 60 g/L was applied to the skin patch (0.169 cm/hour) was similar to that obtained for skin patches
in which the stratum corneum had been removed.  It was concluded that phenol concentrations exceeding
20 g/L may destroy a diffusion barrier normally provided by the intact stratum corneum, permitting
increased percutaneous absorption.
Dermal absorption of phenol in the presence of various types of soil was measured in vitro using skin 
patches from pigs (Skowronski et al. 1994). Maximum phenol penetration occurred between 2 and 
4 hours after treatment in all cases.  Compared to samples with no soil present, the presence of sandy soil
reduced the peak penetration by one-half, and the presence of clay soil reduced peak penetration by two-
thirds.
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3.4.1.4  Other Routes of Exposure 
Nomoto et al. (1987) studied the absorption of phenol after injection into 20 patients as part of lumbar or
thoracic sympathetic blockades.  Patients were injected with 5–10 mL 7% phenol.  The concentrations of
unconjugated and conjugated phenol (sulfate esters and glucuronic esters) were monitored in blood and 
urine samples.  Unconjugated phenol reached a mean peak concentration in blood of 3.01±0.28 μg/mL
18.8±2.5 minutes after the injection.  The mean peak concentration of conjugated phenol in the blood was
4.15±0.25 μg/mL 54.9±4.5 minutes after the injection.  The authors concluded that uptake times indicated 
rapid absorption of phenol after injection. The lag time of unconjugated phenol was 5.3±1.6 minutes, 
indicating that phenol remained at the injection site before being taken up into the blood.  The lag time of
conjugated phenol was 9.9±5.9 minutes.
There is also indirect evidence of phenol being absorbed following phenol injection sclerotherapy for
hemorrhoids.  Suppiah and Perry (2005) reported the case of a 43-year-old man who developed jaundice
after an unspecified number of injections of 2 mL of a 5% solution of phenol at hemorrhoidal tissue
during several months.  Liver function tests returned to normal after 6 months. 
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
No studies were found regarding tissue distribution of phenol in humans after inhalation exposure.
Rats exposed by intratracheal instillation to radiolabeled phenol were sacrificed 72 hours later and 
analyzed for tissue distribution of the radioactivity (Hughes and Hall 1995).  Of the radioactivity
remaining in the body (1–5%), a majority was distributed in the lungs (0.13%), skin (0.13%), blood 
(0.07%), muscle (0.03%), fat (0.02%), and liver (0.02%).
No information was found on the placental transfer and distribution of phenol; however, Ghantous and 
Danielsson (1986) examined this question for benzene, the principal metabolite of which is phenol.  Mice,
at GDs 11, 14, and 17, were exposed by inhalation to [14C]-benzene and the distribution of benzene and 
its volatile and nonvolatile metabolites was examined using whole-body autoradiography and assessment
of tissue concentrations of 14C (day 17 only).  The authors indicated that the exposure regimen (50 μCi of
[14C]-benzene in maize oil, volatilized by gentle heating) would theoretically produce 2,000 ppm in the
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inhalation chamber.  Measurements of the difference between the amount added to the chamber and the 
amount inhaled by the animals indicated an uptake of 90% (i.e., 45 μCi).  These authors did not
specifically characterize the metabolites, but were able to show that the [14C]-labeled volatile and 
nonvolatile activity crossed the placental barrier.  There was no evidence of preferential accumulation.  
Indeed, the concentration of volatile and nonvolatile radioactivity in fetal tissues was much lower than
that observed in the corresponding maternal tissues.  As a metric of the relative accumulation, the authors 
noted that compared to maternal brain tissue, fetal uptake of benzene was only 8%.
In a study conducted by Hiser et al. (1994), rats were exposed 6 hours nose-only to 25 ppm [14C]-phenol
for either 1 or 8 days.  Mean percent of administered dose/g were reported for several tissues.  
Radioactivity was quantified in blood, bone, brain, fat, heart, kidney, liver, lung, muscle, skin, spleen, 
testes, ovaries, and carcass 24 hours after exposure.  No single tissue seemed to preferentially accumulate 
phenol-derived radioactivity and, in all cases, concentrations were <0.02% administered dose/g tissue.  
No significant differences were seen between the 1- and 8-day exposure experiments.
3.4.2.2 Oral Exposure
Limited information in humans is available from cases of accidental or intentional ingestion of phenol 
that resulted in fatalities.  One case involved ingestion of a mixture of phenol and cresol.  The
concentrations of phenol measured in the blood, urine, and stomach content were 58.3, 3.3, and 
115 μg/mL, respectively (Boatto et al. 2004).  Another case involved ingestion of a mixture of phenol and 
chloroform.  Phenol was measured at 60 μg/mL in the blood and 208 μg/mL in the urine. Concentrations
in the brain, lungs, liver, and kidney were 106, 116, 166, and 874 μg/g, respectively (Tanaka et al. 1998).  
The third case involved ingestion of phenol, which resulted in the following tissue concentrations of
phenol:  blood, 130 μg/mL; urine, 47 μg/mL; bile, 187 μg/mL; brain, 486 μg/g; kidney, 331 μg/g; muscle, 
204 μg/g; liver, 228 μg/g; and stomach content, 668 mg (Lo Dico et al. 1989). 
In animals, information is available for rabbits (Deichmann 1944) and rats (Hiser et al. 1994; Hughes and 
Hall 1995; Liao and Oehme 1981).  In rabbits, distribution is rapid, with peak tissue concentrations
achieved in most tissues within 1 hour after dosing.  The highest peak concentrations and fraction of
administered dose are found in the liver; >90% of the administered dose is eliminated from tissues within 
24 hours.
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The levels of phenol in various tissues of five rabbits given a lethal (LD50) oral dose of phenol
(500 mg/kg) were determined (Deichmann 1944).  The rabbits were killed within 1–3 minutes after
dosing when twitching, the first sign of systemic toxicity, appeared.  The highest concentrations of total
phenol (free plus conjugates) were found in the liver (20.9–30.4 mg/100 g tissue), lungs (5.1– 
17.1 mg/100 g), blood (6.1–12.6 mg/100 g), brain and spinal cord (3.1–10.4 mg/100 g), and kidneys (2.3– 
7.1 mg/100 g).  
The kinetics of tissue distribution of [14C]-labeled phenol in rats given 207 mg/kg of [14C]-labeled phenol, 
a sublethal (≈0.5xLD50) oral dose, were studied (Liao and Oehme 1981).  Although all rats survived for
16 hours, signs of systemic toxicity were observed including twitching of muscles around the eyes and
ears, convulsions, and coma persisting for 15–30 minutes.  Thirty minutes after dosing, 28.4% of
administered 14C was recovered in tissues (liver, kidney, adrenal, thyroid, spleen, blood, lung, thymus, 
brain, testes, heart, muscle, and fat).  Sixteen hours after dosing, 0.3% of the administered dose was
recovered in tissues.  Concentrations of 14C were highest in all tissues 30 minutes after dosing, with the
exception of the thyroid gland, in which peak concentrations were achieved after 2 hours.  The highest
concentration and fraction of administered dose were found in the liver; 42% (range 29–56%) of the
administered dose was recovered in the liver 30 minutes after dosing.  Approximately 67–85% of the 14C 
in blood was present in the plasma fraction, of which 41–50% was bound to plasma proteins or other
macromolecules.  The elimination half-time for 14C was <4 hours.  Based on their results, the study
authors suggested that blood flow determines the tissue uptake of the radiolabel from phenol.
Rats exposed orally to radiolabeled phenol were sacrificed 72 hours later and analyzed for tissue
distribution of the radioactivity (Hughes and Hall 1995).  Of the radioactivity remaining in the body, a
majority was distributed in the muscle (0.08%), skin (0.07%), fat (0.02%), liver (0.02%), and blood
(0.02%).
No evidence of exposure-related DNA adduct formation in femur bone marrow, Zymbal gland, liver, or
spleen was seen in rats treated orally with 75 mg/kg/day phenol for 4 days (Reddy et al. 1990).  In this
study, concurrent in vitro exposures of these tissues did produce adducts, suggesting that efficient 
detoxification and excretion mechanisms may be operating in vivo.
In a study conducted by Hiser et al. (1994), rats were exposed to [14C]-phenol via single gavage doses of
1.5, 15, or 150 mg/kg, multiple gavage doses of 1.5 mg/kg/day, 5,000 ppm in drinking water for 1 day, or
5,000 ppm in drinking water for 8 days.  In all cases, phenol-derived radioactivity was detected in blood, 
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bone, brain, fat, heart, kidney, liver, lungs, skin, spleen, testes, ovaries, and carcass 24 hours after
exposures.  Regardless of the dosing method or dose level, no single tissue seemed to accumulate 
radioactivity, with all measured concentrations being <0.02% of the administered dose/g tissue.  
3.4.2.3  Dermal Exposure 
Limited information is available in humans from a fatal case.  Tissue samples (liver, blood, lung, urine, 
and stomach contents) from an individual who was painted with benzyl benzoate with a brush that had 
been soaked in 80% phenol were analyzed for phenol.  The blood contained 4.7 μg/mL phenol and 
unhydrolyzed and hydrolyzed liver samples contained 3.3 and 7.1 μg/g phenol, respectively.  Phenol was
not detected in the lung, urine, or stomach contents (Lewin and Cleary 1982).
Rats exposed dermally to radiolabeled phenol were sacrificed 72 hours later and analyzed for tissue
distribution of the radioactivity (Hughes and Hall 1995).  Of the radioactivity remaining in the body (1– 
5%), a majority was distributed in the skin (0.021%), muscle (0.02%), fat (0.03%), liver (0.01%), and 
blood (0.02%).
3.4.2.4  Other Routes of Exposure 
No studies were located regarding distribution of phenol in humans after exposure by other routes.
Microdialysis sampling has been used in rats infused with phenol (0.181 nmol/minute for 90 minutes) to 
study excretion into the bile (Scott and Lunte 1993).  For all phenol metabolites, bile concentrations were
higher than liver concentrations indicating that the metabolites are actively excreted in the bile.
The distribution of phenol in the liver has been studied in mice treated intravenously with 31.4 mg/kg
phenol (Davies and Lunte 1996).  Microdialysis probes used to monitor the distribution of phenol
metabolites in three regions of the liver (anterior, median, posterior) indicated that phenol-glucuronide
was the most prevalent metabolite in all three regions, but the level was significantly lower in the anterior
region compared to the other regions.  When phenol was delivered to the liver through microdialysis
probes, no regional differences in the delivery of phenol or metabolite formation were observed, 
indicating that clearance of phenol from the liver is dominated by blood flow rather than metabolism.
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3.4.3 Metabolism
Figure 3-3 shows the general metabolic pathways that transform phenol prior to its excretion in the urine.  
Three different enzymes systems catalyze the reactions that transform phenol.  Cytosolic phenol
sulfotransferases catalyze the transfer of inorganic sulfur from the activated 3'-phosphoadenosine-5'­
phosphosulfate donor molecule to the hydroxyl group on phenol.  Microsomal membrane-located uridine
diphosphate (UDP) glucuronosyltransferases catalyze the transfer of an activated glucuronic acid 
molecule to the hydroxyl moiety of phenol to form an O-glucuronide conjugate.  Cytochrome P4502E1, 
also microsomally located, catalyzes the hydroxylation of phenol to form hydroquinone (and to a much 
lesser extent, catechol), which is then acted upon by the phase II enzymes (Buxton 2006; Campbell et al. 
1987; Gut et al. 1996; Koop et al. 1989; McFadden 1996; Powley and Carlson 2001; Snyder et al. 1993).
Hydroquinone can, in turn, form conjugates, undergo peroxidation to form benzoquinone, or undergo 
further oxidation to form trihydroxybenzene.  All three enzyme systems that metabolize phenol are found 
in multiple tissues and there is competition among them not only for phenol, but also for subsequent
oxidative products, like hydroquinone.  As a consequence, the relative amount of the products formed can 
vary based on species, dose and route of administration.  
Cytochromes other than CYP2E1 also seem to be involved in the metabolism of phenol as demonstrated
by Powley and Carlson (2001) in experiments utilizing chemical inhibitors of CYP2E1, CYP2B,
CYP2F2, and CYP2E1 knockout mice.  The investigators found that CYP2E1 was responsible for only
approximately 50% of phenol metabolism in liver, suggesting the participation of other cytochromes.  
Experiments in pulmonary microsomes showed that both CYP2E1 and CYP2F2 played important roles in 
the metabolism of phenol.  
Phenol can also undergo peroxidation to form 4,4’-biphenol and diphenoquinone.  This has been 
demonstrated in studies that used in vitro cell preparations with high peroxidase activity (Eastmond et al. 
1986; Post et al. 1986), purified peroxidase enzymes (Smart and Zannoni 1984; Subrahmanyam and 
O'Brien 1985), or cell lines that have high myeloperoxidase activity (Kolachana et al. 1993).  Thus far,
there is no direct evidence that these peroxidation reactions occur in vivo. 
In vivo, the gastrointestinal tract, liver, lung, and kidney appear to be the major sites of phenol sulfate and 
glucuronide conjugation of simple phenols (Cassidy and Houston 1984; Powell et al. 1974; Quebbemann 
and Anders 1973; Tremaine et al. 1984).  Experiments conducted by Cassidy and Houston (1984) in rats
injected intra-arterially, intravenously, or intraduodenally (doses ranged from 0.5 to 15 mg/kg) allowed 
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Figure 3-3.  Metabolism of Phenol
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them to evaluate the first-pass metabolism by different tissues.  It was assumed that phenol that was 
systemically available had not been conjugated or metabolized and, therefore, the doses at which this 
occurred reflected the doses at which metabolic reactions were saturated.  The investigators found that
metabolism became nearly saturated in the liver at doses 10 times lower than in the endothelial lung, 
whereas metabolism in the gut was not saturated even at the highest dose tested.  They also observed that
the endothelial lung had a much lower affinity for phenol than the liver and gut.  However, caution should 
be exercised when interpreting the results of the metabolic capacity of the lung because normal exposure 
results in exposure of the epithelial respiratory tract rather than the endothelial surface, as occurred in this 
study.   
Four principal metabolites have been identified in mammals:  two phenol and two hydroquinone
conjugates (of sulfate and glucuronide) (Capel et al. 1972; Hoffmann et al. 1999; Kenyon et al. 1995;
Wheldrake et al. 1978).  In humans, rats, and mice given low doses of phenol orally, sulfate conjugates of
phenol were found to predominate.  However, in guinea pigs, pigs, and fruit bats, the glucuronide
conjugates were dominant (Capel et al. 1972).  In humans given an oral dose of 0.01 mg/kg, 77% of the
urinary 14C was identified as phenyl sulfate, 16% as phenyl glucuronide, and trace amounts (<1%) as the
sulfate and glucuronide conjugates of hydroquinone (Capel et al. 1972).
In mice, phenyl sulfate was the predominant urinary metabolite for low doses (1–21 mg/kg) of phenol
administered either by gavage and intravenously; however, as the dose increased, a decrease in phenol
sulfation and a concomitant increase in glucuronidation of both phenol and hydroquinone was seen 
suggesting saturation of the sulfation pathway (Kenyon et al. 1995).  The degree of saturation appeared to 
be slightly greater following gavage administration, and intravenous administration resulted in higher
proportions of the products of oxidative metabolism, with male mice being more prone than female mice.  
These latter observations suggest that the oxidative pathway become more prominent when phenol is 
introduced directly into the circulation, bypassing an initial intestinal sulfate conjugation process, and also 
suggests that the sulfate conjugation process saturates at a lower concentration in males than in females.  
Similarly, in the rat, the ratio of phenyl sulfate/glucuronide conjugates in urine decreased from 2.6 to 
0.7 when the intravenous dose level is increased from 1.2 to 25 mg/kg (Weitering et al. 1979).  This
phenomenon appears to be, at least in part, the result of differences in Km in the two pathways, in relation 
to their respective Vmax (Koster et al. 1981; Weitering et al. 1979).  The range of substrate concentrations
over which the reaction rate remains a linear function of concentration narrows as Vmax/Km decreases.  A
shift toward glucuronide formation as a function of dose would be expected in Vmax/Km, for the sulfation 
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pathway was less significant than the glucuronide pathway.  Treatment of rats with an intraperitoneal dose
of phenol (23–188 mg/kg) has also been shown to result in dose-dependent decreases in hepatic 
3'-phosphoadeonsine 5'-phosphosulfate (PAPS), the co-substrate for the sulfate conjugation of phenol, as
well as sulfate (Kim et al. 1995).  The depletion of PAPS may also contribute to the saturation of sulfation 
at high doses of phenol.  In another study of rats exposed to single and multiple bolus and drinking water
doses of different concentrations, metabolites in the urine were primarily conjugates of phenol, showing
dose-dependant concentrations (Hiser et al. 1994).  For bolus doses, the ratios of glucuronide to sulfate
phenol conjugates were 0.61 for 1.5 and 15 mg/kg doses and 1.16 for 150 mg/kg doses.  Drinking water
exposures resulted in a similar ratio of glucuronide to sulfate as observed for the 150 mg/kg bolus dose, 
with a ratio of 0.60.  For inhalation exposures, ratios ranged from 0.24 to 0.39.  Small amounts of an 
unidentified metabolite (2–4% total urinary radioactivity) were also detected.
All three enzyme systems involved in phenol metabolism have other substrates, which can competitively
inhibit the metabolism of phenol, thereby changing the balance among metabolites.  Inhibition of phenol
sulfotransferase with chlorinated phenols (e.g., pentachlorophenol) results in increased glucuronide
conjugation of simple phenols (Mulder and Scholtens 1977).  Similarly, benzene is metabolized by
CYP2E1; thus, high exposures to benzene may competitively inhibit phenol metabolism, resulting in 
decreasing hydroquinone production (and its corresponding sulfate and glucuronide conjugates)
(Medinsky et al. 1995; Schlosser et al. 1993).  Further information regarding the shift between sulfation, 
glucuronidation, and oxidation reactions is presented in Section 3.5.1, Pharmacokinetics Mechanisms.
Age- and sex-related changes in phenol sulfoconjugation were studied in hepatic cytosolic preparations
from fetal, newborn, and adult rats (Iwasaki et al. 1993).  Phenol sulfoconjugation activity was higher in 
adult males (1.94±0.1 nmol/mg/minute) than females (1.07±0.03 nmol/mg/minute), although there were
no sex-related differences in the younger rats.  Activity in fetal rats was very low
(0.04±0.01 nmol/mg/minute).  Activity at 2 days after birth was half that in adult females and a quarter of
that in adult males, and remained constant until 25 days after birth.  At 2 years of age, activity was 
intermediate between young adult male and female activities, and there were no sex-related differences. 
Heaton and Renwick (1991) found that young rats have a higher production of oxidative metabolism than 
adult rats.  If this were the case in humans, children might be potentially more sensitive to the systemic 
effects of phenol, if a reactive intermediate is responsible for phenol toxicity.  However, since 
glucuronidation does not appear to be limited in the young, production of oxidative products may be a 
smaller risk than anticipated.  Caution should be exercised when extrapolating from adolescent rats to 
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children, since rodents are well known to undergo a number of changes in xenobiotic-metabolizing
enzymes during sexual development (Waxman et al. 1985). 
3.4.4 Elimination and Excretion 
Phenol, in its free and conjugated forms, is a normal constituent of human urine.  Piotrowski (1971)
reported 8.7±2.0 mg/day as the daily excretion rate of total phenol (free plus conjugates) in human 
subjects with no known exposure to phenol.  Others have reported a range of values.  In a study of
workers employed in the distillation of high-temperature phenolic fractions of tar, mean values of phenol
in the urine of 13.8 mg/L in 26 male non-exposed workers and 67.8 mg/L in 89 exposed workers were 
reported (Bieniek 1994).  The highest concentration was found 2 hours after the end of the work shift.  
Quint et al. (1998) evaluated the urinary phenol concentration before and after using phenol to chemically
cauterize the lesion created by excision of chrondroblastoma in 11 patients.  Preoperatively, the average 
urinary concentration of phenol was 5.1 mg/L.  Ling and Hanninen (1991) studied the effect of phenol on
serum and urinary concentrations in patients who switched from a conventional diet to an uncooked 
“vegan” diet.  Patients were tested at week 0, were on the vegan diet for 4 weeks, and then were on the
regular diet for the second month.  Urinary and serum levels of phenol were measured at weeks 0, 2, 4, 
and 9.  A significant decrease in both urinary and serum concentrations of phenol was seen within 
2 weeks of adopting the vegan diet.  At 2 weeks, the serum concentration had dropped from about 0.75 to 
0.5 mg/L (about 30%), and levels in urine had dropped from about 7 mg/L to about 3 mg/L (about 60%).  
These data indicate that phenol is a natural product of metabolism that may vary significantly depending
at least on diet, but probably also due to other factors.
Horch et al. (1994) make the statement “urine phenol concentrations should be monitored in exposed 
persons to determine if they are within normal range (0.5–81 mg/L),” but they provide no citation for the
range given.  It should be noted that as late as 1980, gas chromatographic analyses of urine used to 
determine phenol levels showed fairly large interlaboratory variation (Van Roosmalen et al. 1981).  Thus, 
the range of values given above, if derived from multiple references including the older literature, may be
artificially broad.
3.4.4.1  Inhalation Exposure 
Phenol absorbed through the lungs is excreted rapidly in urine in its free and conjugated forms.  Within 
24 hours after human subjects inhaled phenol at concentrations of 6–20 mg/m3 (1.5–5.1 ppm), 99±8% of
the phenol retained in the lungs was excreted (Piotrowski 1971).  The urinary excretion of phenol was
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studied in 106 men occupationally exposed to phenol, cresols, xylenols, and other phenolic derivatives, 
and 26 unexposed controls (Bieniek 1994).  Urine samples were taken after 4 hours at work, and in
16 workers every 2 hours for 24 hours after an 8-hour shift.  The mean level of phenol in urine of the
exposed workers was 87.3 mg/L, compared to 11.7 mg/L in controls.  The highest phenol concentrations
were recorded between 8 and 10 hours after the beginning of the exposure.  Exposure concentrations were
not reported in this study.
A study of workers in a Bakelite factory reported a linear correlation between concentrations of phenol in 
the air (up to 12.5 mg/m3 or 3.25 ppm) and urinary excretion of total phenol (free plus conjugated)
(Ohtsuji and Ikeda 1972).  However, the urinary concentration of free phenol seemed to be independent of
the environmental phenol, suggesting that under the exposure conditions, the maximum capacity to 
conjugate phenol had not been reached.  
Urinary excretion of total phenol (free and conjugates) is considered a biomarker of exposure for phenol.
The biological exposure index (BEI) for phenol, for exposure to 5 ppm in air, is 250 mg/g creatinine when
measured at the end of the shift (ACGIH 2001).
In rats exposed by intratracheal instillation to radiolabeled phenol, elimination was 95% complete after
72 hours, with the primary elimination route being through the urine (Hughes and Hall 1995).  Fecal
elimination was slower and accounted for less overall.
In a study conducted by Hiser et al. (1994), rats were exposed via nose-only inhalation for 6 hours to 
25 ppm 14C-phenol for either 1 or 8 days.  Thirty hours after initiation of exposure, mean percentages of
phenol-derived radioactivity were measured in urine and feces.  In rats exposed for 1 day, values in urine
were 94.48% (males) and 90.92% (females).  In rats exposed for 8 days, values in urine were 97.40%
(males).  In rats exposed for 1 day, values in feces were 3.33% (males) and 2.02% (females).  In rats 
exposed for 8 days, values in feces were 0.81% (males).  Less than 1% remained in tissues and carcass.  
These results indicate rapid elimination of phenol in urine after inhalation exposure.
3.4.4.2  Oral Exposure
Phenol absorbed from the gastrointestinal tract is excreted rapidly in urine as free phenol or conjugates 
(Capel et al. 1972; Deichmann 1944; Edwards et al. 1986; French et al. 1974; Kao et al. 1979; Kenyon et
al. 1995; Liao and Oehme 1981).  In three human subjects who received a single oral dose of 0.01 mg/kg
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[14C]-labeled phenol, the mean 24-hour urinary recovery of 14C was 90% (range 85–90%) of the
administered dose (Capel et al. 1972).  In this same study, urinary recovery of orally administered 
[14C]-labeled phenol was determined in 18 other mammalian species; the mean 24-hour recoveries of 14C 
ranged from 95% in the rat to 31% in the squirrel monkey.  In three separate fatal cases of ingestion of 
phenol at unknown quantities, phenol was detected in the urine at concentrations of 3.3 μg/mL (Boatto et 
al. 2004), 208 μg/mL (Tanaka et al. 1998), and 47 μg/mL (Lo Dico et al. 1989).
Both urinary and fecal excretion of 14C was determined in rats administered an oral dose of 1.2 mg/kg of
[14C]-labeled phenol (Edwards et al. 1986).  Rats excreted 80.3±11.2% in the urine and 1.8±1.6% in the
feces in 24 hours.  In rats exposed orally to radiolabeled phenol, elimination was 95% complete after
72 hours, with the primary elimination route being through the urine (Hughes and Hall 1995).  Fecal
elimination was slower and less overall.
Hiser et al. (1994) reported results of rats exposed to single and multiple bolus and drinking water doses 
of different concentrations of [14C]-phenol.  After 24 hours, concentrations of administered 14C 
radioactivity were >90% in the urine, regardless of the dose method or concentration.  Less than 1%
remained in tissues and carcass.  This indicates rapid elimination of phenol in urine after oral exposure.
3.4.4.3  Dermal Exposure 
Phenol absorbed through the skin is rapidly excreted in urine as free phenol or conjugates. A 4.5-hour
occlusive exposure of one foot of an adult male to 90% phenol resulted in an elimination half-life of
13.86 hours.  When admitted to the hospital, the phenol urine concentration was 7,909 mg/g in creatine.  
Over the next 12, 20, 43, 58, and 82 hours, phenol concentrations in the urine were measured at 13,416, 
721, 80, 62.8, and 35.7 mg/g creatine, respectively (Bentur et al. 1998).  Following an industrial accident
in which a phenol-water solution was splashed over a man's face, chest wall, hand, and both arms, phenol
in the urine decreased from 566 mg/L after 4 hours to 0.75 mg/L 46 hours after the exposure (Horch et al. 
1994).  Subjects exposed to dermally applied reservoirs containing phenol solutions (2.5–10 mg/L)
excreted 80% (range 58–98%) of the absorbed phenol in the urine within 24 hours (Baranowska-
Dutkiewicz 1981).  Another study in which both clothed and unclothed human subjects were dermally
exposed for 7 hours to phenol vapors while breathing clean air to avoid inhalation exposure, found that
almost 100% of the absorbed phenol was excreted in the urine within 1 day, with clothing providing no 
apparent protection (Piotrowski 1971).
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In rats exposed dermally to radiolabeled phenol, elimination was 95% complete after 72 hours, with the
primary elimination route being through the urine (Hughes and Hall 1995).  Fecal elimination was slower
and less overall.
3.4.4.4  Other Routes of Exposure
Observations of elimination of phenol (5–10 mL 7%) after injection into 20 patients were carried out as 
part lumbar of lumbar and thoracic sympathetic blockade treatments.  Apparent elimination half-lives 
were 30.3±2.8 minutes for unconjugated phenol and 64.0±7.3 minutes for conjugated phenol.  Urinary
excretion of conjugated phenol was 52±5% after 8 hours (Nomoto et al. 1987).
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
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1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-4 shows a conceptualized representation of a PBPK model.
If PBPK models for phenol exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
3.4.5.1 Summary of PBPK Models
A PBPK model simulating phenol disposition has been developed as part of the attempt to understand the
toxicity of benzene, of which phenol is the primary metabolite (Bois et al. 1991).  Human exposure to 
benzene is widespread, and much of the toxicity of benzene is due to the action of its metabolites.  Thus, 
while no studies were located involving PBPK models developed specifically for phenol exposure, the
benzene model of Bois et al. (1991) is capable of predicting the pharmacokinetics of phenol and is
appropriate to this discussion.
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Figure 3-4.  Conceptual Representation of a Physiologically Based
 
Pharmacokinetic (PBPK) Model for a 

Hypothetical Chemical Substance
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Source:  adapted from Krishnan et al. 1994
Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
   
 
    
 
 
 
 
 
 
 
  
  
  
      
 
  
    
    
 
 
 
  
 
    
 
  
    
 
 
     
  
   
 
   
  
  
  
 
  
 
 
 
  
PHENOL 111
3. HEALTH EFFECTS
Two empirical compartmental models for benzene have also been developed, which predict the
production and subsequent metabolism of phenol.  A two-compartment model for quantifying benzene
hepatic metabolism to phenol and other metabolites in an in vitro microsome system was developed by
Schlosser et al. (1993) and enhanced by Medinsky et al. (1995). This model does not predict benzene (or
phenol) absorption, disposition, or excretion from the body of animals or humans.  A one-compartment
model of phenol in humans was developed for assessing the variability of worker biomarkers related to 
occupational exposures (Pierrehumbert et al. 2002).  Methods for model calibration and validation data
were not reported.  Both of these models are limited for use in phenol risk assessment since they do not
reduce uncertainties associated with extrapolation animal internal dosimetry to humans or high exposure
levels to low levels.
3.4.5.2 Discussion of Models 
The Bois et al. (1991) Model
A PBPK model for benzene and phenol was developed by Bois et al. (1991) to explore differences in 
metabolite formation and distribution from benzene or phenol exposures to clarify why benzene, but not 
phenol, is carcinogenic in rats and humans.
Description of the model. The model represents the male rat as a series of flow-limited 
compartments interconnected by arterial and alveolar blood flow.  The disposition of benzene and phenol
was predicted in the liver, fat, bone marrow, and well- and poorly-perfused tissues.  In addition, phenol
distribution to the gut and lung was included.  Routes of exposure included oral gavage dosing, 
inhalation, and intravenous injection of both compounds.  Elimination of benzene was accomplished by
exhalation and metabolism in the liver and bone marrow.  Additionally, phenol was conjugated in the
liver, lung, and gut.  Hepatic and bone marrow metabolism of benzene to phenol was described by
Michaelis-Menten generation of benzene oxide followed by first-order production of phenol.  Michaelis-
Menten kinetics described the transformation of benzene oxide to diols or glutathione conjugates and 
phenol to hydroquinone and sulfo- and glucurono-conjugates.  Physiological flow and metabolic rates and 
constants were allometrically scaled to body weight.  Instead of using point estimates of physiological and
metabolic parameters values, uniform or log-uniform distributions (e.g., ranges) of parameter values were
defined for all 64 model parameters.  The model was executed using Monte Carlo techniques, in which 
individual random values were sampled from each parameter distribution during iterative model runs to 
produce distributions of model outputs rather than single values.  This was done to accommodate 
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variability and uncertainty in the parameter values.  The parameter distributions were taken from the
literature.
The model was calibrated to rat data for gavage (Sabourin et al. 1987, 1989) or inhalation (Sabourin et al. 
1987, 1989) of benzene and intravenous, intra-arterial, intra-duodenal, and hepatic portal injection of
phenol (Cassidy and Houston 1984) by adjusting the bounds of alveolar ventilation and other
nonspecified parameter distributions.  Different compartments pertaining to separate metabolic systems 
were assessed by selective injection as follows: jugular vein to assess first-pass metabolism across lung, 
hepatic portal vein to assess hepatic first-pass metabolism, duodenum to assess intestinal mucosa 
metabolism, and carotid artery to assess immediate tissues distribution.
Validation of the model. Validation of this model against empirical data was not done, introducing
uncertainty into the ability of the model to predict other data.  Of particular interest is the prediction that
hydroquinone production is greater following phenol administration as compared to benzene
administration. This is in opposition to the prediction of Medinsky et al. (1995).
Target tissues. The target tissues were blood and bone marrow.  The expected levels of phenol in
blood and bone marrow, and total hydroquinone were substantially higher after phenol administration 
than after benzene administration.
Species extrapolation. Extrapolation of this model from rats to other animals or humans has not
been done.
Interroute extrapolation. The model included parameter values for intestinal absorption and 
pulmonary partitioning of phenol, which enable simulation of oral and inhalation exposures, respectively.  
However, calibration and validation of these routes was not performed against empirical data.  Predictions
of phenol metabolism and distribution following injection into various sites were used to illustrate
possible consequences of first-pass metabolism following oral exposure to phenol.
Risk assessment. This model has not been applied to a quantitative risk assessment of benzene or
phenol.  The predicted blood and bone marrow phenol and total hydroquinone levels were substantially
higher after phenol administration than after benzene administration.  This finding is counter to the
hypothesis that phenol or hydroquinone plays a direct role in the carcinogenicity of benzene, suggesting
that other metabolites must be involved.  The study authors suggest that catechol, a potentially genotoxic
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oxidation metabolite produced in much larger amounts following benzene, as opposed to phenol
administration, may contribute to benzene's carcinogenicity.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption of phenol occurs fairly rapidly via the inhalation (Hughes and Hall 1995; Ohtsuji and Ikeda
1972; Piotrowski 1971), oral (Capel et al. 1972; Edwards et al. 1986; French et al. 1974; Hughes and Hall
1995; Kao et al. 1979; Kenyon et al. 1995), and dermal (Baranowska-Dutkiewicz 1981; Hughes and Hall
1995; Piotrowski 1971) routes.  Because it is an irritant, tissue damage, inflammation, or other irritation 
effects may occur at the sites of absorption.  Because of its high pKa, ionization will not occur within the
acid environment of the gut.  The action of gut microflora on phenol breakdown is not expected to be
significant.
When it is absorbed through the lungs, gut, or skin, phenol conjugated at the portal-of-entry and free 
phenol enter the bloodstream where it can then be distributed throughout the body (if the conjugation 
capacity of the tissue has been saturated by a high dose).  The dilution of phenol in water enhances the
dermal absorption of phenol, as indicated by the greater toxicity of a water-phenol solution compared to 
neat phenol (Conning and Hayes 1970).  Conning and Hayes (1970) speculated that an undiluted solution 
may produce a coagulative necrosis, which would slow further penetration of phenol resulting in less
phenol absorbed than with more diluted solutions.  
As described in Section 3.4.3, Metabolism, conjugation with glucuronic acid and conjugation with sulfate
are the main routes of detoxification of phenol.  In most species tested, including humans, sulfation 
predominates at lower doses.  As doses increase, glucuronidation increases, as does the formation of
oxidative metabolites.  Some have suggested that the shift from sulfation to glucuronidation is caused by
a reduction in the availability of co-substrates in conjugation reaction and/or reduction in the sulfate pool
(Kim et al. 1995) or due to a difference in Km of the two pathways in relation to their respective Vmax 
(Weitering et al. 1979).  An alternative explanation for the dose-dependent metabolic profiles for phenol
is that the activities of metabolizing enzymes vary across areas of the liver (Medinsky et al. 1995).  As 
blood flows into the liver from the periphery of the lobule towards the central vein, it encounters first a
zone in which both sulfotransferases and glucuronosyltransferases are present (periportal zone 1), the
former predominating.  Glucuronosyltransferases predominate in zone 2, whereas both glucuronosyl­
tranferases and monooxygenases are present in pericentral zone 3.  In this zonal arrangement, phenol
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would be metabolized first by sulfotransferases, and at low doses, little free phenol would be available for
glucuronide conjugation and oxidation.  However, at increasing phenol doses, unconjugated phenol that
reaches zone 2 is available for glucuronidation.  At even higher doses that exceed the conjugation 
capacities of zones 1 and 2, oxidative metabolites are generated (Kenyon et al. 1995).  Studies in isolated 
perfused liver from rats (Ballinger et al. 1995) and mice (Hoffmann et al. 1999) have validated the
‘enzyme zonation’ model. 
The influence of enzyme localization on intestinal metabolism of phenol has also been studied (Kothare
and Zimmerman 2002).  In an in situ perfused intestine preparation from rat, the investigators showed that
sulfation was the predominant metabolic pathway after vascular administration of phenol, whereas 
luminal dosing produced greater glucuronidation.  These results were consistent with the sulfotransferases 
being cytosolic enzymes (Burchell and Coughtrie 1997) and glucuronyltransferase being located between
the nuclear and apical membrane of the epithelial cell (Inoue et al. 1999) and showing a decreasing
expressional gradient from the villus to the crypt (Chowdhury et al. 1985). 
Phenol that is absorbed is rapidly excreted in the urine as free phenol or conjugates (Baranowska-
Dutkiewicz 1981; Capel et al. 1972; Deichmann 1944; Edwards et al. 1986; French et al. 1974; Hughes
and Hall 1995; Kao et al. 1979; Kenyon et al. 1995; Liao and Oehme 1981; Piotrowski 1971).
3.5.2 Mechanisms of Toxicity
Limited information is available regarding the mechanism(s) of toxicity of phenol.  Phenol is irritating
and corrosive at high concentrations as evidenced by numerous cases of accidental dermal exposure or
intentional or accidental ingestion of phenol.  Phenol impairs the stratum corneum and produces
coagulation necrosis by denaturing and precipitating proteins.  Studies in mice suggest that dermal
application of phenol increases the formation of free radicals in the skin, and that the redox cycling of
these radicals reduces antioxidant capacity, leading to significant oxidative damage of protein, DNA, and 
lipids (Murray et al. 2007). 
Phenol is a hydroxylated metabolite of benzene and it further undergoes oxidative metabolism to produce
other compounds; however, it is still unknown with certainty whether the parent compound or a
metabolite(s) is responsible for phenol’s systemic toxicity.  The major tissues in which metabolism
appears to occur are the liver, gut, lung, and kidney (Cassidy and Houston 1984; Powell et al. 1974;
Quebbemann and Anders 1973; Tremaine et al. 1984).  A study by Chapman et al. (1994) provided some
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insight on a possible toxic entity.  These investigators found that incubation of whole rat conceptus in 
vitro with phenol resulted in minor dysmorphogenic and embryotoxic effect.  However, addition of
exogenous hepatic bioactivation system greatly increased the toxicity of phenol.  The major metabolites 
formed were hydroquinone, catechol, and benzoquinone and these three metabolites exhibited similar
potency.  Chapman et al. (1994) also found that adding together phenol and hydroquinone resulted in 
more-than-additive embryotoxicity which, according to the investigators, suggested the involvement of a
peroxidative mechanism for phenol bioactivation. 
Several studies in animals have reported tremors following exposure by oral gavage (Moser et al. 1995;
NTP 1983b).  The mechanism by which phenol or metabolites exert this effect is unknown.  There is little
indication from studies in animals or from fatal poisoning cases in humans that phenol distributes
preferentially to the brain, although tremors also may be caused by actions at the periphery.  Injections of
phenol (2–3%) have been used to block nerve conduction in a number of neurological disorders (i.e., 
spasticity in cerebral palsy, cervical dystonia) or to relieve pain in certain cancers.  This occurs by phenol
physically interrupting the continuity of axons and inducing axonal degeneration. How this may be
related to tremors caused by gavage dosing of phenol, if at all, is unknown.  It has been suggested that
phenol exposure results in cardiac effects because it blocks the cardiac sodium channel subtype, with little 
effect on sodium channels in skeletal muscle (Zamponi et al. 1994).  A preferential block by phenol of
sodium channels in inhibitory pathways would be consistent with a net result of increased activity or even 
tremors, but there is no experimental support for this hypothesis.
3.5.3  Animal-to-Human Extrapolations 
Although mammals all metabolize phenol to the same metabolites, the amounts of each metabolite vary
between species.  For example, in the old world monkeys and prosimians, sulfation is the major phenol
conjugation pathway, while in the new world monkeys, glucuronidation predominates (Mehta et al.
1978).  Cats and pigs have low activities of phenol glucuronyltransferase, and metabolize phenol to 
phenyl sulfate nearly exclusively (Capel et al. 1972; French et al. 1974; Miller et al. 1976).  Because
humans have a greater capacity to glucuronidate phenol, cats and pigs would not be good models for the
metabolism of phenol by humans.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
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with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
Based on the available information, there is no clear evidence that phenol is an endocrine disruptor in 
humans or in animals.  Long-term studies in rats and mice treated with phenol in the drinking water did 
not report alterations in the gross or microscopic appearance of the reproductive organs (NCI 1980).  In 
the 13-week experiment, rats and mice received approximately up to 1,700 and 2,700 mg phenol/kg/day, 
respectively.  In the 2-year study, rats received estimated doses of phenol of up to 600–700 mg/kg/day 
and mice received 1,100–1,200 mg/kg/day.  Similar observations were made in a more recent
two-generation reproductive study in rats (Ryan et al. 2001).  In the latter study, the highest doses of
phenol, 301–321 mg/kg/day, had no significant effect on fertility, estrus frequency, testicular sperm
count, or sperm motility or morphology.  Significant reductions in prostate and uterine weights in all F1 
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treated groups were not considered adverse effects of phenol by Ryan et al. (2001) on the basis of the
absence of histological alterations and functional reproductive effects, and based on the fact that only a
few animals had organ weights outside the range of concurrent control values.
In standard developmental toxicity studies in rats and mice, with one exception, fetotoxicity has only been 
reported at doses that were also toxic to the mothers (Narotsky and Kavlock 1995; NTP 1983b; Ryan et
al. 2001; York 1997).  In the study by NTP (1983a) in rats, a 7% decrease in fetal body weight was
reported at the high-dose level, 120 mg/kg/day, without any evidence of maternal toxicity.  However, 
historical control data showed that the concurrent control fetal weight for the CD rat was much higher
(22%) than the historical control weight.  In addition, a larger litter size in the high-dose group may have
contributed to the smaller fetal weight in the high-dose group.
Only two reports were located with relevant information from assays in vitro. In one of them, phenol
tested negative for estrogenic activity in a reporter gene expression assay using yeast cells (Nishihara et
al. 2000).  A substance was considered positive when its activity was >10% of the activity of 10-7 M 17β­
estradiol.  For phenol, that concentration was >1x10-3 M.  The other study found that phenol had very
weak binding affinity to a purified recombinant human estrogen receptor (Hu and Aizawa 2003).
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
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critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Based on a very limited data set, it is likely that most of the effects of phenol exposure, including cardiac 
arrhythmias and central nervous system depression, observed in adults after exposure to high amounts of
phenol will be observed in children if exposures are comparable.  The data are insufficient to determine
whether children will be especially sensitive to such effects, however.
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IARC (1989), citing Hinkel and Kintzel (1968), indicated that a newborn infant whose umbilicus had 
been bound with a bandage containing 2% phenol, died after 11 hours.  Another newborn whose skin 
ulcer was treated with a solution of 30% phenol/60% camphor developed circulatory failure, cerebral
intoxication, and methemoglobinemia, but recovered after a blood transfusion.  Rogers et al. (1978)
evaluated the percutaneous absorption of phenol in 16 infants, aged 2–5 months, who were treated for
seborrhoeic eczema with Magenta Paint B.P.C., a medicine containing 4% phenol.  The treatment
consisted of twice daily painting of the napkin and skin folds (representing about 11–15% of the body
surface) with the Magenta paint over 48 hours, with an average of 32 mL of paint (approximately 
1,300 mg of phenol) applied to each child.  Phenol was detected in the urine of four of the infants;
however, no information on concentration was presented.  Liver function tests run on 8 of the 16 treated
infants showed no abnormalities.  The study was initiated because of the observation of signs of central
nervous system depression in a 6-month-old who had been treated over a much larger area (all of the body
except the face).
A study of 2,075 infants exposed to phenolic disinfectants used to clean hospital nursery surfaces reported 
a significant increase in mean third-day microbilirubin level and an increase in the proportion of infants
with a microbilirubin level >10 mg/dL (Doan et al. 1979).  However, no cases of severe jaundice were
observed.  Since infants did not come into direct contact with the cleaned surfaces, exposure was assumed 
to have occurred by inhalation of fumes.  
In a 5-year (1987–1991) retrospective review of acute exposures to a phenol-containing disinfectant
(Creolin Disinfectant™ [26% phenol]) reported to a regional poison control center, Spiller et al. (1993)
identified 96 patients, 16 of which were lost to follow-up.  There were 60 oral-only exposures, 7 dermal-
only exposures, 12 oral/dermal exposures, and 1 inhalation exposure.  Sixty (75%) of the patients were
under 5 years of age.  It was not possible to determine from the information presented the degree of
concordance between the 60 patients with oral-only exposures and the 60 under the age of 5, but it is clear
that oral exposure of young children is the predominant characteristic of this population of exposed 
individuals.  In this regard, children have clearly been demonstrated to be at greater risk of exposure to 
phenol via the accidental ingestion of phenol-containing disinfectants.  Vomiting and lethargy were the
main signs of toxicity observed in the children.
Warner and Harper (1985) reported the case of a 10-year-old male developed cardiac arrhythmias 
following a chemical peeling procedure initiated to remove a 12x17 cm hairy nevus of the left scapula 
and nape.  An hour into the procedure, which involved the application of a solution of phenol (60%
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phenol, 0.8% croton oil in hexachlorophene soap and water) to the entire surface of the nevus, multifocal
and coupled premature ventricular complexes developed in the electrocardiogram, but subsided after
infusion of bretylium sulfate.  Although this was a severe reaction, it is difficult to determine, based on 
just one case, whether it reflects a special sensitivity based on age.  A 10-year-old boy who was
hospitalized with serious burns was treated dermally with 7.5 L of an antiseptic solution containing
2% phenol for 2.5 days.  During this period, his urine became dark, his respiration became labored, he fell
into a coma, and he died.  Postmortem analysis of urine revealed 200 mg/L of conjugated phenol (Cronin 
and Brauer 1949).
In a review of the use of phenol as a neurolytic agent, Wood (1978) summarized the results of a number
of studies including one in which children with cerebral palsy were given nerve blocks with 3% phenol in 
water as a treatment for spasticity.  Out of 150 blocks on 46 children, 9 were associated with 
complications, 8 with muscle weakness, and 1 with painful paresthesia.  This degree of complication was
twice that reported by another group who reported on 98 blocks, presumably in adults, with a
complication rate of 3% with all complications being transient paresthesia.  The first group concluded that
in children the risk was too great for the benefit of the procedure.  These two studies in combination 
suggest that children may be especially sensitive to phenol given by injection.  Interestingly, a later study
(Morrison et al. 1991) involving 24 pediatric patients similarly treated for spasticity with injections of 5%
phenol in water at the motor point of insertion during halothane anesthesia concluded that there was no 
increase in the incidence of complications.  In this study the complications of concern were cardiac 
arrhythmias and the incidence was 19%, yet the authors concluded that the procedure appeared 
“appropriate to perform in the day-surgery context.” The difference in these studies is likely due to the
fact that the earlier study evaluated the incidence of delayed complications, whereas the Morrison et al. 
(1991) work evaluated the incidence of an immediate complication, e.g., cardiac arrhythmias.  There was
no indication in the Morrison et al. (1991) study that delayed complications such as subsequent muscle 
weakness or paresthesia were evaluated.
Only one study in animals was located that compared the age-dependency toxicity of phenol.  Deichmann 
and Witherup (1944) administered phenol orally and subcutaneously to three age groups of rats: 10 days 
old, 5 weeks old, and adults.  At a dose of 600 mg/kg orally, death occurred in 90% of 10-day-old rats, in 
30% of 5-week-old rats, and in 60% of adult rats.  Similarly, 3,000 mg/kg administered subcutaneously
caused death in 65% of 10-day-old rats, 25% of 5-week-old rats, and 45% of adult animals.  These results 
suggested that neonates are more sensitive than adults, and that adults are more sensitive than young rats,
but these findings have not been confirmed.  
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Extremely limited data regarding possible adverse developmental effects in humans exposed to phenol
provide no evidence for effects.  As mentioned in Section 3.6, standard developmental toxicity studies in 
rats and mice, with one exception (NTP 1983a), have reported fetotoxicity at doses that were also toxic to 
the mothers (Narotsky and Kavlock 1995; NTP 1983b; Ryan et al. 2001; York 1997).  Results from some
studies in vivo and in vitro suggest that phenol potentially could affect the germ cells, opening the
possibility that parental exposure would result in adverse childhood development or cancer (Bulsiewicz
1977; Li et al. 2005).  However, the results of a well-conducted two-generation reproduction study do not
support that possibility (Ryan et al. 2001).  
There is no information regarding pharmacokinetics of phenol in children.  As discussed in Section 3.4.3, 
phenol is metabolized by CYP2E1 isozymes and also forms sulfate and glucuronide conjugates.  To the
extent that the enzymes involved in the metabolism of phenol are developmentally regulated, the
metabolism, and consequently the toxicity of phenol, in immature humans may be different than in adults.  
If microsomal oxidation transforms phenol into a toxic metabolite, a reduced CYP2E1 activity, as it
seems to occur in neonates, would result in decreased toxicity.  However, the ability of the liver to 
sulfonate phenol, and consequently facilitate elimination, also develops with age (Iwasaki et al. 1993).  
Thus, a lower ability to conjugate could result in more phenol available for oxidative metabolism.  Heaton 
and Renwick (1991) found that young rats have a higher production of oxidative metabolism than adult
rats.  If this were the case in humans, children might be potentially more sensitive to the systemic effects 
of phenol.  Glucuronide conjugation reactions also are considerably reduced in the young and reach adult
values only after the age of 3 in humans.  This would play a role at high doses where the glucuronide
metabolites of phenol predominate.  As previously mentioned, caution should be exercised when 
extrapolating from adolescent rats to children, since rodents are known to undergo a number of changes in 
xenobiotic-metabolizing enzymes during sexual development (Waxman et al. 1985).  
It is not known whether phenol can cross the placenta and there are no reports on levels of phenol in 
maternal milk.
There are no biomarkers of exposure or effects for phenol that have been validated in children or in adults
exposed as children.  No relevant studies were located regarding interactions of phenol with other
chemicals in children or adults.
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3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to phenol are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific.  They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by phenol are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
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biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Phenol
Biological monitoring for exposure to phenol is possible by measuring blood or urine levels of the parent
compound.  However, it should be noted that phenol and metabolites of phenol may also come from other
sources.  For example, phenol is a metabolite of benzene and of protein metabolism.  Urine samples taken 
from male workers employed in the distillation of high-temperature phenolic fractions of tar revealed a 
phenol excretion rate of 4.20 mg/hour compared to a control rate of 0.53 mg/hour for non-exposed 
workers (Bieniek 1994).  Samples were taken 4 hours into the workers' workday, but the worker exposure
levels were not reported.  A study of workers in a Bakelite factory reported a linear correlation between 
concentrations of phenol in the air (up to 12.5 mg/m3 or 3.25 ppm) and urinary excretion of total phenol
(free plus conjugated) (Ohtsuji and Ikeda 1972).  However, the urinary concentration of free phenol
seemed to be independent of the environmental phenol, suggesting that under the exposure conditions, the
maximum capacity to conjugate phenol had not been reached. 
The biological exposure index (BEI) for occupational exposure to 5 ppm phenol is 250 mg total phenol in 
urine/g creatinine (ACGIH 2005).  The urine should be collected at the end of the 8-hour work shift. The
sample can be stored in the refrigerator for 4 days or frozen for at least 3 months before analysis.  ACGIH
(2005) warns that the test is nonspecific and should not be used when workers are exposed to benzene or
to household products or medications that contain phenol.  Dermal exposure may result in overestimation 
of inhalation exposure.
Phenol can also be measured in the urine after oral exposure, although a dose-response relationship 
between oral exposure to phenol and phenol in the urine has not been established.  In persons not exposed 
to phenol or benzene, the total phenol concentration in the urine does not exceed 20 mg/L and is usually
<10 mg/L (ACGIH 2005).
3.8.2 Biomarkers Used to Characterize Effects Caused by Phenol
Specific biomarkers used to characterize effects caused by phenol have not been identified.  Dark urine 
has been reported in persons exposed to phenol (orally, dermally, or by inhalation) (Baker et al. 1978;
Bentur et al. 1998; Cronin and Brauer 1949; Kim et al. 1994; Merliss 1972).  The dark urine may be a
result of an oxidation product of phenol or hemoglobin or hemoglobin breakdown products.  Further
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research is required to identify the cause of the dark urine.  If it is the result of an oxidation product of
phenol, it should be considered a biomarker of exposure.
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC
Subcommittee Report on Biological Indicators of Organ Damage (Agency for Toxic Substances and 
Disease Registry 1990) and for information on biomarkers for neurological effects see OTA (1990).
3.9  INTERACTIONS WITH OTHER CHEMICALS
Phenol is a tumor promoter in laboratory animals.  In mice, dermal exposure to phenol in benzene
(Boutwell and Bosch 1959) or in acetone (Salaman and Glendenning 1957; Wynder and Hoffmann 1961)
increased the incidence of tumors resulting from dermal exposure to the tumor initiator, 9,10-DMBA.  
The mechanism of phenol promotion activity is not known, but may be related to the dermal damage that
it causes and subsequent rapid cell division that may take place to repair the damage.  When injected with 
mixtures of phenol and hydroquinone, a hydroxylated metabolite of phenol, mice exhibited significantly
depressed bone marrow erythropoiesis compared to injection with phenol alone (Chen and Eastmond 
1995a).  The involvement of peripheral acetylcholine in phenol-induced tremors was implicated by
studies in which mice were injected with phenol and pentobarbital, an inhibitor of acetylcholine release
(Itoh 1995).
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to phenol than will most persons
exposed to the same level of phenol in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These
parameters result in reduced detoxification or excretion of phenol, or compromised function of organs
affected by phenol.  Populations who are at greater risk due to their unusually high exposure to phenol are
discussed in Section 6.7, Populations with Potentially High Exposures.
Potentially, individuals with low activities of the enzymes phenol sulfotransferase and glucuronyl­
transferase may be more susceptible to phenol toxicity.  Persons with ulcerative colitis may have an 
impaired capacity to sulfate phenol (Ramakrishna et al. 1991), which may increase the amount of
unchanged phenol that is absorbed following oral exposure.  Neonates may also be more susceptible to 
toxicity from dermally-applied phenol because of increased skin permeability and proportionately greater
surface area.  A study in which 10-day-old rats were more sensitive to lethality following oral exposure to 
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phenol than 5-week-old or adult rats (Deichmann and Witherup 1944) further suggests that the young
may be more sensitive to phenol.  For a more detailed discussion, please see Section 3.7.  Because phenol
is a vesicant, individuals with sensitive skin or pulmonary incapacity may be more sensitive to phenol.  
Individuals with kidney or liver diseases that impair metabolism or excretion of phenol and phenol
metabolites may be more susceptible to phenol.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to phenol.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to phenol.  When specific
exposures have occurred, poison control centers and medical toxicologists should be consulted for
medical advice.  The following texts provide specific information about treatment following exposures to 
phenol:
Goldfrank LR, Flomenbaum NE, Lewin NA, et al. 2002.  Goldfrank’s toxicologic emergencies.  7th ed.  
New York, NY:  McGraw-Hill. 
Haddad LM, Shannon MW, Winchester JF.  1998. Clinical management of poisoning and drug overdose.  
3rd ed.  Philadelphia, PA: WB Saunders Company.
Viccellio P. 1998. Emergency toxicology.  2nd ed.  Philadelphia, PA:  Lippincott-Raven Publishers. 
3.11.1 Reducing Peak Absorption Following Exposure 
Human exposure to phenol may occur by inhalation, ingestion, or dermal contact.  Mitigation methods for
reducing exposure to phenol include the general recommendation of separating contaminated food, water, 
air, and clothing from the exposed individual.  Externally, phenol can produce mild irritation; acute
exposure may produce dermatitis and abnormal pigmentation (HSDB 2008).  Dermal exposure to 
relatively low concentrations of phenol (5–6%) over a sufficient surface area can result in death.  
Therefore, speed in removing phenol from the skin is important (HSDB 2008).  A study was conducted to 
assess the efficacy of 10 different strategies to decontaminate the skin of anesthetized pigs that were 
exposed to 89% aqueous phenol for 1 minute (Monteiro-Riviere et al. 2001).  The treatment included 
plain water washes for different periods of time, as well as soap, polyethylene glycol, and isopropanol
solutions.  The evaluation was based on scoring of erythema, edema, and histological parameters of the
skin.  The result showed polyethylene glycol (PEG 400) and 70% isopropanol were superior to the other
treatments and equally effective in reducing skin damage.  The study also found that PEG 400, 70%
   
 
    
 
 
 
 
 
 
 
 
  
 
  
   
  
  
  
 
     
 
  
 
 
    
 
 
       
 
   
   
   
  
  
  
  
 
   
 
  
 
   
  
 
PHENOL 126
3. HEALTH EFFECTS
isopropanol, and 15-minute water treatments significantly reduced phenol absorption in the isolated 
porcine skin flap relative to no treatment.
Emesis is not recommended following oral ingestion of phenol because of phenol’s corrosive effects and 
potential for seizures and rapid central nervous system depression.  Instead, in the absence of esophageal
injury, repeated gastric lavage is recommended followed by administration of olive oil or vegetable oil to 
remove surface phenol and prevent deeper penetration.  This can be followed by administration of a
cathartic such as castor oil, sorbitol, or saline.  Lavage is contraindicated if esophageal injury is suspected.
3.11.2 Reducing Body Burden
Phenol is excreted in the breath, urine, and feces.  Mitigation strategies to increase urinary output and 
dilute the chemical once it is in the bloodstream may be useful.  One method for this may be increased 
hydration of the individual in order to stimulate diuresis.  Hemodialysis is not effective in removing
phenol. Information on the distribution of phenol is limited and provides little insight on how distribution 
might be altered to facilitate any attempts at mitigation of effects.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The mechanism of action of phenol in the body is not well understood.  Reports of cardiac arrhythmias
resulting from phenol exposure are not uncommon (Gross 1984; Horch et al. 1994; Truppman and 
Ellenby 1979; Warner and Harper 1985).  Specific methods to interfere with the mechanism of action for
phenol were not identified.  Treatment of phenol toxicity is essentially supportive.  Patients exposed by
inhalation should be removed from the contaminated area and given 100% humidified oxygen and 
ventilatory assistance.  Cardiovascular support includes the use of intravenous saline and vasopressors to 
support the blood pressure.  Lidocaine can be used to treat ventricular dysrhythmias and bretilium for
lidocaine-refractory arrhythmias.  Administration of sodium bicarbonate intravenously may rapidly
reverse central nervous system depression in the presence of metabolic acidosis.  Also, if
methemoglobinemia is >30%, ingestion of methylene blue may be warranted.    
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phenol is available.  Where adequate information is not
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available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of phenol.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Phenol
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
phenol are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing information 
concerning the health effects of phenol.  Each dot in the figure indicates that one or more studies provide
information associated with that particular effect.  The dot does not necessarily imply anything about the 
quality of the study or studies, nor should missing information in this figure be interpreted as a “data
need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is 
substance-specific information necessary to conduct comprehensive public health assessments.  
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from
the scientific literature.
The existing information on the health effects of phenol in humans comes from case reports of people 
who accidentally or intentionally swallowed phenol-containing substances or whose skin came in contact
with phenol, subjects exposed to phenol (and possibly to other substances at the same time) at work, and 
populations whose drinking water was contaminated with phenol (and other substances).  Acute oral and 
dermal exposure to high amounts of phenol caused serious systemic effects and even death in humans due
phenol’s irritant and corrosive properties.
Acute- and intermediate-duration inhalation studies in animals are available, but only one of these studies 
can be considered a modern study.  Inhalation studies in animals showed adverse respiratory, 
cardiovascular, liver, renal, and neurological effects.  Phenol administered by oral gavage is much more 
toxic than in drinking water; this is related to differences in toxicokinetics between the two means of
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Figure 3-5.  Existing Information on Health Effects of Phenol
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administration.  Phenol exhibited relatively little toxicity in drinking water studies, including studies of
reproductive and developmental end points.  Of special interest is a study that reported hematological, 
immunological, and neurological effects in mice exposed to low concentrations of phenol in the drinking
water for 28 days.  Longer-term studies examined mostly systemic end points. Data are extensive
regarding genotoxicity of phenol in bacterial systems and mammalian systems.  Data regarding the oral
carcinogenicity of phenol in rats and mice are available, as well as data on the dermal carcinogenicity, 
and tumor-promoting and tumor-inhibiting activities of phenol.   
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Case reports of humans exposed to high doses of phenol, either orally or
dermally, have provided acute toxicity information.  Both ingestion of phenol (Boatto et al. 2004; Soares
and Tift 1982; Stajduhar-Caric 1968; Tanaka et al. 1998) and contact of phenol with a significant area of
the skin (Cronin and Brauer 1949; Griffiths 1973; Soares and Tift 1982) have caused deaths in humans.  
The cardiovascular system also might be considered a target for acute phenol toxicity.  Supraventricular
and ventricular dysrhythmias were reported in a case of acute ingestion of phenol (Langford et al. 1998)
and cardiac arrhythmia and bradycardia were reported following acute dermal exposure to phenol (Gross
1984; Horch et al. 1994; Truppman and Ellenby 1979; Warner and Harper 1985).  Two acute-duration 
inhalation studies in animals of limited scope indicated that the respiratory tract and the nervous system
are targets for phenol toxicity (De Ceaurriz et al. 1981; Flickinger 1976).  A more recent well-conducted 
study that used modern methodology to evaluate a number of relevant end points, including upper and 
lower respiratory tract histology, defined a study NOAEL of 25 ppm, the highest exposure level tested 
(Hoffman et al. 2001).  Because no adverse effects were reported in that study, it was considered an 
unsuitable basis for an MRL.  Therefore, additional studies may be necessary to establish NOAELs and 
LOAELs that can be used to construct dose-response relationships for acute exposure to phenol.  
Acute-duration oral gavage studies in animals provided information on lethal doses (Berman et al. 1995;
Deichmann and Witherup 1944; Flickinger 1976; von Oettingen and Sharpless 1946) and other effects, 
including renal (Berman et al. 1995), hematological (Ciranni et al. 1988), neurological (Moser et al. 
1995), and developmental effects (Narotsky and Kavlock 1995; NTP 1983a, 1983b).  A study in which 
pregnant rats were administered phenol by oral gavage, but divided in three daily doses and in a relatively
high volume to minimize the effects of a bolus dose of phenol, reported a significant reduction in body
weight gain in the dams at ≥120 mg/kg/day, but no significant developmental effects were reported at this 
dose level (York 1997).  The maternal NOAEL was 60 mg/kg/day.  Decreased fetal weight and decreased 
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ossification sites were only seen at the highest dose level, 360 mg/kg/day.  The reduction in maternal
weight gain during pregnancy was used as the basis for the derivation of an acute-duration oral MRL of
1 mg/kg/day for phenol.  A need for additional acute-duration oral studies is not apparent at this time.  
Phenol is a well known skin irritant and further acute-duration dermal studies in animals are unlikely to 
provide new key information.
Intermediate-Duration Exposure. Limited information exists regarding effects of phenol in 
humans exposed for intermediate durations.  A study of office workers exposed to vapors of a liquid 
wood preservative containing phenol, among a number of other chlorinated compounds, reported adverse
respiratory, hematological, hepatic, and ocular effects, but the specific role of phenol, if any, could not be
ascertained (Baj et al. 1994).  Studies of populations whose drinking water was contaminated with phenol
found increased incidences of nausea and diarrhea, but exposure to chlorophenols may have also occurred 
(Baker et al. 1978; Jarvis et al. 1985; Kim et al. 1994).  Only three studies were identified that exposed 
animals to airborne phenol for intermediate durations (Dalin and Kristoffersson 1974; Deichmann et al. 
1944; U.S. Air Force 1961).  These studies provided evidence of respiratory, heart, liver, kidney, and 
neurological effects, but had numerous limitations including poor control of exposure levels, unclear
scope of the evaluations, and limited reporting, and were inadequate for MRL derivation.  Therefore, a
well-conducted 90-day inhalation study that examines a comprehensive number of end points would
provide valuable information for dose-response analyses and possibly MRL derivation.  Since phenol is
well absorbed through the skin, a nose-only exposure protocol may be considered.
Several studies provided information on the effects of phenol following intermediate-duration oral
exposure and all of them used drinking water to administer phenol.  A 13-week drinking water study in 
rats and mice evaluated clinical signs and gross and microscopic appearance of a number of organs and 
tissues and found little evidence of toxicity (NCI 1980).  A two-generation reproduction study found no 
evidence of reproductive effects in male or female rats, but reported decreased pup weight and reduced 
viability (Ryan et al. 2001).  A specialized 13-week neurotoxicity study reported decreased motor activity
in female rats (Beyrouty 1998).  In these three studies, the doses tested were higher than doses tested in 
acute-duration oral studies.  The most significant findings in the intermediate-duration oral database were 
those of Hsieh et al. (1992) who reported hematological, neurochemical, and immunological effects in 
mice at dose levels much lower than those used in other studies that tested similar end points.  The Hsieh 
et al. (1992) study was not used for derivation of an intermediate-duration oral MRL largely due to the
unconfirmed nature of findings and because only five mice comprised each dose group.  Replication of
Hsieh’s findings seems necessary before using the data for risk assessment.  Skin ulcerations were 
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reported in mice treated dermally with 20% phenol in acetone once each week for 24–32 weeks (Salaman 
and Glendenning 1957).  Because humans are more likely to be dermally exposed to phenol in water, and 
phenol is readily absorbed through the skin, additional intermediate-duration studies examining the
effects of dermal exposure to different concentrations of phenol in water may fill a data gap.
Chronic-Duration Exposure and Cancer. There is limited information on health effects in 
humans exposed chronically to phenol.  Neither morbidity nor mortality was significantly increased in 
workers in five companies that used formaldehyde and phenol (Dosemeci et al. 1991).  In another study
of workers in the rubber industry, exposure to phenol was associated with an increased incidence of 
cardiovascular disease, independently of being associated with exposure to other solvents such as carbon 
disulfide (Wilcosky and Tyroler 1983).  Liver effects, as judged by increased serum activities of ALT and 
AST, were reported in a case of prolonged inhalation exposure to phenol (Merliss 1972) and in workers in 
an oil-refining plant (Shamy et al. 1994), but exposure to other solvents could not be ruled out in the latter
case.  The lack of exposure data and simultaneous exposure to other chemicals precluded using the human 
data for derivation of a chronic-duration inhalation MRL for phenol.  No chronic-duration inhalation
studies in animals were identified.  This constitutes a data gap that may need to be filled.   
The only chronic-duration animal studies are the NCI (1980) 103-week studies in rats and mice.  NCI
(1980) evaluated clinical signs, organ weights, and gross and microscopic appearance of organs and 
tissues.  Under the conditions of the study, phenol showed essentially no systemic toxicity.  A chronic-
duration oral drinking water study with emphasis on immunological end points may be necessary if the
intermediate-duration immunotoxicity study that NTP is currently conducting confirms that
immunocompetence is the most sensitive end point for phenol toxicity.  Since, as previously mentioned, 
phenol is readily absorbed through the skin and the possibility exists of dermal exposure via contaminated 
water (bathing or showering) at or near waste sites, a chronic-duration dermal study of phenol in water
may be considered if the results of a shorter-term study suggest that adverse effects might happen.
A study of phenol-exposed wood industry workers reported a small, nonsignificant excess of respiratory
cancers (Kauppinen et al. 1986) and a study of phenol production workers reported a small, 
nonsignificant excess of Hodgkin’s disease and of lung, esophageal, and kidney cancers (Dosemeci et al.
1991).  However, the interpretation of these findings is complicated due to lack of dose-response and 
potential for confounding.  Phenol has been tested for carcinogenicity in long-term drinking water
bioassays in rats and mice (NCI 1980).  Statistically significant increased incidences of
pheochromocytomas of the adrenal gland and leukemia or lymphomas were observed in male rats 
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exposed to the low dose of phenol, but not to the high dose of phenol.  No significant effects were seen in 
female rats or in mice.  Additional bioassays do not seem necessary at this time.
Genotoxicity. Phenol has been tested extensively for genotoxicity in a variety of in vivo (Amlacher
and Rudolph 1981; Barale et al. 1990; Bulsiewicz 1977; Chen and Eastmond 1995a; Ciranni et al. 1988;
Gocke et al. 1981; Li et al. 2005; Miyagawa et al. 1995; Pashin et al. 1987; Shelby and Witt 1995; Skare
and Schrotel 1984; Sturtevant 1952) and in vitro (Crebelli et al. 1987; Demerec et al. 1951; Erexson et al. 
1985; Florin et al. 1980; Gocke et al. 1981; Haworth et al. 1983; Jansson et al. 1986; Kubo et al. 2002; Li
et al. 2005; Miller et al. 1995; Morimoto and Wolff 1980; Morimoto et al. 1983; Nagel et al. 1982;
Painter and Howard 1982; Paschin and Bahitova 1982; Pellack-Walker and Blumer 1986; Poirier et al.
1975; Pool and Lin 1982; Schwartz et al. 1985; Sze et al. 1996; Tsutsui et al. 1997) tests.  The results of
these assays have been equivocal.  Phenol appears to be potentially genotoxic, although this may be more
a result of the action of its metabolites than the parent compound.  Additional genotoxicity studies of
phenol do not seem to be necessary.
Reproductive Toxicity. Extremely limited data regarding possible adverse reproductive effects in 
humans following exposure to phenol provide no evidence for effects (Axelsson et al. 1984).  Histopatho­
logical changes in reproductive organs were not observed in rats or mice treated with phenol in the
drinking water for 13 or 103 weeks (NCI 1980).  In a two-generation study in which rats were 
administered phenol in the drinking water, there were no significant alterations in gross or microscopic
appearance of the reproductive organs of males and females from the parental and F1 generations (Ryan et
al. 2001).  In addition, there were no significant effects on estrus frequency, testicular sperm count, or
sperm motility or morphology.  Significant reductions in prostate and uterine weights in all F1 treated 
groups were not considered adverse effects of phenol by Ryan et al. (2001) on the basis of the absence of
histological alterations and functional reproductive effects, and based on the fact that only a few animals 
had organ weights outside the range of concurrent control values.  Additional reproductive toxicity
studies by the oral route do not seem necessary.  Studies by the inhalation or dermal route also do not
seem necessary since there is no indication that reproductive effects would be route-dependent. 
Developmental Toxicity. Extremely limited data regarding possible adverse developmental effects 
in humans following exposure to phenol provide no evidence for effects (Axelsson et al. 1984). Phenol
has been evaluated for developmental effects in rats and mice exposed by oral gavage (Ciranni et al. 
1988; Kavlock 1990; Narotsky and Kavlock 1995; NTP 1983a, 1983b; York 1997) and in rats dosed 
through the drinking water in a two-generation reproduction study (Ryan et al. 2001). These studies 
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indicated that fetotoxicity occurs only at dose levels that are also toxic to the mother.  The study by York 
(1997) was used to derive an acute-duration oral MRL of 1.0 mg/kg/day for phenol.  Additional
developmental studies by the oral route of exposure do not seem necessary at this time.  Also, studies by
the inhalation or dermal route also do not seem necessary since there is no indication that developmental
effects would be route-dependent. 
Immunotoxicity. Immunological effects were reported in workers exposed for 6 months to a mixture
of phenol, formaldehyde, and organic chlorohydrocarbons, although there is some question whether the
exposure was due to phenol or a substituted phenol (Baj et al. 1994).  Increased susceptibility to bacteria
was not observed in mice exposed by inhalation to phenol (Aranyi et al. 1986).  Necrosis or atrophy of the
spleen or thymus, which was not described further, was observed in rats given a single dose of phenol by
oral gavage (Berman et al. 1995).  Effects on the spleen or thymus were not observed in rats given 
14 daily doses of phenol (Berman et al. 1995). Decreased antibody production in response to 
immunization with SRBC was observed in mice treated with relatively low doses of phenol in the
drinking water for 28 days (Hsieh et al. 1992).  Ryan et al. (2001) conducted similar tests in rats in the
two-generation reproductive study and found no significant effects of phenol.  It would be useful to try to 
replicate Hsieh’s findings before the results can be used for risk assessment.  In longer-term studies, 
histopathologic changes in the spleen or thymus were not observed in rats or mice exposed to phenol in 
the drinking water for 13 or 103 weeks, but immunocompetence was not assessed (NCI 1980).  Studies by
the inhalation and dermal routes are not necessary since there is no evidence of route-dependency.
Neurotoxicity. An increase in the number of headaches was reported by persons exposed to phenol in
drinking water following an accident, but chlorophenols may have contributed to the observed effects
(Kim et al. 1994).  As reported in a retrospective review (Spiller et al. 1993), 11 patients with oral
exposures to phenol-based disinfectants experienced rapid central nervous system depression, but no 
seizures occurred. Neurological effects (muscle tremor, loss of coordination) have been reported in 
laboratory animals after single exposures to high concentrations of phenol in the air (Flickinger 1976), 
continuous exposure in the air (Dalin and Kristoffersson 1974), repeated intermittent exposures in the air
(Deichmann et al. 1944), and oral gavage dosing (Deichmann and Witherup 1944; Liao and Oehme 1981;
Moser et al. 1995; NTP 1983b).  In contrast, no such effects were observed in rats and mice in drinking
water studies of longer durations and with higher doses of phenol (Beyrouty 1998; NCI 1980).  These
neurological effects correlate with peak blood concentrations of phenol achieved during gavage dosing.  
Drinking water studies suggest that the nervous system is not a sensitive target for phenol toxicity by this
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route of exposure.  A need to conduct additional toxicity studies is not apparent, but studies aimed at
elucidating the mechanism(s) of phenol neurotoxicity are needed.
Epidemiological and Human Dosimetry Studies. As previously mentioned, information about
the health effects of phenol in humans is derived from studies of workers and members of the general
population following inhalation, oral, and dermal exposure.  Specific effects and references are mentioned 
in previous sections.  Doses were generally not available, but Deichmann and Keplinger (1981) estimated 
that an oral dose as low as 1 g could be fatal in humans, but also pointed out that patients occasionally
survived doses as high as 65 g.  Other than the skin and mucosal membranes, the liver and cardiovascular
system might by considered targets for phenol toxicity.  Wilcosky and Tyroler 1983 studied workers in 
the rubber industry and found that exposure to phenol was associated with an increased incidence of
cardiovascular disease, independently of being associated with exposure to other solvents such as carbon 
disulfide.  Cardiac arrhythmia and bradycardia were reported following acute dermal exposure to phenol
(Gross 1984; Horch et al. 1994; Truppman and Ellenby 1979; Warner and Harper 1985) and 
supraventricular and ventricular dysrhythmias were reported in a case of acute ingestion of phenol
(Langford et al. 1998).  Liver effects were reported in a case of prolonged inhalation exposure to phenol
(Merliss 1972) and in workers in an oil-refining plant (Shamy et al. 1994), but exposure to other solvents
could not be ruled out in the latter case.  Prolonged exposure to low levels of phenol may occur at or near
waste sites via contaminated water.  Since such contamination may lead to inhalation exposure 
(evaporation of phenol when bathing or showering, particularly if the water is acidic), dermal exposure
(absorption through the skin), and oral exposure (ingestion of water or cooking with contaminated water), 
a dosimetric model that predicts total exposure and intake of phenol from contaminated water would be
valuable.  The specific end points that should be monitored under such exposure scenario (prolonged low
level) are not immediately apparent.  Phenol administered in the drinking water to rats and mice for
2 years showed almost no systemic toxicity (NCI 1980).
Biomarkers of Exposure and Effect.
Exposure.  Measurement of total phenol in the urine is the most useful biomarker following inhalation 
exposure to phenol (ACGIH 2001).  The test is nonspecific and should not be used when workers are
exposed to benzene, to household products, or to medications containing phenol.  Dermal exposure may
also result in overestimation of inhalation exposure.  In persons not exposed to phenol or benzene, the
total phenol concentration in the urine does not exceed 20 mg/L and the mean is usually <10 mg/L
(ACGIH 2001).  Phenol can also be measured in the urine after oral exposure, although a dose-response 
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relationship between oral exposure to phenol and phenol in the urine has not been established.  Benzene
metabolism yields not only phenol, 1,4-dihydroxybenzene, and their sulfates and glucuronides, but also 
the benzene-specific t,t-muconic acid.  For both t,t-muconic acid and S-phenylmercapturic acid, 
significant correlations were shown with benzene concentrations in air and in blood (Popp et al. 1994;
Stommel et al. 1989).  Thus, determination of urinary concentrations of these metabolites allows
delineation of the portion of metabolites stemming from phenols and the portion derived from benzene
exposure.  Further research on the relationship between exposure doses and urinary levels of phenol is
needed.
Effect. Specific biomarkers used to characterize effects caused by phenol have not been identified.  Dark
urine has been reported in persons occupationally exposed to phenol (inhalation, dermal) (ACGIH 2001;
Merliss 1972), and following oral exposure (Baker et al. 1978; Kim et al. 1994).  The dark urine may be a
result of an oxidation product of phenol or hemoglobin. Further research is required to identify the cause
of the dark urine.
Absorption, Distribution, Metabolism, and Excretion. The toxicokinetics of phenol have been 
studied extensively in laboratory animals and humans.  Phenol is readily absorbed from the lungs, 
gastrointestinal tract, and skin.  A study that examined the absorption of phenol vapor through the skin 
indicates that it is readily absorbed and clothing does not serve as a barrier (Piotrowski 1971).  Dermal
absorption is considered the primary route of entry for vapor, liquid, and solid phenol (ACGIH 2001).  
Conjugation of phenol with glucuronic acid and sulfate are the main detoxification pathways.  
Conjugation occurs predominantly in the lungs, gastrointestinal tract, liver, and kidneys.  The skin has 
relatively low potential to detoxify phenol.  Therefore, absorption through the skin may represent the
greatest hazard from phenol because it readily passes through the skin and because there is no first-pass 
metabolic effect as is observed following oral exposure.  Further studies regarding the metabolism of
phenol following dermal exposure are needed. In vitro studies of phenol metabolism have demonstrated 
that reactive intermediates are produced during the metabolism of phenol (Chapman et al. 1994;
Eastmond et al. 1986; Lunte and Kissinger 1983; Subrahmanyam and O'Brien 1985).  These reactive
compounds may be involved in mediating phenol toxicity.  Further investigation of these compounds in 
tissues suspected of being targets for phenol toxicity (i.e., the lungs, skin, liver, kidney, and heart) are
needed to provide information for extrapolating from animals to humans.
There is no PBPK model specifically designed for phenol, although phenol, as a major metabolite of
benzene, has been considered in a PBPK model of benzene discussed in this profile (Bois et al. 1991).  
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The model does not adequately explain the differences in carcinogenicity observed between benzene and 
phenol, and needs additional refinements in order to incorporate all the observations and be validated.  
Additional efforts to develop a PBPK model for phenol are needed.
Comparative Toxicokinetics. The metabolism and excretion of orally administered phenol in 
18 animal species have been compared to metabolism and excretion in humans (Capel et al. 1972).  The
rat was the most similar to the human with respect to the fraction of administered dose excreted in urine
in 24 hours (95%) and the number and relative abundance of the four principal metabolites excreted in 
urine (sulfate and glucuronide conjugates of phenol and 1,4-dihydroxybenzene).  The rat excreted a larger
fraction of the orally administered dose than the guinea pig or the rabbit (Capel et al. 1972) and appears to 
be the least susceptible of the three species to respiratory, cardiovascular, hepatic, renal, and neurological
effects of inhaled phenol (Deichmann et al. 1944).  More rapid metabolism and excretion of absorbed 
phenol may account for the lower sensitivity of the rat to systemic effects of phenol.  More information 
on the relative rates of metabolism of phenol in various species is needed to identify the most appropriate 
animal model for studying potential health effects in humans.
Methods for Reducing Toxic Effects. Removing a person from phenol exposure is the most
important method for reducing toxic effects of phenol.  This is especially important following dermal
exposure, after which speed in removing phenol from the skin is important (HSDB 2008).  Because a 
study has shown that dilution in water increases the dermal absorption of phenol (Conning and Hayes
1970), it has been recommended that polyethylene be used to remove dermal contamination with phenol
(Viccellio 1998).  Because water is readily available, others believe that its use is more appropriate for the
decontamination of skin following phenol exposure (Pullin et al. 1978).  A study is available that
evaluated several strategies to decontaminate the skin of pigs following acute dermal exposure to phenol
(Monteiro-Riviere et al. 2001).  The study showed that polyethylene glycol (PEG 400) and 70%
isopropanol were superior to other treatments and equal effective in reducing skin damage induced by
phenol.  The general recommendations for reducing the absorption of phenol following acute oral
exposure are well established and have a proven efficiency (HSDB 2008).  No additional investigations
are considered necessary at this time.
No clinical treatments, other than supportive measures, are currently available to enhance elimination of
phenol following exposure.  Studies designed to assess the potential risks or benefits of increasing
ventilation to enhance pulmonary elimination or of stimulating excretion of phenol and its metabolic
products are needed.
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Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
Deichmann and Witherup (1944) found that 10-day-old rats were more sensitive to lethality following
oral exposure to phenol than 5-week-old or adult rats; however, this work has never been repeated and 
there was little other information evaluating the toxicity of phenol at various ages.  Such studies need to 
be conducted in order to follow up this earlier observation.  However, caution should be exercised when 
extrapolating from adolescent rats to children, since rodents are known to undergo a number of changes in 
xenobiotic-metabolizing enzymes during sexual development (Waxman et al. 1985).  
Studies that specifically evaluated age-related changes in the phase I and phase II metabolic 
transformations of phenol are not available.  However, in general, it is known that there is a reduced 
capacity to metabolize xenobiotics in the first 15 days of life, and that the different enzyme systems have 
different time courses of development thereafter (Morselli et al. 1980).  For example, glucuronide
conjugation reactions are considerably reduced in young humans, and reach adult values only after the
age of 3, whereas sulfate conjugations and oxidative reactions catalyzed by the cytochrome 
P450 enzymes apparently develop more rapidly (Buxton 2006; Morselli et al. 1980).  Thus, there could be
age-related differences in the balance among metabolites, particularly at high doses where the glucuronide
metabolites begin to dominate.  While there is agreement that conjugation reactions represent a 
detoxification mechanism for phenol, it is still unknown whether parent compound or an oxidation 
product(s) is the entity responsible for the systemic toxicity of phenol in vivo. Studies are needed to 
examine how age affects the metabolism of phenol, and particularly how age changes the balance 
between phase I and phase II metabolism at either high or low doses.
There was no information found on the placental transfer of phenol or on the concentrations of phenol
present in breast milk.  There is evidence that benzene and its (not specifically identified) metabolites do 
cross the placenta, although there is no evidence of selective accumulation (Ghantous and Danielsson 
1986).  Additional studies of this issue are needed to determine if phenol and its metabolites are among
the metabolites of benzene that cross the placenta, and if so whether phenol behaves like benzene in the
lack of accumulation.  Information is also needed on the content of phenol in breast milk under various
conditions (e.g, smoking versus nonsmoking mothers) in order to determine if breast milk could ever be a 
source of phenol exposure for children.
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Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No ongoing studies pertaining to phenol were identified in the Federal Research in Progress database 
(FEDRIP 2006).
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Information regarding the chemical identity of phenol is located in Table 4-1.
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of phenol is located in Table 4-2.
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Table 4-1.  Chemical Identity of Phenol
Characteristic Information Reference
Chemical name Phenol Lide 2005
Synonym(s) Benzenol, hydroxylbenzene, Lewis 2000
monophenol, oxybenzene, phenyl
alcohol, phenyl hydrate, phenyl
hydroxide, phenylic acid, phenylic
alcohol
Registered trade name(s) Carbolic acid, phenic acid, phenic Gardner et al. 1978
alcohol
Chemical formula C6H6O Lide 2005
Chemical structure OH Budavari et al. 1989
Identification numbers:
CAS registry 108-95-2 HSDB 2008
NIOSH RTECS SJ3325000 RTECS 2006
EPA hazardous waste U188 EPA 1998; HSDB 2008
DOT/UN/NA/IMCO shipping UN 1671 (solid) HSDB 2008
UN 2312 (molten)
UN 2821 (solution)
IMO 6.1 (solid, molten, solution)
HSDB 113 HSDB 2008
NCI C50124 Lewis 2000
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; RTECS=Registry of Toxic Effects of Chemical Substances
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Table 4-2.  Physical and Chemical Properties of Phenol
Property Information Reference
Molecular weight 94.111 Lide 2005
Color Colorless to light pink HSDB 2008
Physical state Crystalline solid liquid (w/ 8% H2O)
Melting point 40.89 °C Lide 2005
Boiling point 181.87 °C Lide 2005
Density at 20 °C/4 °C 1.0545 at 45 °C/4 °C Lide 2005
Vapor density 3.24 Lewis 2000
Odor Distinct aromatic, somewhat sickening, sweet HSDB 2008
and acrid odor
Odor threshold:
Water 7.9 ppm (w/v) Amoore and Hautala 1983
1 ppm (w/v) Baker et al. 1978
Air 0.040 ppm (v/v) Amoore and Hautala 1983
Solubility:
Water at 25 °C 8.28x104 mg/L Southworth and Keller 1986
Organic solvent(s) Soluble in water and ethanol, very soluble in Lide 2005
ether, miscible with acetone and benzene
Partition coefficients:
Log Kow 1.46 HSDB 2008
Log Koc 1.21–1.96 Artiola-Fortuny and Fuller
1982; Boyd 1982; Briggs
1981; Sacan and Balcioglu 
1996; Scott et al. 1983
Vapor pressure at 25 °C 0.35 mmHg HSDB 2008
Henry's law constant 3.0x107 atms m3-mol Gaffney et al. 1987
Autoignition temperature 715 °C Lewis 2000
Flashpoint, open cup 85 °C HSDB 2008
Flashpoint, closed cup 79 °C HSDB 2008
Flammability limits (in air, 1.7–8.6% HSDB 2008
by % v)
Conversion factors:
ppm (v/v) to mg/m3 in ppm (v/v)x3.92=mg/m3 
air (25 °C)
mg/m3 to ppm (v/v) in mg/m3x0.225=ppm (v/v)
air (25 °C)
atm = atmosphere; v = volume; w = weight
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
Table 5-1 lists the number of facilities in each state that manufacture or process phenol, the intended use, 
and the range of maximum amounts of phenol that are stored onsite.  The data listed in Table 5-1 are 
derived from the Toxics Release Inventory (TRI) (TRI05 2007).  Only certain types of facilities were
required to report.  Therefore, this is not an exhaustive list.
Phenol has been obtained by distillation from petroleum and synthesis by oxidation of cumene or toluene, 
and by vapor-phase hydrolysis of chlorobenzene (Wallace 1998).  In 2004, nearly 98% of U.S. phenol
production was based on oxidation of cumene except at one company that used toluene oxidation and a
few companies that distilled phenol from petroleum (CMR 2005).  In 2004, the total annual capacity of
phenol production approached 6.6 billion pounds (CMR 2005).  A list of current U.S. producers of phenol
is found in Table 5-2.
5.2  IMPORT/EXPORT
According to the National Trade Data Bank (USITC 2008), exports of phenol were 503 million kg
(1,110 million pounds) (USITC 2008).  The major importer of phenol from the United States was Canada,
with an import value of 117 million kg during 2007.  The total amount of phenol imported to the United 
States was 1.3 million kg (2.8 million pounds) in 2005.  The largest exporter of phenol to the United 
States was South Africa, which exported 1 million kg of phenol (USITC 2008).
5.3  USE 
The two major uses of phenol in 2004 were the production of bisphenol-A (48%) and the production of
phenolic resins (25%) (CMR 2005).  The largest use for bisphenol-A is as an intermediate in the
production of epoxy resins (Thurman 1982).  Phenol-formaldehyde resins comprise over 95% of this 
market (Thurman 1982).  Other major uses of phenol include the production of caprolactam (11%), 
aniline (2%), alkylphenols (4%), xylenols (4%), and miscellaneous uses (6%) (CMR 2005).  Phenol is
used as a slimicide (a chemical toxic to bacteria and fungi characteristic of aqueous slimes) and as a 
general disinfectant in solution or mixed with slaked lime for toilets, stables, cesspools, floors, drains, and 
other areas (Budavari et al. 1989; Hawley 1981).
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Table 5-1.  Facilities that Produce, Process, or Use Phenol
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 1 100 999 1, 13
AL 93 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 39 0 49,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AZ 17 0 9,999,999 1, 5, 6, 7, 8, 11, 12
CA 122 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 6 0 99,999 1, 2, 5, 6, 9, 10, 11
CT 24 0 999,999 2, 3, 6, 7, 8, 10, 11, 12, 14
DE 10 1,000 999,999 1, 3, 5, 6, 7, 12, 13
FL 27 0 9,999,999 1, 5, 6, 7, 8, 11, 12, 13
GA 68 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14
GU 2 0 9,999 9
IA 31 0 999,999 2, 3, 5, 6, 7, 8, 10, 11, 12
ID 6 0 9,999 1, 2, 3, 5, 7, 11, 13
IL 105 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 126 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS 36 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13
KY 51 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
LA 100 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 38 0 499,999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13
MD 19 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 11, 13
ME 23 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14
MI 88 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN 41 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
MO 42 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
MS 49 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MT 15 0 9,999,999 1, 2, 3, 5, 6, 9, 13, 14
NC 69 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND 3 0 99,999 1, 5, 7
NE 9 100 999,999 1, 3, 5, 6, 8, 11, 12
NH 11 0 999,999 1, 2, 3, 5, 7, 8, 10, 11, 12, 13
NJ 47 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NM 3 10,000 999,999 1, 2, 3, 7, 10, 12, 13
NV 2 1,000 99,999 7
NY 62 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OH 122 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 45 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OR 50 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
PA 108 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
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Table 5-1.  Facilities that Produce, Process, or Use Phenol
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
PR 15 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13
RI 5 100 99,999 6, 7, 8
SC 53 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
SD 1 1,000 9,999 3, 6, 10, 11
TN 72 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX 155 0 10,000,000,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 25 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
VA 41 0 49,999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13, 14
VI 4 100 999,999 1, 2, 3, 4, 5, 6, 7, 9
VT 6 1,000 9,999 2, 3, 6, 8, 10
WA 58 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI 60 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13
WV 27 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13
WY 13 0 999,999 1, 3, 4, 5, 6, 7, 12, 13
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
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Table 5-2.  Current U.S. Producers of Phenol
Capacity

Company Location (millions of pounds)
 
Dakota Gasification Company Beulah, North Dakota 35
The Dow Chemical Company Oyster Creek, Texas 650
General Electric Company, GE Advanced Mount Vernon, Indiana 750
Materials Plastics
Georgia Gulf Corporation Pasadena, Texas 160
Georgia Gulf Corporation Plaquemine, Louisiana 500
INOES Phenol Inc. Theodore, Alabama 1200
JLM Chemicals Blue Island, Illinois 100
Merisol USA LLC Houston, Texas 25
Noveon Inc. Kalama, Washington 75
Shell Chemical Company Deer Park, Texas 1,180
Sunoco Inc. Haverhill, Ohio 1,000
Sunoco Inc. Philadelphia, Pennsylvania 1,115
Source:  Derived from SRI 2006
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5.4  DISPOSAL
Phenol is listed as a toxic substance under Section 313 of the Emergency Planning and Community Right
to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act (SARA)
(EPA 1998c). Disposal of wastes containing phenol is controlled by a number of federal regulations (see
Chapter 8).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
Phenol has been identified in at least 595 of the 1,678 hazardous waste sites that have been proposed for
inclusion on the EPA National Priorities List (NPL) (HazDat 2006).  However, the number of sites
evaluated for phenol is not known.  The frequency of these sites can be seen in Figure 6-1.  Of these sites, 
589 are located within the United States and 4 are located in the Commonwealth of Puerto Rico (not
shown) and 2 are located in the Virgin Islands (not shown).
Phenol is released to the air and water as a result of its manufacture, its use in phenolic resins, and organic
synthesis (Wallace et al. 1996).  Phenol is found in petroleum products such as coal tar, and creosote and
can be released by combustion of wood and auto exhaust (Wallace et al. 1996).  Phenol is also produced 
by the natural degradation of organic wastes including benzene.  Phenol is a major metabolite of benzene
(Rothman et al. 1998), which is found extensively in the environment (Agency for Toxic Substances and 
Disease Registry 2006), therefore, phenol may be formed in the environment as a result of the natural
degradation of benzene.
Phenol mainly enters the water from industrial effluent discharges.  Phenol is degraded rapidly in air by
gas-phase hydroxyl radical reaction (estimated half-life 14.6 hours), but may persist in water for a
somewhat longer period.  Half-lives for biodegradation range from <1 day in samples of lake water to 
9 days in estuarine water; a typical half-life for photooxidation by photochemically produced peroxyl
radicals is approximately 19 hours.  In soil, phenol will generally biodegrade rapidly; however, 
biodegradation of phenol in water or soil may be hindered or precluded by the presence of high, toxic
concentrations of phenol or other chemicals, or by other factors such as a lack of nutrients or
microorganisms capable of degrading phenol.  If biodegradation is sufficiently slow, phenol in sunlit
water will undergo photooxidation with photochemically produced peroxyl radicals, and phenol in soil
will leach to groundwater.  Phenol may remain in air, water, and soil for much longer periods if it is
continually or consistently released to these media from point sources.  Since plants can metabolize 
phenol readily, exposure through eating food derived from plants grown in phenol-containing soil is
probably minimal.  
Phenol has been measured in effluents (up to 53 ppm), ambient water (1.5–>100 ppb), drinking water (not
quantified), groundwater (1.9–>10 ppb), rain (0.075–1.2 ppb), sediment (>10 ppb), and ambient air (0.03– 
44 ppb). Occupational exposures occur through inhalation and dermal exposure; air concentrations

   
 
  
 
 
 
 
 
 
 
    
  
 
   
 
  
   
 
    
  
 
 
  
  
    
   
 
     
 
     
    
   
 
 
  
 
   
     
  
     
  
   
   
PHENOL 151
6.  POTENTIAL FOR HUMAN EXPOSURE
monitored in various workplaces range from 0.1 to 12.5 mg/m3 (0.03–32 ppm).  Occupational as well as 
consumer exposure may also occur through dermal contact with phenol or phenol-containing products.
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
6.2.1 Air
Estimated releases of 7.6 million pounds (~3,480 metric tons) of phenol to the atmosphere from
677 domestic manufacturing and processing facilities in 2004, accounted for about 64% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are
summarized in Table 6-1.
During manufacturing, phenol is released primarily to the atmosphere from storage tank vents and during
transport loading (EPA 1979c).  Other major sources of release to the atmosphere are residential wood 
burning and automobile exhaust (EPA 1981a). Volatilization from environmental waters and soils has 
been shown to be a slow process (see Section 6.3.1) and is not expected to be a significant source of
atmospheric phenol.  Phenol is released into the atmosphere from industrial combustion processes.  For
example, phenol has been detected at a concentration of 0.36 ppb in the emissions of a waste incinerator
plant in Germany (Jay and Stieglitz 1995).  In Brazil, an estimated 64 kg/year of phenol is released to the
urban areas located near coal-fired power stations, indicating that people who live near coal-fired power
stations may have an increased risk of exposure to phenol (Moreira dos Santos et al. 2004).  Phenol is also 
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
 
Use Phenola
 
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AL 33 407,745 278 0 8,213 0 408,261 7,975 416,236
AR 15 53,803 136 0 4,781 0 54,241 4,479 58,720
AZ 2 5,499 No data 0 100 0 5,499 100 5,599
CA 33 100,135 1,974 0 5,544 305 102,117 5,841 107,958
CO 2 32 No data 0 0 0 32 0 32
CT 4 5,631 No data 0 649 728 5,631 1,377 7,008
DE 2 160 44,595 0 0 0 44,755 0 44,755
FL 12 114,230 950 0 91 0 115,272 0 115,272
GA 25 146,687 518 0 1,468 2,102 147,242 3,533 150,775
IA 5 17,126 36 0 100,501 0 17,162 100,501 117,663
ID 2 1,005 5 0 4,428 0 1,010 4,428 5,438
IL 28 614,954 602 0 50,925 251 616,526 50,206 666,732
IN 32 391,396 3,660 100,000 35,975 5 495,190 35,845 531,035
KS 7 76,565 54 0 5,869 1,829 76,637 7,680 84,317
KY 13 108,867 809 0 56,542 0 109,676 56,542 166,218
LA 36 124,638 15,173 150,002 10,660 120 295,401 5,192 300,593
MA 6 15,108 No data 0 803 0 15,108 803 15,911
MD 2 13,004 No data 0 0 0 13,004 0 13,004
ME 5 25,852 15 0 906 0 25,893 880 26,773
MI 29 121,520 660 19 78,038 44,762 122,188 122,810 244,998
MN 8 55,892 150 0 98 3 56,117 26 56,143
MO 9 15,024 0 0 0 0 15,024 0 15,024
MS 12 67,983 207 0 1,238 0 68,190 1,238 69,428
MT 5 3,724 25 0 23 0 3,772 0 3,772
NC 23 186,812 311 0 164,098 0 187,269 163,952 351,221
ND 1 220 49 2,100 0 0 2,369 0 2,369
NE 4 888 No data 0 147 0 896 139 1,035
NH 2 6,203 No data 0 1 0 6,203 1 6,204
NJ 10 6,218 1,828 0 10,327 0 16,022 2,351 18,373
NM 1 1,078 No data 0 0 0 1,078 0 1,078
NY 23 57,689 62 0 22,704 56,518 57,777 79,196 136,973
OH 45 522,126 1,219 34 119,210 807 528,880 114,516 643,397
OK 10 21,713 558 0 17,557 4,855 38,249 6,434 44,683
OR 22 186,431 189 0 12,935 3,453 187,736 15,272 203,008
PA 29 424,309 9,699 0 4,994 2,093 434,776 6,319 441,096
PR 3 4,974 No data 0 4,561 0 4,974 4,561 9,535
RI 1 724 No data 0 0 0 724 0 724
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
 
Use Phenola
 
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
SC 20 93,387 1,284 0 148,473 0 115,489 127,656 243,145
TN 15 81,725 305 0 2,006 45 82,439 1,642 84,081
TX 75 233,116 7,659 1,225,465 99,083 118 1,416,533 148,909 1,565,442
UT 3 31,100 No data 0 7,600 0 38,700 0 38,700
VA 12 56,625 299 0 31,225 750 87,264 1,635 88,899
VI 1 78,848 612 0 1 0 79,460 1 79,461
WA 19 127,933 5,382 0 427 181 133,355 568 133,923
WI 23 305,630 55 0 27,762 30 305,685 27,792 333,477
WV 6 20,279 188 0 69 44 20,475 105 20,580
WY 2 750 No data 0 0 0 750 0 750
Total 677 4,935,360 99,546 1,477,621 1,040,033 118,999 6,561,054 1,110,505 7,671,559
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
 
and metal compounds).

gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.

iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
 
disposal, unknown

jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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found in cigarette smoke and in plastics (Graedel 1978), but no data are available to determine the extent
of exposure to phenol from these sources.
6.2.2 Water
Estimated releases of 99,546 pounds (~45 metric tons) of phenol to surface water from 677 domestic 
manufacturing and processing facilities in 2005, accounted for about 0.1% of the estimated total
environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are
summarized in Table 6-1.
The most common anthropogenic sources of phenol in natural water include coal tar (Thurman 1982) and 
waste water from manufacturing industries such as resins, plastics, fibers, adhesives, iron, steel, 
aluminum, leather, rubber (EPA 1981b), and effluents from synthetic fuel manufacturing (Parkhurst et al.
1979).  Phenol is also released from paper pulp mills (Keith 1976) and wood treatment facilities (Goerlitz
et al. 1985).  Other releases of phenol result from commercial use of phenol and phenol-containing
products, including slimicides, general disinfectants (Budavari et al. 1989; Hawley 1981), and medicinal
preparations such as throat lozenges, mouthwashes, gargles, and antiseptic lotions (Darisimall 2006).  
Two natural sources of phenol in aquatic media are animal wastes and decomposition of organic wastes
(EPA 1980).  As a metabolite of benzene, phenol may be released from publicly owned treatment works
(POTWs) and sewage overflow.  For example, it has been estimated that 3.8 kg/day of phenol are released
to Newark Bay, in New Jersey, from municipal treatment facilities (Crawford et al. 1995).  Phenol was 
detected in 2% of the effluent samples from New York City sewage waste facilities collected during 1989 
to 1993 at concentrations of 6–310 g/L (Stubin et al. 1996). Because it is a metabolite, phenol is likely to 
be found in other sewage and POTWs facilities.  No data are available to determine the extent of exposure 
from these sources.
Estimated releases of 85,700 pounds (~39 metric tons) of phenol to surface water from 689 domestic 
manufacturing and processing facilities in 2004, accounted for about 0.1% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI05 2007).  These releases are
summarized in Table 6-1.
The most common anthropogenic sources of phenol in natural water include coal tar (Thurman 1982) and 
waste water from manufacturing industries such as resins, plastics, fibers, adhesives, iron, steel, 
aluminum, leather, rubber (EPA 1981b), and effluents from synthetic fuel manufacturing (Parkhurst et al.
   
 
  
 
 
 
 
 
 
 
   
   
  
   
 
    
 
     
  
     
   
  
 
    
  
    
  
     
    
 
   
    
 
  
  
    
   
    
 
  
   
   
    
PHENOL 155
6.  POTENTIAL FOR HUMAN EXPOSURE
1979).  Phenol is also released from paper pulp mills (Keith 1976) and wood treatment facilities (Goerlitz
et al. 1985).  Other releases of phenol result from commercial use of phenol and phenol-containing
products, including slimicides, general disinfectants (Budavari et al. 1989; Hawley 1981), and medicinal
preparations such as throat lozenges, mouthwashes, gargles, and antiseptic lotions (Darisimall 2006).
6.2.3 Soil 
Estimated releases of 1 million pounds (~472 metric tons) of phenol to soils from 689 domestic 
manufacturing and processing facilities in 2005, accounted for about 14% of the estimated total
environmental releases from facilities required to report to the TRI (TRI05 2007).  An additional
1.5 million pounds (~670 metric tons), constituting about 19% of the total environmental emissions, were 
released via underground injection (TRI05 2007).  These releases are summarized in Table 6-1.
Phenol may be released to the soil during its manufacturing process, when spills occur during loading and 
transport, and when it leaches from hazardous waste sites and landfills (Xing et al. 1994).  Generally, data
on concentrations of phenol found in soil at sites other than hazardous waste sites are lacking.  This may
be due in part to a rapid rate of biodegradation and leaching (see Sections 6.3.1 and 6.3.2.3).  Phenol can 
be expected to be found in soils that receive continuous or consistent releases from a point source.  Phenol
that leaches through soil to groundwater spends at least some time in that soil as it travels to the 
groundwater.  Phenol has been found in groundwater, mainly at or near hazardous waste sites.
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Phenol is released into the air and discharged into water from both manufacturing and use.  Based on its
high water solubility (see Table 4-2) and the fact that it has been detected in rainwater, some phenol may
wash out of the atmosphere; however, it is probable that only limited amounts wash out because of the
short atmospheric half-life of phenol.  During the day, when photochemically produced hydroxyl radical
concentrations are highest in the atmosphere, very little atmospheric transport of phenol is likely to occur.
In water, neither volatilization nor sorption to sediments and suspended particulates are expected to be
important transport mechanisms.  Using the Henry's Law constant of 3x10-7 atm m3/mol (Gaffney et al. 
1987), a volatilization half-life of 88 days was calculated for phenol evaporation from a model river 1 m 
deep with a current of 1 m/second, and wind velocity of 3 m/second (Lyman et al. 1982). The biological
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treatment of waste water containing phenol has shown that <1% of phenol is removed by stripping
(Kincannon et al. 1983; Petrasek et al. 1983).
Phenol has been reported in sediments at levels as high as 608 ppm dry weight; however, it is not known 
whether the location of the site where this concentration was reported is at or near a point source of
release, such as a hazardous waste dump.  The concentrations of the overlying waters were not reported.  
The moderately low soil sorption partition coefficient (1.21–1.96) suggests that sorption to sediment is
not an important transport process.  There is very little sorption of phenol onto aquifer materials (Ehrlich 
et al. 1982), suggesting that phenol sorption to sediments may also be minimal.  Based on the soil
adsorption coefficient, phenol is expected to leach to groundwater; however, the rate of phenol
biodegradation in the soil may be so rapid, except in cases of large releases such as spills or continuous 
releases such as leaching from landfill sites, that the probability of groundwater contamination may be
low (Ehrlich et al. 1982).  Phenol has been detected in groundwater as a result of leaching through soil
from a spill of phenol (Delfino and Dube 1976), from landfill sites (Clark and Piskin 1977), and from
hazardous waste sites (Plumb 1987).  The sorption coefficient for phenol by soils increases with 
increasing soil organic matter which may indicate that soil organic matter may be the primary phenol
sorbent in soil (Xing et al. 1994).
Phenol is not expected to bioconcentrate significantly in aquatic organisms.  Reported log bioconcentra­
tion factors (BCF) in fish for phenol include 0.28 for goldfish, (Kobayashi et al. 1979) and 1.3 for golden 
orfe (Freitag et al. 1984).  The highest mean level of phenol detected in bottom fish from Commencement
Bay in Tacoma, Washington, was 0.14 ppm (Nicola et al. 1987).  The levels of phenol in the water or
sediments were not stated.
The pKa of phenol is 10 (O’Neil 2001), indicating that phenol will primarily exist as the protonated acid 
at environmental pH values.  In alkaline soils and water, phenol will partially exist as an anion, which can 
affect its fate and transport processes.
Although it has been shown that plants readily uptake phenol (DOE 1987), bioaccumulation does not take
place due to a high rate of respiratory decomposition of phenol to CO2.
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6.3.2 Transformation and Degradation
6.3.2.1  Air
The gas-phase reaction of phenol with photochemically produced hydroxyl radicals is probably a major
removal mechanism in the atmosphere.  An estimated half-life for phenol for this reaction is 0.61 days 
(EPA 1979a).  The reaction of phenol with nitrate radicals during the night may constitute a significant
removal process.  This is based on a rate constant of 3.8x10-12 cm3/molecule second for this reaction, 
corresponding to a half-life of 15 minutes at an atmospheric concentration of 2x108 nitrate radicals per
cm3 (Atkinson et al. 1987).  The reaction of phenol with nitrate radicals present in the atmosphere during
smog episodes may decrease the half-life of phenol in polluted atmospheres. The above data indicate that
phenol has a short half-life in the atmosphere, probably <1 day.  Phenol does not absorb light in the
region of 290–330 nm (Lide and Milne 1994); therefore, it should not photodegrade directly in the
atmosphere.  
6.3.2.2  Water
Although phenol does not absorb light at wavelengths >290, phenols react rapidly to sunlit natural water
via an indirect reaction with photochemically produced hydroxyl radicals and peroxyl radicals; typical
half-lives for hydroxyl and peroxyl radical reactions are on the order of 100 and 19.2 hours of sunlight, 
respectively (Canonica et al. 1995; Mill and Mabey 1985).  These reactions require dissolved natural
organic materials that function as photosensitizers (Canonica et al. 1995).  The estimated half-life for the
reaction of phenol with photochemically produced singlet oxygen in sunlit surface waters contaminated 
by humic substances is 83 days (assuming Switzerland summer sunlight and a singlet oxygen 
concentration of 4x10-14 molar [M]) (Scully and Hoigne 1987).  
Phenol is readily biodegradable in natural water, provided the concentration is not high enough to cause
significant inhibition through microbial toxicity.  Complete degradation in <1 day has been reported in 
water from three lakes; the rates of degradation were affected by the concentration of organic and 
inorganic nutrients in the water (Rubin and Alexander 1983).  Complete removal of phenol in river water
has been reported after 2 days at 20 °C and after 4 days at 4 °C (Ludzack and Ettinger 1960).  The
degradation of phenol is somewhat slower in salt water, and a half-life of 9 days has been reported in an 
estuarine river (EPA 1979b).  Rapid degradation of phenol also has been reported in various sewage and 
water treatment processes.  Removal in aerobic activated sludge reactors is frequently >90% with a
retention time of 8 hours (Stover and Kincannon 1983).  In aerobic reactors using municipal seed 
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(conventional activated sludge organisms) and in reactors using an industrial seed (mixture of organisms), 
it was noted that concentrations as low as 50 mg/L inhibited organism respiration rates, but complete
inhibition was not observed at concentrations as high as 200 mg/L (Davis et al. 1981).  Utilization is also 
very high in anaerobic reactors, although acclimation periods are longer and degradation usually takes
about 2 weeks (Boyd et al. 1983; Healy and Young 1978).  One method of phenol breakdown is
accomplished by the bacterium Pseudomonas sp. CF600, which uses a set of enzymes encoded by the
plasmid dmp operon (Powlowski and Shingler 1994). The use of sequence batch reactors (SBR) in 
treating sludge contaminated with phenolic compounds has proven effective in breaking down the
compounds biologically with no evidence of phenol volatility (Al-Harazin et al. 1991).  Levels as high as
a one-time treatment of 1,600 mg/L can be broken down by 75% with a 1-day retention time.  Lower
concentrations as high as 800 mg/L can be broken down to <0.5 mg/L with a 1-day retention time.  The 
alga Ochromonas danica has also been shown to degrade phenol (Semple and Cain 1996).  When grown 
in the dark with 0.1–1 mM phenol as the sole carbon source, phenol was removed within 3 days.  Because 
of the rapid rate of biodegradation, groundwater is generally free of phenol even though it is highly
mobile in soil.  However, monitoring data in Section 6.4.2 contain groundwater concentrations in areas of
large phenol releases.
While the evidence presented in the literature cited above suggests that phenol can be rapidly and 
virtually completely degraded under both natural water and sewage treatment plant conditions, 
monitoring data presented in Section 6.4 below indicate that phenol, despite this apparent
biodegradability, is still present in the environment.  This suggests that the exact conditions under which 
phenol is rapidly degraded are not present in all instances.  In some situations, the concentration of phenol
may be too high or the populations of microorganisms may not be present in sufficient concentration for
significant biodegradation to occur.
6.3.2.3  Sediment and Soil
Available data indicate that phenol biodegrades in soil under both aerobic and anaerobic soil conditions.  
The half-life of phenol in soil is generally <5 days (Baker and Mayfield 1980), but acidic soils and some 
surface soils may have half-lives of up to 23 days (Shiu et al. 1994).  Mineralization in an alkaline, para-
brown soil under aerobic conditions was 45.5, 48, and 65% after 3, 7, and 70 days, respectively (Haider et
al. 1974).  Half-lives for degradation of low concentrations of phenol in two silt loam soils were 2.70 and 
3.51 hours (Scott et al. 1983).  Plants have been shown to be capable of metabolizing phenol readily
(DOE 1987).
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While degradation is slower under anaerobic conditions, evidence presented in the literature suggests that
phenol can be rapidly and virtually completely degraded in soil under both aerobic and anaerobic
conditions (Baker and Mayfield 1980).
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to phenol depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
phenol in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of
current analytical methods.  In reviewing data on phenol levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring phenol in a
variety of environmental media are detailed in Chapter 7.
6.4.1 Air
There are very few monitoring data concerning the presence of phenol in ambient air.  Phenol was found 
at a median concentration of 30 parts per trillion (ppt) in 7 samples from 1 U.S. urban/suburban site in 
1974 and at an overall median concentration of 5,000 ppt in 83 samples from 7 source-dominated sites
between 1974 and 1978 (EPA 1982).  The individual medians of the seven source sites ranged from
520 to 44,000 ppt (EPA 1982).  Phenol was detected, but not quantified, in air above the Niagara River in 
September of 1982 (Hoff and Chan 1987).  Phenol concentrations in two urban areas ranged from 13 to 
91 ppt and from <5 to 75 ppb with 50% of all measurements <8 ppb (EPA 1981a).  Phenol was found at
approximately 1 ppb in the ambient air near a fishmeal factory in Japan (Hoshika et al. 1981).  In a study
to determine contaminants in the air of agricultural areas, phenol was found in 42 out of 53 air samples
taken from 8 farms at an average concentration of 10 μg/m3 (Sunesson et al. 2001).  Phenol was detected 
in indoor and outdoor air in the city of Ottawa, Canada at concentration ranges of 0.01–5.16 and 0.01– 
1.41 μg/m3, respectively (Zhu et al. 2005).  
In a study of various air samples from Helsinki, Finland, 92% of outdoor air and 86% of indoor air did 
not have detectible quantities of phenol (Edwards et al. 2001).  Workplace and personal exposure samples 
also had low relative percentages of phenol with only 12 and 11% of the samples above the limits of
detection, respectively (Edwards et al. 2001).  
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Higher phenol concentrations may occur when there is smog or in highly contaminated air.  During a 
smog episode in West Covina, California, in July of 1973, phenol concentrations ranged from 16 to 
91 ppt, with a mean concentration of 60 ppt (Cronn et al. 1977).  During a haze episode in 1998 in Brunei,
Syria, phenol was found in 8 out of 15 sites tested in concentrations ranging from 0.07 to 0.41 μg/m3; of
these sites, 4 were near a hospital (Muraleedharan et al. 2000).  
Phenol and other volatile organic compounds were measured in the air of 50 homes or apartments in 
Finland (Kostiainen 1995).  The average concentration was 0.23 ppb, with a range of 0–0.77 ppb.  Phenol
levels were not significantly higher in houses in which people complained of symptoms that resembled 
those of a sick building syndrome.  
Phenol has been detected in the ash phase of burning pine, oak, and eucalyptus in concentrations of 524, 
300, and 434 mg/kg, respectively (Schauer et al. 2001).  Phenol has also been identified in the combustion 
of soft fireplace wood, hard fireplace wood, stove wood, and synthetic wood at concentrations of 158, 
247, 142, and 8.58 mg/kg, respectively (McDonald et al. 2000).
Phenol is released to the atmosphere from burning coal.  In a study of three urban sites in Brazil near
coal-fired power stations, phenol was detected in all three locations with concentrations ranging from
0.98 to 1.60 μg/m3 (Moreira dos Santos et al. 2004).  This indicates that families living near coal-fired 
power stations may be exposed to higher concentrations of phenol.
6.4.2 Water
Phenol has been detected in surface waters, rainwater, sediments, drinking water, groundwater, industrial
effluents, urban runoff, and at hazardous waste sites.  Background levels of phenol from relatively pristine
sites can be as high as 1 ppb for unpolluted groundwater and have been reported to range from 0.01 to 
1 ppb in unpolluted rivers (Thurman 1985).  Phenol has been detected in Lake Huron water at 3–24 ppb 
(Konasewich et al. 1978) and industrial rivers in the United States at 0–5 ppb (Sheldon and Hites 1978,
1979).  The annual mean concentration of phenol in water from the lower Mississippi River was 1.5 ppb 
(EPA 1980).  River water in an unspecified location in the United States was reported to contain 10– 
100 ppb of phenol (Jungclaus et al. 1978).  Phenol was detected, but not quantified, in a Niagara River 
watershed (Elder et al. 1981) and in 2 of 110 raw water samples analyzed during the National Organic
Monitoring Survey (EPA 1980).
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In a study of 95 organic waste components from 139 streams in 30 states from 1999 to 2000, phenol was
detected in 85 samples with a median concentration of 0.7 μg/L (Kolpin et al. 2002).  Phenol has been 
detected in China in water samples taken near the Huanchao River water factory, in the Tanking River, 
and near the Tanking River water factory at concentrations of 0.053, 0.044, and 0.033 μg/L, respectively
(Huang et al. 2003).
Each year about 30 million m3 of mine water is pumped into the Samara River in the Ukraine.  Phenol
was detected in the surface water in the Samara River from 1987 to 1990 with concentrations ranging
from 1.5 to 8.3 μg/L (Goncharuk and Milyukin 1999).  In a study of organic contaminants in the
groundwater from creosote contaminated sites in Denmark, phenol was detected in all 11 sites tested with 
concentrations ranging from 11 to 249 μg/L (Johansen et al. 1997).
In general, higher levels of phenol appear to be found in lakes and rivers that serve as water sources and 
discharge receivers for industrial and population centers, probably as a result of industrial activity and 
commercial use of phenol-containing products.  For example, the presence of higher levels of phenol in 
the Delaware River near Philadelphia is the result of industrial effluents discharged into the sewer system
(Sheldon and Hites 1979).  Phenol was detected in 23% of samples of influent of waste water from New 
York City during 1989 to 1993 at concentrations ranging from 8 to 490 g/L; phenol was detected in 2% of
effluent samples at concentrations ranging from 6 to 310 g/L during the same period (Stubin et al. 1996).
The presence of phenol in drinking water probably results from using contaminated surface water or
groundwater as a source. Its presence in groundwater is probably the result of release to soil, often 
industrial releases or leachate from waste dumps, and the subsequent leaching of phenol through the soil
to the groundwater. Phenol has been detected, but not quantified, in drinking water from 5 of 14 drinking
water treatment plants between July 1977 and June 1979 in one of three sites (groundwater source), in 
three out of ten (surface water source) as well as water source used after distribution (Fielding et al. 
1981). Phenol levels in tap water, spring water, and mineral water in Italy were 0.58, 0.051, and 
0.161 μg/L, respectively (Achilli et al. 1995). Phenol was detected at a maximum concentration of
1,130 ppm in ninewells in Wisconsin after a spill, and was detected for at least 1.5 years after the spill
(Delfino and Dube 1976). It was found at concentrations up to 10.4 ppm in groundwater from a sand 
aquifer adjacent to waste ponds at a wood-preserving facility in Florida (Goerlitz et al. 1985), and was
detected at 6.510,000 ppb in two aquifers 15 months after the completion of a coal gasification project 
(Stuermer et al. 1982). Phenol was detected at a maximum concentration of 1.9 ppm in leachates from
landfill sites in Illinois (Clark and Piskin 1977). Near a landfill in central Florida, phenol was found in 
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groundwater and surface water at about 17and 15 ppb, respectively (Chen and Zoltek 1995). Phenol was
detected, but not quantified, in the groundwater at 13.6% of 178 CERCLA hazardous waste sites (Plumb 
1987).
Phenol was detected during seven rain events in Portland, Oregon, between February and April of 1984.  
Concentrations in rain ranged from >75 to 1,200 ppt, and averaged above 280 ppt.  Gas-phase 
concentrations ranged from 220 (56.1 ppt) to 410 ng/m3 (105 ppt) and averaged 320 ng/m3 (82 ppt)
(Leuenberger et al. 1985).  
Phenol can also be transported in snow and rain.  In Germany, phenol has also been detected in clouds at
Mount Brocken in June 1994 and during April to May in Great Dun Fell with mean concentrations of
3.0 μg/L and 5.4 μg/L, respectively (Lüttke 1999).  Snow from Neulaniemi, Muonio, and Levi, Finland, 
contained phenol in concentrations of 0.16, 0.04, and 0.02 μg/kg, respectively (Poliakova et al. 2000).  In 
Russia, phenol was detected in snow samples at concentrations of 0.02, 0.21, and 1.3 μg/kg in Butovo,
Moscow State University, and Shosse Entuzoastov (a heavily industrial district in Moscow), respectively
(Poliakova et al. 2000).
Phenol has been detected in the effluent discharges of a variety of industries.  It was found in petroleum
refinery waste water at concentrations of 33.5 ppm (Pfeffer 1979) and 100 ppb (Paterson et al. 1996), in 
the treated and untreated effluent from a coal conversion plant at 4 and 4,780 ppm, respectively
(Parkhurst et al. 1979), and in shale oil waste water at a maximum of 4.5 ppm (Hawthorne and Sievers
1984).  It has also been detected in the effluent from a chemical specialties manufacturing plant at 0.01– 
0.30 ppm (Jungclaus et al. 1978), in effluent from paper mills at 5–8 ppb (Keith 1976; Paterson et al. 
1996), and at 0.3 ppm in a 24-hour composite sample from a plant on the Delaware River, 2 and 4 miles 
downriver from a sewage treatment plant (Sheldon and Hites 1979).
A study of the seasonal effects on the concentration of pesticides as well as other contaminants in Gulf of
Gdansk in the Baltic Sea from autumn 2001 to spring 2003 showed only 1 out of 14 samples taken in 
autumn to have a detectable level of phenol with a concentration of 2.3 μg/L (Kot-Wasik et al. 2004).  In 
the spring, phenol was detected in 11 of the 14 samples at concentrations ranging from 0.3 to 0.8 μg/L
(Kot-Wasik et al. 2004).
Phenol has also been found in the primary and secondary effluent from the Los Angeles City Treatment
Plant at concentrations of 32 and <10 ppb, respectively (Young et al. 1983).  It was found in 3 of
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86 samples of runoff from 2 of 15 cities at 3–10 ppb by the U.S. Nationwide Urban Runoff Program as of
July of 1982 (Cole et al. 1984).  
6.4.3 Sediment and Soil
Very few data concerning the presence of phenol in soils were found.  Phenol generally does not adsorb 
very strongly to soils and tends to leach rapidly through soil, which may account for the lack of
monitoring data, since any phenol released to soils is likely to leach to groundwater.  Moreover, phenol is
readily degraded in the environment, which is expected to attenuate its levels in soil.
Sediment collected 6 km northwest of the Los Angeles County waste-water treatment plant discharge 
zone at Palos Verdes, California, contained 10 ppb (dry weight) phenol (Gossett et al. 1983).  
In a study of contaminants in stream bed sediments across the United States, phenol was detected at
536 sites at a maximum concentration of 210 μg/kg (Lopes and Furlong 2001).  
6.4.4 Other Environmental Media 
Phenol has been reported at concentrations of 7 and 28.6 ppm in smoked summer sausage and smoked 
pork belly, respectively (EPA 1980), and was identified but not quantified in mountain cheese (Dumont
and Adda 1978), fried bacon (Ho et al. 1983), fried chicken (Tang et al. 1983), and black fermented tea
(Kaiser 1967).  Phenol has also been found in honey at concentrations ranging from 0 (detection limit 
0.1 ppm) to 19 ppm (Sporns 1981).  It was present each time the honey was collected with phenol-treated 
boards.  Phenol has been reported in three different types of fermented soybean curds at concentrations
ranging from 450 to 6,000 μg/kg (Chung 1999).
Phenol has been found in bottomfish from five sites in Commencement Bay in Tacoma, Washington, at a 
highest maximum average and overall maximum concentration of 0.14 and 0.22 ppm, respectively
(Nicola et al. 1987).  Phenol has been reported to be a natural component of animal matter; it has been 
found at 0–1.6 ppm in rabbit muscle tissue (EPA 1980).
Phenol has been detected in the eggs of birds in the Lake Baikal Region of Italy in concentrations ranging
from 840 to <20 μg/kg dry weight (Lebedev et al. 1998).
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Phenol is also found in medicinal preparations including throat lozenges, mouthwashes, gargles, and 
antiseptic lotions (Darisimall 2006).  Commercial antiseptic lotions may contain up to 1.4% phenol
(Darisimall 2006).  Package labeling information indicates that commercial throat lozenges contain up to 
29 mg of phenol per lozenge (Darisimall 2006).  Other consumer products such as disinfectants and 
cleaners may contain phenol (O’Neil 2001)..  It has been found that the smoke of 1 nonfilter cigarette 
contains 60–140 μg of phenol, 19–35 μg for a filter-tipped cigarette, and 24–107 μg in cigars (IARC
1986; NCI 1998).  Using a testing method developed by the U.S. Federal Trade Commission (FTC), 
analysis of the smoke from several different brands and types of cigarettes found phenol in concentrations 
ranging from 0.3 to 68 μg/cigarette (Roemer et al. 2004).  The lowest concentration came from an 
electrically heated prototype cigarette, while most of the commercial brands were within a range of 2.6– 
23.4 μg/cigarette (Roemer et al. 2004).
While not detected in topsoil from Holy Cross Mountain Park, Poland, and surrounding area, phenol was
detected in 4 out of the 12 pine needle samples taken from the same area (Migaszewski 1999).
Phenol was detected in 303 of 389 samples of settled dust from indoor residences in Sweden; the mean 
concentration of phenol was 4 μg/g dust (Nilsson et al. 2005).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Data concerning concentrations of phenol in ambient air are insufficient to estimate the potential for
exposure by inhalation.  However, smoke from a single nonfilter cigarette was observed to contain 60– 
140 μg phenol, while levels of phenol range from 19 to 35 μg in the smoke of filter-tipped cigarettes, and
from 24 to 107 μg in the smoke of cigars (IARC 1986; NCI 1998).  Therefore, indoor environments
polluted with tobacco smoke are likely to contain measurable amounts of phenol (Guerin et al. 1992).  
Nonsmokers who live with smokers are thought to be exposed to as much as 1.1 μg/m3. This would 
account for a daily inhalation of 6–14 μg/day (Nazaroff and Singer 2004).
Phenol concentrations in surface and drinking waters are expected to vary with location and proximity to 
varying industrial and municipal discharges.  Considering the lack of quantitative, current monitoring data
and the probable seasonal, spatial, and temporal variations in the concentrations of phenol at these 
sources, it is not possible to estimate accurately a potential daily dose of phenol from drinking
contaminated water or from dermal exposure to contaminated water.  Nonetheless, it is probable that only
those systems that receive their water from contaminated surface water and groundwater contain phenol.
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Although phenol has been identified in various food products, a quantitative estimate regarding the intake
of phenol from the ingestion of food has not been estimated.
Few data concerning occupational exposures to phenol were located. The average airborne 
concentrations of phenol to which workers were exposed at three locations within two wood creosote
impregnation plants ranged from 0.03 to 0.5 ppm (Heikkila et al. 1987).  A phenol concentration of
approximately 0.5 ppm was measured in the workroom air at a casting factory in Osaka City, Japan 
(Kuwata et al. 1980), and concentrations as high as 3.2 ppm were measured in Japanese Bakelite factories 
(Ohtsuji and Ikeda 1972).  Considering the lack of quantitative monitoring data for phenol in occupational
atmospheres, it is not possible to estimate the potential for occupational exposure to phenol.  The data, 
however, do show that exposure to phenol through breathing and dermal contact with contaminated 
workroom atmospheres is possible. The National Occupational Exposure Survey (NOES) conducted by
NIOSH estimated that 584,372 workers were exposed to phenol in the United States (NIOSH 1990).  The
NOES database does not contain information on the frequency, concentration, or duration of exposures.  
The survey provides only estimates of workers potentially exposed to chemicals in the workplace.  
Other occupations that may have increased exposure risk include laboratory workers, morticians, and 
house cleaners.  Phenol is a common solvent used in laboratory research as well as a component of
embalming fluid.  The general population may be exposed to phenol found in consumer products such as
general disinfectants used to clean toilets, floors, drains, and other areas (Lewis 2001; O’Neil 2001).  
House cleaners and people who work with these products daily are likely to have increased exposure.
Exposure to phenol also occurs through the use and subsequent ingestion of phenol-containing products, 
including mouthwashes, gargles, and throat sprays (Darisimall 2006).  The concentration of phenol in 
throat sprays ranged from 0.5 to 1.4% phenol.  Determining actual dosage from these sprays would be
difficult as the delivery method is not precise.  Cepastat® lozenges, a readily available remedy for sore 
throats, contains 14.5–29 mg phenol/lozenge (Darisimall 2006).  If a patient (adults and children over 6)
takes the maximum recommended daily number of 18 lozenges, this would result in approximate doses of
270–520 mg phenol/day.  There is no control over the intake of non-prescription drugs and therefore, 
some individuals may consume considerably higher doses of phenol.
The estimated relative contributions of the various exposure routes and sources of total phenol exposure
cannot be estimated using the available data.  Nonetheless, for persons not exposed to phenol in the
workplace, exposure will most likely result from:  inhalation of contaminated ambient air, primarily in the
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vicinity of industries and municipalities that release significant amounts of phenol into the atmosphere;
ingestion of drinking water from contaminated surface waters or groundwaters; ingestion of phenol-
containing products; and dermal exposure to contaminated water and to phenol-containing products.  
Dermal contact with phenol or ingestion of phenol-containing products probably constitutes the largest
consumer exposure, although this exposure may occur on an acute basis.  Inhalation and dermal
exposures appear to be most significant in occupational settings.  Total phenol exposure for workers
exposed to phenol in the workplace is probably substantially higher than for those not exposed in the
workplace.  
Exposure to benzene is likely to increase phenol exposure because phenol is a metabolite of benzene and 
is often used to detect benzene exposure.  Major releases of benzene include cigarette smoke, auto 
exhaust, and gasoline fumes.  
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Oral, dermal, and combined oral-dermal exposures are the most likely routes by which children will be
exposed to phenol.  Oral exposure to low levels of phenol among children is likely because many
consumer products contain phenol, particularly in medicines such as gargles, throat lozenges, and others
(Darisimall 2006).  Products other than medicines that contain phenols include general disinfectants, 
cleaners, and epoxies.  
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Some foods containing phenol have been identified (see Section 6.4.4) and ingestion of these could result
in low levels of phenol exposure in children.  In addition, phenol is produced endogenously as a
breakdown product of protein metabolism; normal concentrations in urine generally do not exceed 
20 mg/L (ACGIH 2001).
Since phenol can be readily absorbed through the skin (ACGIH 2001), children may be more susceptible
to low levels of phenol exposure since they have a higher skin-surface-area to weight ratio.  Since young
children are more likely to come in contact with the floor and other low-lying areas, they may be exposed
to phenol found in consumer products such as general disinfectants used to clean toilets, floors, drains, 
and other areas (Lewis 2001; O’Neil 2001).
Exposure to phenol through inhalation is a less probable route than oral and dermal.  It is known that both 
cigarettes and cigars contain small amounts (19–140 μg) of phenol (IARC 1986; NCI 1998), and smoking
these products indoors produces a measurable amount of phenol (Guerin et al. 1992).  If children are
present in indoor environments polluted with tobacco smoke, they may be exposed to low levels of
phenol.
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Populations with potentially high exposure to phenol generally include those who are exposed to 
relatively highly contaminated environments over long periods of time.  These include populations
exposed to both identified and unidentified phenol-containing waste disposal sites and landfills. 
Populations residing in the vicinity of industries that manufacture or use phenol and large population 
centers may be exposed to potentially high levels of phenol.  Persons who work at establishments that
manufacture or use phenol have a risk for high exposure to phenol.  Populations that regularly ingest food 
contaminated with phenol or that regularly ingest or come in contact with phenol-containing products are
at risk for high exposure to phenol.  Populations that live near a phenol spill site, especially those whose
water supply sources are near the spill sites, have a risk for high exposure to phenol.  Relatively high 
exposure may also result from exposure to emissions from municipal waste incinerators and cigarette
smoke, although no quantitative data concerning phenol emission from these sources were located.  Low
income communities and minority populations are more likely to live adjacent to waste disposal sites and 
landfills where phenol is present.
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THE NOES conducted by NIOSH estimated that 584,372 workers were exposed to phenol in the United 
States (CDC Website).  Workers in the petroleum industry, as well as workers in industries that 
manufacture of caprolactam (nylon manufacture), bisphenol A (epoxy resin and polycarbonate
manufacture), herbicides, wood preservatives, hydraulic fluids, heavy-duty surfactants, lube-oil additives, 
tank linings and coatings, and intermediates for plasticizers and other specialty chemicals, may be
exposed to phenol.  Phenol is also used in throat lozenges, disinfectants, and ointments.  It is also used for
facial skin peels and to cause nerve block (Gingell et al. 2001).  A list of estimated work induced 
exposure events for 19 different industries is presented in Table 6-2 (Brandorff et al. 1995).
People who are exposed to large amounts of benzene are also likely to be exposed to large amounts of
phenol, a metabolite of benzene.  Elevated levels of phenol have been detected in workers occupationally
exposed to benzene.  Workers exposed to 0.8–25.1 or 33.1–331.7 ppm for 2.5–3 hours during an 8-hour
workday had median urinary phenol levels of 55.6 and 351 ng/g creatine, respectively (Rothman et al. 
1998).  Control workers who were not exposed to benzene at the workplace had urinary phenol levels of
17.3 ng/g creatine (Rothman et al. 1998).
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phenol is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of phenol.
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. Knowledge of physical and chemical properties is essential for 
estimating the partitioning of a chemical in the environment.  Information about the physical and 
chemical properties of phenol is available (Hawley 1981; HSDB 2008; IARC 1989), and the database is
adequate for the input requirements of environmental models that predict the behavior of a chemical
under specific conditions.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
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Table 6-2.  Estimated Exposure To Phenol At Various Industry Sites
Estimated number of Estimated weight used in
Industry exposure events tonnes of substance
Manufacture of basic metals 180 1.7
Manufacture of fabricated metal products 8,200 27
Electrical machinery and apparatus 1,400 0.0012
Manufacture of transport equipment 700 40
Painters and carpenters 440 0.021
Construction 4,300 11
Wholesale trade 840 16
Manufacture of textiles and leather 2,600 1
Manufacture of wood and furniture 670 1.2
Manufacture of chemicals 580 0.85
Manufacture of non-metallic mineral 1,300 4,100
products
Manufacture of precision and optical 1,300 0.0023
instruments
Manufacture of plastic and boat building 840 <0.0001
repair
Personal services, cleaning, and hair 260 0.0002
dressing
Sewage and refuse disposal 210 0.0009
Agricultural, hunting, and forestry 550 0.65
Health sciences and pharmacies 1,200 0.25
Source:  Brandorff et al. 1995
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to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2005, became available in May of 2007.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Additional production data are available from the Chemical Marketing Reporter (CMR 2005), and 
import/export data for phenol are available on the U.S. International Trade Commission website (USITC
2008).  Additional data are not needed at this time.
Environmental Fate. Based on the physical properties of phenol, volatilization and sorption of
phenol to sediments are not expected to be important transport mechanisms (Lyman et al. 1982).  The
adsorption of phenol to soils has been shown to increase with increasing organic matter (Xing et al. 
1994).  Photochemical degradation of phenol is thought to be an important process both in air (EPA
1979a) and water (Scully and Hoigne 1987).  Phenol is also readily biodegradable (Ludzack and Ettinger
1960; Rubin and Alexander 1983; Scott et al. 1983; Stover and Kincannon 1983).  Soil sorption data are
available (Artiola-Fortuny and Fuller 1982; Boyd 1982; Briggs 1981; Sacan and Balcioglu 1996; Scott et 
al. 1983).  Additional data are not needed at this time.
Bioavailability from Environmental Media. Data from monitoring studies indicate that phenol is
present in the environment (EPA 1981a, 1982; Gossett et al. 1983; Hoff and Chan 1987; Konasewich et
al. 1978; Sheldon and Hites 1978, 1979; Thurman 1985) as well as in environmental organisms (Nicola et
al. 1987).  Exposure to phenol is most likely to be highest in areas at or near industrial centers and 
population centers where drinking and bathing water, ambient air, and certain foods, such as fish, are
obtained from sources contaminated with phenol.  Reliable data on the bioavailability of phenol from
inhaled air and from skin exposed to phenol vapor have been reported for humans (Piotrowski 1971).  
Studies of bioavailability of phenol from ingested soil and foods and dermal contact with contaminated 
water are needed for evaluating the hazards posed by ingesting materials that have been contaminated 
with phenol.
Food Chain Bioaccumulation. No studies were located regarding the food chain bioaccumulation 
of phenol from environmental media.  Data from monitoring studies indicate that phenol is present in the
environment as well as in environmental organisms (Nicola et al. 1987).  The available bioaccumulation 
studies are concerned only with exposure of fish to aqueous concentrations of phenol.  Although the
results of these studies indicate a low potential for bioaccumulation (see Section 6.3.1), the detection of
phenol in fish (see Section 6.4.4) indicates that phenol can be found in aquatic organisms; it is possible
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that food chain bioaccumulation may occur.  A clearer understanding of the potential for bioaccumulation 
would aid in determining how levels in the environment affect the food chain and potentially impact
human exposure levels.  A study examining phenol levels in organisms from several trophic levels is
needed.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of phenol in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
phenol in the environment can be used in combination with the known body burden of phenol to assess
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
Phenol has been measured in air (Cronn et al. 1977; EPA 1981a, 1982), water (EPA 1980; Sheldon and 
Hites 1978, 1979; Thurman 1985), and sediments (Gossett et al. 1983).  Additional more recent
monitoring data would help to estimate human exposure to phenol.
Exposure Levels in Humans. Data concerning exposure levels in humans are incomplete and not
current (Heikkila et al. 1987; Kuwata et al. 1980; Ohtsuji and Ikeda 1972).  A detailed recent database of
exposure would be helpful in determining the current exposure levels, thereby allowing the estimation of
the average daily dose associated with various scenarios such as living near a hazardous waste site or
landfill, or with drinking water containing phenol.  An environmental media monitoring program would 
provide the necessary information for estimating environmental exposures, while a detailed examination 
of the uses of phenol and the kinds of potential exposure in addition to workplace monitoring would
probably provide adequate workplace information.  The environmental media that would provide the most
useful information are air, groundwater, and surface and drinking water in urban and industrial locations, 
and air, groundwater, and surface water at hazardous waste sites.  Performing the monitoring over a
1-year period would allow estimation of seasonal variations.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are likely to be exposed to low levels of phenol from the use of
many consumer products including medicines and cleaning agents (Budavari et al. 1989; Douglas 1972;
EPA 1980; Hawley 1981). There are no known data that quantify the level of exposure to phenol in 
children.  It is likely that young children may be exposed to low levels of phenol because they come into 
contact with the floor and other areas where disinfectants containing phenol might be used.  More studies 
are needed to assess whether children differ in their weight-adjusted intake of phenol, as little or no 
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information is known.  Studies are needed to measure the baseline phenol level in children’s urine in 
order to use phenol levels in urine as a biomarker of exposure.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for phenol were located.  This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2006) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  The only
study pertaining to the potential for human exposure found in this database was an exposure assessment
study done at Mount Sinai School of Medicine at New York University and supported by National
Institute of Environmental Health Sciences.  Part of this research is to design new approaches to assess
and quantify the levels of exposures to known toxicants in children and infants.
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring phenol, its metabolites, and other biomarkers of exposure and effect to 
phenol.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Analytical methods for the detection of phenol in biological materials are summarized in Table 7-1.  
Phenol is expected to be present in blood and urine in its free acid and conjugated forms (glucuronide and 
sulfate).  The average urinary phenol concentration in unexposed individuals is 9.5±3.6 mg/L when 
corrected to a standard specific gravity of 1.024 (Piotrowski 1971).  In exposed individuals, the urinary
phenol level may vary from 10 to 200 mg/L (Tesarova and Packova 1983). The two common methods
for quantifying conjugated phenol are chemical and enzymatic hydrolysis of the conjugate to the free 
phenol form.  The chemical method uses acidic hydrolysis (Baldwin et al. 1981; Needham et al. 1984).  
Both the nature of the acid (sulfuric versus perchloric) and the temperature should be controlled carefully
to obtain a quantitative yield and to avoid thermal decomposition of other phenolic or related compounds
that may interfere with phenol quantification (Baldwin et al. 1981; Rick et al. 1982).  The best available
method appears to be specific enzyme hydrolysis or hydrolysis at ambient temperature with sulfuric acid.  
Enzymatic hydrolysis with an extract of Helix pomatia has also been used to liberate phenol from its
conjugates (Ahmed and Hale 1994).
High-performance liquid chromatographic separation with electrochemical detection may provide the best
sensitivity for phenol quantification in biological samples (Tesarova and Packova 1983).  The use of gas
chromatography with a flame ionization detector may be a more versatile method, if other non-ionic
pollutants must be quantified.  The advantages and disadvantages of different methods available for the
quantification of phenol and metabolites in biological and environmental samples have been discussed by
Tesarova and Packova (1983).
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Table 7-1. Analytical Methods for Determining Phenol in Biological Samples
Sample 
Analytical detection Percent
Sample matrix Preparation method method limit recovery Reference
Whole blood	 Sample extracted with ethyl
acetate, extract concentrated 
and analyzed (for free phenol),
packed blood cells previously
extracted for free phenol
incubated with β-glucuronidase 
containing sulfatase at 37 °C,
extracted with ethyl acetate
after addition of normal saline 
solution, and extract
concentrated and analyzed (for
conjugated phenol)
Whole blood	 Sample with spiked internal
standard extracted with ethyl
acetate and extract
concentrated and analyzed
Urine	 Sample mixed with phosphoric
acid, passed through a pre-
column at 165 °C for hydrolysis
of conjugates (for free and 
conjugated phenol), and 
analyzed
Urine	 Sample heated under reflux
with HClO4, solvent extracted,
concentrated, and separated 
by TLC; spot developed by
p-nitro-benzenediazonium
fluoroborate, removed 
quantitatively and solvent
extracted (for free and 
conjugated phenol), and 
analyzed
Urine	 Acidified sample stream
distilled, reacted with ammonia,
N-chloro-succinimide, and
sodium nitroprusside at basic
pH (method probably for free 
phenol), and analyzed
Urine	 Sample incubated with 
glucuronidase and sulfatase at
pH 5 and 3.7 °C, H2SO4 added 
and steam distilled (total
phenol) and analyzed
Urine	 Sample hydrolyzed at room
temperature and extracted with 
methyl tert-butyl ether (total
phenol) and analyzed
GC-FID <1 mg/mL
GC-FID 0.1 mg/L
GC-FID NG
Spectro- NG
photometry
Spectro- 0.3 mg/L
photometry
HPLC- 2 ng/
electro- inection
chemical
detector
GC-FID NG
97% (free O’Grodnick et
phenol); 103% al. 1983
(conjugated 
phenol)
>90% at Handson and 
concentrations Hanrahan 1983
above 0.5 mg/L
89% (for Baldwin et al.
conjugates) 1981
NG	 Bienick and 
Wilczok 1986
>95%	 Amlathe et al.
1987
95–107%	 Schaltenbrand
and Coburn 
1985
NG	 Rick et al. 1982
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Table 7-1. Analytical Methods for Determining Phenol in Biological Samples
Sample 
Analytical detection Percent
Sample matrix Preparation method method limit recovery Reference
Urine Sample spiked with internal GC-FID NG 93–97% at 20– Needham et al.
standard, hydrolyzed with 70 mg/L 1984
H2SO4, and extracted with ethyl
acetate (free and conjugated)
and analyzed
Urine Sample spiked with internal GC-FID 0.1 mg/L 99% at Van 
standard, distilled with H2SO4 5.9 mg/L Roosmalen et
in a special apparatus, distillate al. 1981
directly injected into GC (free 
and conjugated)
Urine Two spot urine samples GC-FID 0.5 μg/mL 94–95% NIOSH 1994a
(before and after exposure), (Method 
hydrolyzed with HCl or 8305)
perchloric acid, extracted with 
diethyl ether, and directly
injected into GC
FID = flame ionization detector; GC = gas chromatography; H2SO4 = sulfuric acid; HCl = hydrochloric acid;
HClO4 = perchloric acid; HPLC = high performance liquid chromatography; NG = not given; TLC = thin layer
chromatography
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The level of phenol detected in blood or urine may not accurately reflect actual phenol exposure because
phenol may also appear as a metabolite of benzene or other drugs.  It has been shown that under certain 
acidic conditions used for the hydrolysis of conjugated phenols, acetyl salicylic acid (aspirin) may
produce phenol (Baldwin et al. 1981) and yield spuriously higher values for phenol in blood and urine.
For occupational exposure, it is recommended that urine samples be collected at the end of an 8-hour
work shift (ACGIH 2001).  Small amounts of thymol can be used as a preservative, and the urine can be
stored for 4 days if refrigerated, or at least 3 months if frozen.
7.2  ENVIRONMENTAL SAMPLES 
Analytical methods for detecting phenol in environmental samples are summarized in Table 7-2.  The
accuracy and sensitivity of phenol determination in environmental samples depends on sample precon­
centration and pretreatment and the analytical method employed.  The recovery of phenol from air and 
water by the various preconcentration methods is usually low for samples containing low levels of phenol.
The two preconcentration methods commonly used for phenols in water are adsorption on XAD resin and 
adsorption on carbon.  Both can give low recoveries, as shown by Van Rossum and Webb (1978).  
Solvent extraction at acidic pH with subsequent solvent concentration also gives unsatisfactory recovery
for phenol.  Even during carefully controlled conditions, phenol losses of up to 60% may occur during
solvent evaporation (Handson and Hanrahan 1983).  The in situ acetylation with subsequent solvent
extraction as developed by Sithole et al. (1986) is probably one of the most promising methods.  
Capillary columns may provide the best method for the separation of phenols prior to their quantification 
(Eichelberger et al. 1983; Shafer et al. 1981; Sithole et al. 1986).  Of the various methods available for
detection, the two commonly used methods that are most sensitive are mass spectrometry and flame 
ionization detection.  Although electron capture detectors provide good sensitivities for higher chlorine-
substituted phenols, they are poor for phenol itself (Sithole et al. 1986). The best method for the
quantification of phenol may be mass spectrometric detection in the selected ion mode, but the loss of
qualitative information may be significant (Eichelberger et al. 1983).
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of phenol is available.  Where adequate information is not
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Table 7-2. Analytical Methods for Determining Phenol in Environmental Samples
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Urban air
Air
Occupational
air
Occupational
air
Occupational
air
Total
particulate 
matter in 
cigarette 
smoke
Industrial
emission,
auto exhaust,
and tobacco 
smoke
Drinking 
water, waste 
water, and 
natural water
Waste water
and natural
water
Water
Sample collected in bubbler
containing NaOH, derivatized 
as nitrobenzeneazo compound
Sample collected on a solid
sorbent tube, desorbed using 
methanol
Sorption on activated carbon,
desorption by solvent and 
derivatized to trimethylsilyl
product
Sorption on XAD-2, desorption 
by acetonitrile and
concentrated if necessary
Sample collected with a 
thermal desorption tube using a 
sorbent capable of capturing a 
C6 organic compound
Extract particulate matter with 
NaOH, buffer to pH 4.6
Sample collected in NaOH
bubbler and derivatized to 
p-nitrobenzene-diazonium
tetrafluoroborate
Direct distillation of solvent-
cleaned sample (if necessary)
at acidic pH, react with
4-amino-antipyrine and
potassium ferricyanide at pH 8,
extract in chloroform
None
1-L sample acidified and
extracted with methylene 
chloride
HPLC-UV
GC-FID
(Method 
2546)
GC-FID
HPLC­
electro­
chemical
detector and 
HPLC-UV
GC-MS
(Method 
2549)
HPLC-
fluorescence 
spectrophoto­
meter
HPLC-UV
Spectrophoto­
metric
(Method 
5530c)
GC-FID
(Method 
6420b)
GC-FID
(Method 604)
Kuwata et al.
1980
NIOSH 1994b
Yrjanheikki 
1987
Nieminen and 
Heikkila 1986
NIOSH 1996
Tomkins et al.
1984
Kuwata et al.
1980
APHA 1998a
APHA 1998b
EPA 2001a
0.05 ppb for
150-L sample;
58–60% at
0.33–0.5 μg 
phenol
1–3 μg/sample ND
72.3% at
10–50 μg 
phenol
0.5 mg/m3 
(0.13 ppm)
8 μg/m3 
(2.04 ppb) with 
12 L air
(electro­
chemical);
0.16 mg/m3 
(0.04 ppm) with 
12 L air (UV)
100 ng/tube or
less
0.3 mg/L
0.05 ppb for
150-L sample
1 μg/L for
500-mL sample
<1 mg/L
0.14 μg/L
96–102%
at 2.5– 
100 mg/m3 
ND
NA
91% at 20– 
30 μg
ND
ND
ND
44%
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Table 7-2. Analytical Methods for Determining Phenol in Environmental Samples
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Water
Water, waste 
water
Water, waste 
water
Water
Water
Waste water
Potable water
and raw
source water
Drinking 
water
1-L sample is adjusted to pH
>11 and extracted with 
methylene chloride
Acidified sample extract with 
solvent, concentrated or
derivatized to pentafluoro­
benzylbromide product
Sample extracted in acidic pH,
extract concentrated
Sample passed through 
graphitized carbon black,
eluted with methylene chloride
Sample passed through a 
mixed XAD-4/8 column, solvent
eluted and concentrated
Distillation of acidified solution,
reacted with ammonia,
N-chloro-succinimide, and
sodium nitro-prusside at basic
pH
Sample acetylated in situ by 
addition of acetic anhydride,
solvent extracted and 
concentrated; alternatively,
extracted acidic sample 
derivatized by
pentafluorobenzyl bromide and 
cleaned up by column 
chromatography
1-L sample is extracted using a 
solid phase extraction cartridge
GC-MS 
(Method 635)
GC-FID; GC­
ECD (for
derivatized 
EPA Method 
604)
GC-MS (EPA
Method 625);
HRGC-MS 
(EPA Method 
625.1)
Ion-
suppression;
reversed 
phase LC
with UV
detection
GC-MS
Spectrophoto­
metric
HRGC-ECD 
(for 
pentafluoro­
benzyl
derivative);
HRGC-MS 
(for acetyl
derivative)
GC-MS 
(Method 528)
1.5 μg/L
0.14 μg/L 
(FID); 2.2 μg/L
(ECD)
1.5 μg/L (GC­
MS); 1–10 μg/L
(HRGC-MS)
50–100 ng/L
ND
<0.3 mg/L
<50 ng/L 
(pentafluoro­
benzyl);
<50 ng/L 
(acetyl
derivative)
0.026 μg/L 
56%
41% (FID);
ND (ECD)
36% (GC­
MS) at 10– 
1,500 μg/L;
25% (GC­
MS) at
8.3 μg/L; 
42%
(HRGC­
MS) at
20 μg/L
91–97%
46-70%
(distilled
water); 9%
(tap water)
96.7% at
3 mg/L
10–64%
(penta­
fluoro­
benzyl
derivative);
70–132%
(acetyl
derivative)
85
EPA 2001c
EPA 1982
Eichelberger
et al. 1983;
EPA 1982
Di Corcia et
al. 1996
Van Rossum
and Webb 
1978
Amlathe et al.
1987
Sithole et al.
1986
EPA 2000a 
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Table 7-2. Analytical Methods for Determining Phenol in Environmental Samples
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Water The sample is extracted at pH
12–13, then at pH <2 with 
methylene chloride using 
continuous extraction 
techniques; the extract is dried 
over sodium sulfate and 
concentrated to a volume of
1 mL
Drinking 
water
Water samples collected and 
analyzed via GC-MS
Aqueous
samples
Samples extracted and cleaned
up (according to sample matrix)
and the solvent appropriately 
exchanged; the phenols are 
then determined with or without
derivatization 
Sediment Homogenized sample solvent
extracted at acidic pH,
fractionated by GPC and 
fractions concentrated
Groundwater Solvent extraction in acidic pH,
extract concentrated
Soil, sediment Sample mixed with anhydrous
powdered Na2SO4, solvent
extracted ultrasonically, extract
subjected to GPC if necessary,
extract concentrated
Water and 	 Phenols separated on a Nova-
waste water	 Pak Phenyl column eluted with 
ammonium acetate:acetonitrile
Groundwater	 Solvent extraction, column 
chromatographic cleanup,
concentration of extract
Bottom	 Wet sediment samples dried 
sediment	 and compounds extracted 
using dichloromethane
Water	 Water samples filtered using 
glass fiber filters; samples
extracted using SPE cartridges
Soil, sludge,	 Extracted by soxhlet or
or solid waste	 sonication, extract subjected to 
column chromatographic
cleanup and concentrated
GC-MS 
(Method 
1625)
GC-MS 
(Method 
OM100R
GC-MS 
(Method 
8041A
HRGC-MS
GC-MS (EPA­
CLP Method)
GC-MS (EPA­
CLP Method
LC-ED
GC-MS (EPA
Method 
8250A)
GC-MS 
(Method 0­
5130-95)
GC-MS 
(Method 0­
1433-01)
GC-MS (EPA
Method 
8250A)
Not applicable
Not applicable
 
Not applicable
 
ND
10 μg/L
330 μg/kg
0.5 mg/L
1.5 mg/L
23.5 μg/kg
0.11 μg/L 
1.5 mg/kg
Not
applicable
Not
applicable
93%
112–128%
at 400 ng/g
ND
ND
91–100%
0.43c+
1.26)/cx
100 where 
c is the 
actual
concentra­
tion
84
93
ND
EPA 2001b 
DOE 1997
 
EPA 2000b 

Lopez-Avila
et al. 1983
EPA 1987
EPA 1987
Paterson et
al. 1996
EPA 1994b
USGS 1995
USGS 2002
EPA 1994b
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Table 7-2. Analytical Methods for Determining Phenol in Environmental Samples
Sample 
matrix Preparation method 
Analytical 
method
Sample 
detection limit
Percent
recovery Reference
Aqueous and 
nonaqueous
samples
Samples are extracted; extracts
are cleaned up, as necessary,
and the solvent exchanged to 
one that is compatible with the 
GC detector to be used
EPA Method 
8041A
ND 93% EPA 2007
Soil, air,
water,
Soxhlet extraction with 
acetone/hexane
GC-MS 
(Method 
8270D)
10 μg/L 46% EPA 1998 
Honey Sample dissolved in water,
steam distilled; distillate
cleaned up by column 
chromatography
HPLC-UP 0.1 ppm (for
10-g sample
98% at
111 μg 
added 
phenol
Sporns 1981
C6 = 6 carbon; ECD = electron capture detector; ED = electrochemical detection; FID = flame ionization detector;
GC = gas chromatography; GPC = gel permeation chromatography; HPLC = high performance liquid 
chromatography; HRGC = high resolution gas chromatography; LC = liquid chromatography; MS = mass
spectrometry; Na2SO4 = sodium sulfate; NaOH = sodium hydroxide; ND = no data; SPE = solid-phase extraction;
UV = ultraviolet detection
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available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of phenol. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Measurement of total phenol in urine serves as a biomarker of exposure for persons 
occupationally exposed to phenol (ACGIH 2001).
Effect.  Specific biomarkers used to characterize effects caused by phenol have not been identified.  Dark
urine has been reported in persons occupationally exposed to phenol (inhalation, dermal) (ACGIH 2001;
Merliss 1972) and following oral exposure (Baker et al. 1978; Kim et al. 1994).  The dark urine may be a
result of an oxidation product of phenol, or hemoglobin and hemoglobin breakdown products.  Further
research is required to identify the cause of the dark urine and relate it to exposure concentration.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. The analytical methods available (Amlathe et al. 1987; Baldwin et al. 1981; Bieniek and 
Wilczok 1986; Handson and Hanrahan 1983; Needham et al. 1984; O'Grodnick et al. 1983; Rick et al. 
1982; Schaltenbrand and Coburn 1985; Van Roosmalen et al. 1981) are adequate for the quantification of
phenol and its conjugates in biological samples.  The study of the levels of parent compound in human 
blood, urine, or other biological matrices can be useful in deriving a correlation between the levels of this
compound found in the environment and those found in human tissue or body fluid.
The changes in metabolite concentrations in human blood, urine, or other appropriate biological media
over time may be useful in estimating phenol's rate of metabolism in humans.  In some instances, the 
quantification of metabolites may be useful in correlating the exposure doses to the human body burden.  
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Studies that correlate phenol exposure with levels of metabolites in human biological matrices are not
available for this compound, although analytical methods for the quantification of the metabolites are 
available.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. The analytical methods available (Eichelberger et al. 1983; EPA 1982, 1986b, 1986c, 1987;
Kuwata et al. 1980; Nieminen and Heikkila 1986; NIOSH 1994a, 1994b, 1996; Sithole et al. 1986;
Tomkins et al. 1984; Van Rossum and Webb 1978; Yrjanheikki 1978) are adequate for the quantification 
of phenol in environmental materials.  Knowledge of the levels of this compound in environmental media, 
such as air, water, and food, can be used to indicate exposure of humans to this compound through the
inhalation of air and ingestion of drinking water and foods containing phenol.
Although the products of environmental biotic and abiotic degradation of phenol have been identified 
adequately, no systematic study measuring the concentrations of the degradation products in the
environment was found.  Analytical methods are available for determining the levels of the degradation 
products such as hydroxylated phenol.  Knowledge of the levels of degradation products would allow the
development of a monitoring program designed to assess the ambient concentrations of phenol
degradation products in the environment.  Such a program could provide information concerning both 
human and environmental exposure to phenol since it might allow an estimation of the concentration of
phenol in the environment prior to degradation.
7.3.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2006) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 7.3.1.  Two 
studies pertaining to analytical procedures for phenol detection were found in this database.  Research 
being done at Mount Sinai School of Medicine at New York University and supported by National
Institute of Environmental Health Sciences is looking into more accurate methods for quantitative
detection to toxicants in children and infants.  A study from A.D. Grosso sponsored by the Center for
Biologics and Evaluation—Quality Control is looking at chromatographic determination of phenol used 
as an antimicrobial preservative in vaccines and allergenic extracts.
The Environmental Health Laboratory Sciences Division of the National Center for Environmental
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of phenol and 
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other volatile organic compounds in blood.  These methods use purge and trap methodology, high-
resolution gas chromatography, and magnetic sector mass spectrometry, which give detection limits in the
low parts per trillion (ppt) range. 
The Environmental Health Laboratory Sciences Division of the National Center for Environmental
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of phenol and 
other phenolic compounds in urine.  These methods use high-resolution gas chromatography and 
magnetic sector mass spectrometry, which give detection limits in the low parts per trillion (ppt) range.
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8. REGULATIONS AND ADVISORIES
 
International and national regulations and guidelines pertinent to human exposure to phenol are
summarized in Table 8-1.
ATSDR has derived an acute-duration oral MRL of 1.0 mg/kg/day based on a BMDL of 125 mg/kg/day
for changes in body weight gain in pregnant rats exposed to phenol by gavage using divided dosing
during GDs 6–15 (York 1997).  An uncertainty factor of 100 was used (10 for animal to human 
extrapolation and 10 for human variability).
EPA (IRIS 2006) derived an oral reference dose (RfD) of 0.3 mg/kg/day for phenol based on a BMDL of
93 mg/kg/day for decreased maternal weight gain observed in Sprague-Dawley rats dosed with phenol
during gestation (York 1997).  
The IARC classification for phenol is Group 3, not classifiable with regard to its carcinogenicity to 
humans (IARC 2004).  The EPA cancer classification for phenol is D, not classifiable as to human 
carcinogenicity (IRIS 2006).  The National Toxicology Program has not classified phenol for human 
carcinogenicity (NTP 2005).  The American Conference of Governmental Industrial Hygienists (ACGIH)
has classified phenol as an A4 carcinogen (not classifiable as a human carcinogen) (ACGIH 2005).
OSHA has required employers of workers who are occupationally exposed to phenol to institute
engineering controls and work practices to reduce and maintain employee exposure at or below
permissible exposure limits (PELs) (OSHA 2005a).  The employer must use engineering and work
practice controls to reduce exposures to or below an 8-hour time-weighted average (TWA) of 5 ppm for
phenol (OSHA 2005a).  ACGIH (2005) and NIOSH (2005) also recommend a TWA exposure limit of
5 ppm for occupational exposure.
Phenol is regulated by the Clean Water Effluent Guidelines for the following industrial point sources:  
electroplating, organic chemicals, steam electric, asbestos, timber products processing, metal finishing, 
paving and roofing, paint formulating, ink formulating, gum and wood, carbon black, metal molding and 
casting, aluminum forming, and electrical and electronic components; see the electronic Code of Federal
Regulations for a complete listing (NARA 2006).
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Table 8-1.  Regulations and Guidelines Applicable to Phenol
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification Group 3a IARC 2004
WHO Air quality guidelines No data WHO 2000
Drinking water quality guidelines No data WHO 2004
NATIONAL
Regulations and 
Guidelines:
a.  Air
ACGIH TLV (8-hour TWA)b 5 ppm ACGIH 2005
EPA AEGL-1c,d EPA 2006a
10 minutes 19 ppm
30 minutes 19 ppm
60 minutes 15 ppm
4 hours 9.5 ppm
8 hours 6.3 ppm
AEGL-2c,d 
10 minutes 29 ppm
30 minutes 29 ppm
60 minutes 23 ppm
4 hours 15 ppm
8 hours 12 ppm
AEGL-3c,d Not recommended due 
to insufficient data
Hazardous air pollutant Yes EPA 2006d
42 USC 7412
NIOSH REL (10-hour TWA)e 5 ppm NIOSH 2005
Ceiling limit (15-minute TWA) 15.6 ppm
IDLH 250 ppm
OSHA PEL (8-hour TWA) for general industryf 5 ppm OSHA 2005c
29 CFR 1910.1000
PEL (8-hour TWA) for construction 
industryf 
5 ppm OSHA 2005b
29 CFR 1926.55,
Appendix A
PEL (8-hour TWA) for shipyard 
industryf 
5 ppm OSHA 2005a
29 CFR 1915.1000
b.  Water
EPA Designated as a hazardous substances Yes EPA 2006b
in accordance with Section 311(b)(2)(A) 40 CFR 116.4
of the Clean Water Act
Designated as a toxic pollutant in Yes EPA 2006c
accordance with Section 307(a)(1) of 40 CFR 401.15
the Federal Water Pollution Control Act
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8.  REGULATIONS AND ADVISORIES
Table 8-1.  Regulations and Guidelines Applicable to Phenol
Agency Description	 Information Reference
NATIONAL (cont.)
EPA Drinking water standards and health EPA 2004
advisories
1-day health advisory for a 10-kg 6 mg/L
child
10-day health advisory for a 10-kg 6 mg/L
child
DWEL 11 mg/L
Lifetime 2 mg/L
National primary drinking water No data EPA 2003
standards
Reportable quantities of hazardous 1,000 pounds EPA 2006g
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act
Toxics criteria for those states not EPA 2006m
complying with Clean Water Act 40 CFR 131.36
Section 303(c)(2)(B) for human health 
(10-6 risk for carcinogens) for
consumption of:
Water + organism	 21 mg/L
Organism only 4,600 mg/L
Water quality criteria for human health EPA 2006f
consumption of:
Water + organism 21 mg/L
Organism only 1,700 mg/L
c.  Food
EPA	 Exemptions from the requirement of a Yes EPA 2006k
tolerance as an inert ingredient (as a 40 CFR 180.920
solvent) when used pre-harvest
Exemptions from the requirement of a Yes EPA 2006l
tolerance as an inert ingredients (as a 40 CFR 180.930
solvent) when applied to animals
FDA	 Bottled drinking water 0.001 mg/L FDA 2005
 
Included on the “Everything Added to Yes FDA 2006
 
Foods in the United States” List
 
d.  Other
ACGIH	 Carcinogenicity classification A4g ACGIH 2005
Biological exposure indices (end of 250 mg/g creatinine
shift) for total phenol in urine
CPSC	 Substance named in the Federal ≤5% CPSC 2005
Caustic Poison Act; phenol and any
preparation containing phenol in a 
concentration
EPA	 Carcinogenicity classification Group Dh IRIS 2006
 
Oral slope factor Not applicable
 
Inhalation unit risk Not applicable
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Table 8-1.  Regulations and Guidelines Applicable to Phenol
Agency Description Information Reference
NATIONAL (cont.)
RfC Not applicablei IRIS 2006
RfD 0.3 mg/kg/day
Identification and listing of hazardous U188 EPA 2006e
waste; hazardous waste number 40 CFR 261,
Appendix VIII
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous Yes EPA 2006h
substance 40 CFR 302.4
Reportable quantity 1,000 pounds
Effective date of toxic chemical 01/01/87 EPA 2006j
release reporting 40 CFR 372.65
Extremely hazardous substances 500/10,000 pounds EPA 2006i
and their threshold planning 40 CFR 355,
quantities Appendix A
NTP Carcinogenicity classification No data NTP 2005
aGroup 3:  not classifiable as to carcinogenicity to humans

bSkin notation:  refers to the potential significant contribution to the overall exposure by the cutaneous route,
 
including mucous membranes and the eyes, either by contact with vapors, liquids, or solids.

cAEGL-1 is the airborne concentration of a substance above which it is predicted that the general population,
 
including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory
 
effects.  AEGL-2 is the airborne concentration of a substance above which it is predicted that the general population,
 
including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or
 
an impaired ability to escape.  AEGL-3 is the airborne concentration of a substance above which it is predicted that
 
the general population, including susceptible individuals, could experience life-threatening health effects or death.

dLevel of distinct odor awareness = 0.25 ppm

eSkin designation: indicates the potential for dermal absorption; skin exposure should be prevented as necessary
 
through the use of good work practices, gloves, coveralls, goggles, and other appropriate equipment.

fSkin designation

gA4:  not classifiable as a human carcinogen
 
hGroup D:  not classifiable as to human carcinogenicity
 
iNot applicable:  no adequate inhalation exposure studies exist from which an inhalation RfC may be derived.  A
 
route-to-route extrapolation is not appropriate, because phenol can be a direct contact irritant, and so portal-of-entry
 
effects are a potential concern.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = Acute Exposure Guideline Level;
 
CERCLA = Comprehensive Environmetnal Response, Compensation, and Liability Act; CFR = Code of Federal
 
Regulations; CPSC = Consumer Product Safety Commission; DWEL = drinking water equivalent level;
 
EPA = Environmental Protection Agency; FDA = Food and Drug Administration; IARC = International Agency for
 
Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System;
 
NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program;
 
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 

exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values;
 
TWA = time-weighted average; USC = United States Code; WHO = World Health Organization
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EPA regulates phenol under the Clean Water Act (CWA) and the Clean Air Act (CAA) and has 
designated it as a hazardous substance and a hazardous air pollutant (HAP) (EPA 2006b, 2006c).  Phenol
is on the list of chemicals appearing in “Toxic Chemicals Subject to Section 313 of the Emergency
Planning and Community Right-to-Know Act of 1986" (EPA 2006j) and has been assigned a reportable
quantity (RQ) limit of 1,000 pounds (EPA 2006h).  The RQ represents the amount of a designated 
hazardous substance which, when released to the environment, must be reported to the appropriate
authority.  Phenol is also considered to be an extremely hazardous substance (EPA 2006i).
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10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a 
   
 
  
 
 
 
 
 
 
 
 
  
 
 
    
 
 
     
 
   
 
       
  
 
 
 
 
 
  
   
  
  
  
 
  
      
 
    
    
 
 
 
  
  
   
 
 
 
     
 
    
 
 
 
     
  
 
 
   
PHENOL 225
10.  GLOSSARY
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
   
 
 
 
 
 
 
 
 
 
  
   
   
 
 
 
  
  
 
   
   
    
   
  
  
 
 
PHENOL A-2
APPENDIX A
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333.
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Phenol
CAS Numbers: 108-95-2
Date: July 2008
Profile Status: Draft 3 Post-Public
Route: [ ] Inhalation   [x] Oral
Duration: [x] Acute  [ ] Intermediate   [ ] Chronic
Graph Key: 13
Species: Rat
Minimal Risk Level:  1 [x] mg/kg/day   [ ] ppm
Reference:  York.  1997. Oral (gavage) developmental toxicity study of phenol in rats.  Procter &
Gamble Co.  Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D.  
OTS0573686.
Experimental design:  Groups of pregnant Sprague-Dawley rats (25/dose group) were dosed 3 times daily
with 0, 20, 40, or 120 mg phenol/kg (total daily doses of 0, 60, 120, and 360 mg/kg) by gavage in water
on gestation days (GDs) 6–15; the dosing volume was 10 mL/kg.  Maternal end points evaluated included 
clinical signs, body weight, and food consumption.  Dams were also observed for abortions and premature
deliveries.  Dams were sacrificed on GD 20 and a gross necropsy was conducted. The uterus was 
examined for pregnancy, number and distribution of implantations, live and dead fetuses, and early and 
late resorptions.  Fetuses were weighed and examined for sex and gross external alterations.  Half of the
fetuses were examined for soft tissue alterations and the remaining fetuses were examined for skeletal
alterations.  
Effect noted in study and corresponding doses:  One dam in the 360 mg/kg/day group died on GD 11 and 
the death was attributed to phenol treatment.  Clinical signs considered treatment-related included excess 
salivation and tachypnea in rats exposed to 360 mg/kg/day.  Gross necropsy of the dams did not reveal
any treatment-related alterations.  In the 120 mg/kg/day group, maternal body weight gain was
significantly reduced for GDs 6–16 (11%) and for GDs 12–16 (19%), whereas in the 360 mg/kg/day
group, body weight gain was reduced 38% for gestation days 6–16.  Maternal final body weight in the
360 mg/kg/day group was reduced, but <10% relative to controls.  Food consumption was reduced in the
360 mg/kg/day group by 16% for GDs 6–20 and by 15% for GDs 0–20; in the 120 mg/kg/day group, food 
consumption for GDs 6–16 was reduced 11%.  Fetal body weight at the 360 mg/kg/day level was reduced 
5–7% relative to controls.  There was a significant decrease in ossification sites on the hindlimb 
metatarsals in the 360 mg/kg/day group.  At the 120 and 360 mg/kg/day dose levels, there were increases 
in litters with fetuses with "any alteration" and with "any variation", but neither reached statistical 
significance and there were no clear dose-response relationships.  There were no significant effects on 
corpora lutea, implantations, litter sizes, live fetuses, early and late resorptions, and percent resorbed 
conceptuses.  Based on decreased fetal body weight and delayed ossification, the dose of 360 mg/kg/day 
is a LOAEL for developmental effects; the NOAEL is 120 mg/kg/day.  Based on decreased weight gain
during gestation, the dose of 120 mg/kg/day is a LOAEL for decreased maternal body weight gain; the
NOAEL is 60 mg/kg/day.  
Data from York (1997) were analyzed using the BMD approach for MRL derivation.  BMD models in the
EPA Benchmark Dose Software (BMDS version 2.0) (linear, polynomial, power, and Hill models) were
fit to the maternal body weight gain data to determine potential points of departure for the MRL.  The
linear model with homogeneous variance, which is the simplest model and the model that provided the
best fit for the data, was selected.  In the absence of a clear criteria as to what level of change in weight
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gain during pregnancy should be considered adverse, the benchmark response (BMR) was defined as a
change in mean body weight gain equal to one standard deviation from the control mean (EPA 2000c).  
The corresponding BMD was 152 mg/kg/day; the corresponding benchmark dose limit (BMDL) was
125 mg/kg/day.  Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for
human variability) to the BMDL results in an acute-duration oral MRL of 1 mg/kg/day.  
Dose and end point used for MRL derivation:  BMDL of 125 mg/kg/day for decreased maternal weight
gain.
[  ] NOAEL   [ ] LOAEL   [x] BMDL
Uncertainty Factors used in MRL derivation:
[x]  10 for extrapolation from animals to humans
[x]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: In another developmental
study, rats were gavaged with phenol in doses of 0, 30, 60, and 120 mg/kg/day in a dosing volume of
5 mL/kg during GDs 6–15 (NTP 1983a).  There was no maternal toxicity, but mean fetal body weight at
this dose level was approximately 7% lower than controls.  However, since historical control data showed 
that the concurrent control fetal weight for the CD rat was much higher (22%) than the historical control 
weight and a larger litter size in the high-dose group may have contributed to the smaller fetal weight in 
the high-dose group, the dose of 120 mg/kg/day can be considered an equivocal LOAEL for
developmental effects; the NOAEL was 60 mg/kg/day and supports the NOAEL of 60 mg/kg/day 
identified in the York (1997) study.
As discussed in Section 2.3, effects of phenol administered to animals by oral gavage are different than 
those observed in drinking water studies.  Phenol administered by gavage is much more toxic than 
administered in the drinking water and this is related to the pharmacokinetics of phenol.  Furthermore, it
has been shown that the volume of administration is important; the smaller the volume, the greater the
toxicity of a given amount of phenol (NTP 1983a).  Studies have shown that the toxicity of phenol is
correlated with peak blood concentration rather than with total dose, such as the area under the phenol
blood concentration curve (AUC) (Hiser et al. 1994).  In general, NOAELs in oral gavage studies were 5– 
10 times lower than in drinking water studies.  The York (1997) study was considered an appropriate
study for MRL derivation because it used a divided dosing protocol that resembles more closely a 
potential environmental exposure scenario to phenol.
Agency Contacts (Chemical Managers): Jewel Crawford; Obaid Faroon; Jewell Wilson
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BENCHMARK MODELING OF MATERNAL WEIGHT GAIN IN RATS
Benchmark dose models in the EPA Benchmark Dose Software (BMDS version 2.0) (linear, polynomial, 
power, and Hill models) were fit to the maternal body weight gain data (see Tables A-1, and A-2, and 
Figure A-1) to determine potential points of departure for the MRL.  The linear model with homogeneous
variance (which was identical to the power model), was selected because it was the simplest model and
provided the best fit.  In the absence of a clear criteria as to what level of change in weight gain during
pregnancy should be considered adverse, the BMR was defined as a change in mean body weight gain 
equal to one standard deviation from the control mean (EPA 2000c).  
Table A-1.  Data for the Change in Body Weight Gain in Pregnant Rats Exposed 
to Phenol on Gestation Days 6–15 
Dose (mg/kg/day) Number of animals tested Body weight gain (g) Standard deviation
0 23 64 10.7
60 25 58 9.4
120 23 56.8 10.8
360 25 39.8 9.5
Source: York 1997
The corresponding BMD was 152.1 mg/kg/day; the corresponding BMDL was 124.6 mg/kg/day.  
Applying an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability) to the BMDL results in an acute-duration oral MRL of 1 mg/kg/day.
Table A-2.  Model Predictions for Changes in Body Weight Gain in Pregnant Rats
Exposed to Phenol on Gestation Days 6–15
Model BMD1stddev (mg/kg/day) BMDL1stddev (mg/kg/day) p-valuea AIC-fitted
Linearb,c 152.1 124.6 0.6055 542.79
2-degree polynomial c 157.0 124.6 0.3191 544.78
Powerb 152.1 124.6 0.6055 542.79
Hill 151.2 123.7 0.3156 544.79
aValues <0.05 fail to meet conventional goodness-of-fit criteria.

bBest-fitting models
 
cThe polynomial coefficients are restricted to be negative.
 
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 

benchmark dose; NA = not applicable; p = p value from the Chi-squared test
 
Source:  York 1997
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Figure A-1.  Changes in Body Weight Gain in Pregnant Rats Exposed to Phenol
on Gestation Days 6–15*
Linear Model with 0.95 Confidence Level
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*BMDs and BMDLs indicated are for a change of 1 standard deviation and are in units of mg/kg/day.
Source:  York 1997
The homogeneous variance linear model form of the response function for the change in maternal body
weight gain is:
Y[dose] = beta_0 + beta_1*dose + beta_2*dose^2 + ...
Linear Model Parameter Estimates for the Change in Maternal Body Weight Gain:
Variable Estimate Standard Error
alpha 98.6 14.2
beta_0 63.4 1.4
beta_1 -0.07 0.007
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.  
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2,
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
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LEGEND
See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7)	 System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data
exists.  The same health effects appear in the LSE table.
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
 
 
 
 
 
      
 
  
 
     
 
 
 
 
    
  
 
 
 
 
 
 
    
      
    
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE
 
1 →	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Key to 	 frequency/ NOAEL Less serious Serious (ppm)
figurea Species duration System (ppm) (ppm)	 Reference
2
3
4
→	 INTERMEDIATE EXPOSURE
5 6 7 8 9 10
→ Systemic ↓	 ↓ ↓ ↓ ↓ ↓
18 Rat	 13 wk Resp 3b 10 (hyperplasia)
→	 5 d/wk Nitschke et al. 1981
6 hr/d
CHRONIC EXPOSURE
Cancer	 11
↓
38 Rat	 18 mo 20 (CEL, multiple Wong et al. 1982
5 d/wk organs)
7 hr/d
39 Rat	 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse	 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
12 →	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD benchmark dose
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMCO North America/Intergovernmental Maritime Dangerous Goods Code
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DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
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MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
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PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
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> greater than
≥ greater than or equal to
= equal to
< less than
≤ less than or equal to
% percent
α alpha
β beta
γ gamma
δ delta
μm micrometer
μg microgram
q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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absorbed dose............................................................................................................................................ 122
 
acetylcholine ............................................................................................................................................. 124
 
adrenal gland........................................................................................................................... 14, 67, 75, 131
 
adsorption.................................................................................................................................. 156, 170, 176
 
aerobic................................................................................................................................... 9, 157, 158, 159
 
alanine aminotransferase (see ALT) ..................................................................................................... 10, 36
 
ALT (see alanine aminotransferase) ........................................................................... 10, 36, 37, 65, 82, 131
 
ambient air ................................................................................................................ 149, 159, 164, 165, 170
 
anaerobic ....................................................................................................................................... 9, 158, 159
 
aspartate aminotransferase (see AST)................................................................................................... 35, 36
 
AST (see aspartate aminotransferase)......................................................................... 10, 36, 37, 65, 82, 131
 
bioaccumulation................................................................................................................................ 156, 170
 
bioavailability ........................................................................................................................................... 170
 
bioconcentration factor ............................................................................................................................. 156
 
biodegradation............................................................................................................. 10, 149, 155, 156, 158
 
biomarker .................................................................. 106, 111, 121, 122, 123, 124, 134, 135, 172, 173, 181
 
blood cell count............................................................................................................................... 12, 36, 64
 
body weight effects ......................................................................................................................... 39, 68, 85
 
breast milk............................................................................................................................... 5, 10, 137, 166
 
cancer ...................................................................................................... 4, 22, 44, 75, 86, 87, 118, 121, 185
 
carcinogen................................................................................................................................... 86, 185, 188
 
carcinogenic ...................................................................................................................... 14, 21, 75, 86, 111
 
carcinogenicity............................................................................ 4, 14, 75, 87, 112, 129, 131, 136, 185, 188
 
carcinoma.............................................................................................................................................. 86, 87
 
cardiac arrhythmia ........................................................................................ 12, 77, 118, 119, 120, 126, 129
 
cardiovascular ............................................................................... 4, 10, 23, 34, 62, 127, 129, 131, 134, 136
 
cardiovascular effects...................................................................................................................... 34, 62, 77
 
catechol ............................................................................................................................... 93, 101, 112, 115
 
chromosomal aberrations ................................................................................................................ 87, 91, 92
 
clearance ............................................................................................................................................. 95, 100
 
consumer products ............................................................................................ 1, 9, 164, 165, 166, 167, 171
 
death.......................................... 4, 11, 18, 21, 22, 23, 35, 43, 44, 61, 70, 75, 76, 77, 85, 120, 125, 127, 188
 
deoxyribonucleic acid (see DNA)................................................................................................... 87, 88, 90
 
dermal effects............................................................................................................................ 38, 39, 67, 83
 
disinfectant.................................................................................................................... 1, 5, 67, 70, 119, 143
 
DNA (see deoxyribonucleic acid)..................................................... 87, 88, 89, 90, 91, 92, 93, 99, 114, 122
 
dopamine............................................................................................................................................... 20, 71
 
elimination half-time................................................................................................................................... 99
 
endocrine..................................................................................................................................... 67, 115, 116
 
endocrine effects ......................................................................................................................................... 67
 
erythema............................................................................................................................ 11, 63, 77, 83, 125
 
estrogen receptor....................................................................................................................................... 117
 
estrogenic .................................................................................................................................................. 117
 
fetal tissue ................................................................................................................................................... 98
 
fetus........................................................................................................................................................... 117
 
gastrointestinal effects .............................................................................................................. 34, 35, 63, 81
 
general population..................................................................................... 10, 22, 35, 44, 122, 134, 165, 188
 
genotoxic............................................................................................................................... 21, 91, 112, 132
 
genotoxicity................................................................................................................................. 87, 129, 132
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germinal cell................................................................................................................................................ 72
 
glucuronide ............................................................................... 100, 101, 103, 104, 114, 121, 136, 137, 173
 
groundwater ...................................................................... 2, 9, 149, 155, 156, 158, 160, 161, 163, 164, 171
 
growth retardation....................................................................................................................................... 73
 
half-life.............................................................................................. 9, 94, 95, 107, 122, 149, 155, 157, 158
 
hematological effects ...................................................................................................................... 35, 64, 81
 
hematopoietic.............................................................................................................................................. 35
 
hepatic effects ......................................................................................................................... 36, 65, 82, 124
 
hydrolysis.......................................................................................................................... 143, 173, 174, 176
 
hydroquinone ...................................................................................... 93, 101, 103, 104, 111, 112, 115, 124
 
hydroxyl radical ........................................................................................................................ 149, 155, 157
 
immune system ........................................................................................................................................... 40
 
immunological .............................................................. 12, 13, 19, 21, 35, 40, 41, 69, 70, 85, 129, 130, 131
 
immunological effects................................................................................................................... 19, 69, 130
 
Kow ............................................................................................................................................................ 141
 
LD50..................................................................................................................................... 45, 61, 76, 77, 99
 
leukemia........................................................................................................................................ 14, 75, 131
 
lymphoreticular ............................................................................................................. 13, 20, 41, 69, 70, 85
 
metabolic effects ......................................................................................................................................... 40
 
micronuclei ................................................................................................................................................. 91
 
milk ............................................................................................................................................... 5, 121, 137
 
musculoskeletal effects ............................................................................................................. 36, 65, 81, 82
 
neurobehavioral......................................................................................................................................... 116
 
neurochemical ............................................................................................................................... 12, 19, 130
 
norepinephrine ...................................................................................................................................... 20, 71
 
nuclear................................................................................................................................................. 82, 114
 
ocular effects................................................................................................................................. 68, 84, 130
 
odds ratio..................................................................................................................................................... 44
 
pharmacodynamic ..................................................................................................................................... 108
 
pharmacokinetic........................................................................................................ 108, 109, 110, 118, 121
 
placenta ............................................................................................................................................. 121, 137
 
placental barrier .......................................................................................................................................... 98
 
rate constant ........................................................................................................................................ 94, 157
 
renal effects..................................................................................................................................... 38, 66, 82
 
retention .................................................................................................................................. 93, 94, 95, 157
 
salivation............................................................................................................................................... 18, 85
 
solubility ................................................................................................................................................... 155
 
spermatogonia............................................................................................................................................. 91
 
sulfate.................................... 93, 97, 101, 103, 104, 113, 115, 120, 121, 124, 135, 136, 137, 173, 179, 180
 
thyroid................................................................................................................................................... 67, 99
 
toxicokinetic.................................................................................................................... 12, 16, 21, 127, 135
 
tremors .............................................................................. 4, 11, 12, 14, 15, 16, 40, 42, 70, 73, 85, 115, 124
 
tumors ..................................................................................................................................... 77, 86, 87, 124
 
volatility .................................................................................................................................................... 158
 
volatilization ..................................................................................................................................... 155, 170
 
  
 
 
 
 
 
